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1. INTRODUCTION 
1.1 Hematopoiesis 
As the life span of most mature hematopoietic cells is limited, blood cells have 
to be regenerated by a process called hematopoiesis: the formation and 
development of blood cells in the body. In vertebrae, hematopoiesis occurs in 
two distinct phases: primitive (embryonic) and definitive (adult) hematopoiesis, 
both of which originate in the embryo (Liao et al., 2002). 
1.1.1 Blood Formation in the Embryo 
Distinct regions of the embryonic primitive streak (PS) give rise to different 
mesodermal populations like blood, vasculature, kidney, cardiac and skeletal 
muscle (Tam and Beddington, 1987; Lawson et al., 1991). Clustered homeobox 
(Hox) genes are involved in the anterior-posterior (AP) patterning of this 
mesodermal region and the establishing of cell identities by forming overlapping 
gradients along the AP axis (Favier and Dolle, 1997; Veraksa et al., 2000). 
According to the “Hox code” hypothesis, a specific combinatorial expression of 
different Hox genes leads to the specification of a certain tissue type. 
Perturbation of this defined expression pattern by an alteration of the anterior 
expression boundaries results in a change in cell fate (Kessel and Gruss, 1991, 
Figure 1). Hemangioblasts, common progenitors for both the hematopoietic and 
the vascular lineage, are found at highest frequency at the posterior region of 
the primitive streak. After migration to the yolk sac, they give rise to both 
lineages in response to the interaction of the vascular endothelial growth factor 
(VEGF) with its receptor FLK-1 (Huber et al., 2004; Choi et al., 1998). 
Introduction  
 
2 
Figure 1: Genomic organization and expression patterns of Hox genes (Veraksa et al., 
2000). 
Depicted are the four clusters and the expression patterns of mammalian Hox genes vertically 
aligned with their Drosophila orthologs. A hypothetical ancestral Hox cluster is presented in the 
middle, arrows indicate predicted evolutionary origins of both Drosophila and mammalian Hox 
genes. The four mammalian Hox clusters each contain eight to eleven genes and are located 
on four different chromosomes. Individual genes in different Hox clusters can be aligned into 
paralogous groups (indicated by identical colors) based on the sequence homology within their 
homeobox regions, and with the homeotic genes of the Drosophila HOM-C cluster. 
Beside factors defining the AP axis, also signaling molecules involved in the 
dorsal ventral (DV) patterning collaborate in the embryonic blood formation. 
One important factor is BMP-4 which, as well as VEGF, TGF-β and FGF2, is 
considered a ventralizing factor in contrast to the dorsalizing factors TGF-α and 
EGF (Pardanaud and Dieterlen-Lievre, 1999, Figure 2). Whereas the latter 
antagonize hematopoietic induction, most ventralizing factors are thought to 
positively induce hematopoiesis (Faloon et al., 2000; Winnier et al., 1995). 
Introduction 3 
BMP-4, for example, induces hematopoietic activity in developing murine 
embryonic HSCs in aorta-gonad-mesonephros (AGM) explants (Johansson and 
Wiles, 1995; Durand et al., 2007). In contrast, deficiency of BMP-4 in the mouse 
generally leads to embryogenic lethality due to mesodermal defects (Winnier et 
al., 1995). 
Figure 2: Model for the generation of hematopoietic cell from the embryonic mesoderm 
within the mammalian AGM region. 
mc: mesenchymal cell, ha: hemangioblast, i: intermediate endothelial cell, E: committed 
endothelial cell, H: committed hematopoietic cell (modified from Marshall and Thrasher, 2001). 
In the mouse conceptus, the first primitive hematopoietic cells can be found at 
day 7.0-7.5 after fertilization when primitive nucleated erythrocytes arise in the 
yolk sac. One day later myeloid progenitors can be detected (Palis and Yoder, 
2001; Dzierzak and Speck, 2008, Figure 3). GATA-1 and PU.1 are key factors 
for this first primitive wave of hematopoiesis with the ratio of both determining 
the production of primitive erythroid and myeloid cells. Whereas a knockdown of 
pu.1 in the zebrafish leads to a shift towards the erythroid lineage, loss of gata-1 
expression induces formation of myeloid cells (Galloway et al., 2005; Berman et 
al., 2005). 
However, these first embryonic hematopoietic cells are a transitory population. 
Definitive adult hematopoietic stem cells (HSCs), with the capacity to 
reconstitute BM of lethally irradiated adult mice, can be found only at day 10.5 
in the AGM region of the embryo. RUNX-1 is a pivotal regulator for this second 
hematopoietic wave, and lack of RUNX-1 results in complete absence of 
definitive HSCs in the AGM region as well as embryonic lethality (Chen and 
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Zon, 2009). At this time, other transcription factors such as c-MYB, LMO2, 
IKAROS and SCL are expressed in the AGM (de Jong and Zon, 2005). The 
contribution of yolk sac-derived progenitors to adult hematopoiesis is still 
uncertain and may vary between species (Orkin and Zon, 2002). 
During the second half of embryogenesis, the fetal liver becomes the major site 
of blood formation. Importantly, HSCs in the fetal liver are not generated de 
novo. Starting at day 9.5 to 10.0, the liver is colonized by HSCs originating from 
the AGM as well as the yolk sac and the placenta, which undergo a massive 
expansion in the liver (Johnson and Moore, 1975; Kumaravelu et al., 2002, 
Gekas et al., 2005; Ottersbach and Dzierzak, 2005). Subsequently, other 
secondary hematopoietic organs such as spleen and thymus are seeded by 
HSCs derived from either their primary production sites or from fetal liver. Only 
shortly before birth definitive hematopoiesis shifts towards the BM (Figure 3). 
Figure 3: Timeline of hematopoietic events in the mouse conceptus. 
Upper arrows indicate the onset of hematopoietic cell generation and/or appearance; lower 
arrows indicate the first colonization of secondary hematopoietic organs (Dzierzak and Speck, 
2008). 
1.1.2 Adult Hematopoiesis 
Beside sporadic disease induced hematopoietic activity in extramedullary sites 
like spleen or liver, the BM is the exclusive site of blood formation in adult 
mammals (Wang et al., 2009; Wolber et al., 2002). The HSC population residing 
within the BM constitutes the top of the hematopoietic hierarchy and throughout 
life replenishes the pool of rapidly proliferating multipotent hematopoietic 
progenitors, which in turn give rise to the different hematopoietic lineages. 
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Blood cells can be divided into a myeloid-erythroid and a lymphoid 
compartment. The lineage restriction of the blood cells progressively increases 
with differentiation towards the mature cell types. The classical model of 
hematopoiesis suggests a branching point at which the multipotent progenitors 
become restricted to either one of the two branches. Source of all lymphoid 
cells hereby is the common lymphoid progenitor (CLP) whereas the common 
myeloid progenitor (CMP) gives rise to the myeloid and the erythroid lineage 
(Reya et al., 2001, Figure 4). However, recently the existence of additional 
branching points in differentiation was described: With both granulocyte-
monocyte and lymphoid potential, the lymphoid-primed multipotent progenitor 
(LMPP) and the granulocyte-monocyte-lymphoid progenitor (GMLP) are able to 
contribute to B- and T-lymphoid as well as to granulocyte/macrophage lineages 
(Adolfsson et al., 2005; Lai et al., 2005; Iwasaki and Akashi, 2007). 
Figure 4: Classical model of hematopoietic differentiation. 
Whereas long-term (LT) HSCs possess unlimited self-renewal, the ability to self-renew is limited 
in the short-term (ST) HSC population. Multipotent progenitors (MPP) do not self-renew or only 
briefly and give rise to the oligolineage-restricted progenitors CMP and CLP which in turn 
produce a progeny becoming more and more lineage-restricted (according to Passegue et al., 
2003). 
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Lymphoid Lineage 
The two main types of lymphoid cells, T- and B-cells, constitute the adaptive 
immune system and are derived from a common lymphoid progenitor. 
Chromatin remodeling activities as well as a complex network of transcription 
factors leading to the expression of either myeloid or lymphoid transcripts is 
responsible for the initial step of lineage priming. The LEF/TCF-dependent 
WNT/β-Catenin pathway is one key regulatory component for the specification 
of the T- and B-cell lineages. Mice deficient for TCF1 and LEF-1 for example 
show a severe defect of the early thymocyte compartment with a reduced T-cell 
count (Verbeek et al., 1995). NOTCH1 receptor signaling is critical for initiation 
of T-cell development by upregulating the transcription of TCF1 or GATA3 (Dias 
et al., 2008). 
Proper expression of LEF-1 furthermore is of importance for survival and 
proliferation in normal B-cell development (Bruhn et al., 1997; Reya et al., 
2000). EBF1, its target PAX5, and FLT3 are also central to B-lymphopoiesis: 
Whereas early B-lymphopoiesis requires FLT3, with a knockout leading to 
severe reduction in the number of B-cell progenitors, FLT3 has to be repressed 
by PAX5 to allow further differentiation (Mackarehtschian et al., 1995; Holmes 
et al., 2006; Dias et al., 2008). PAX5 on the other hand is critical for B-lymphoid 
commitment and loss of PAX5 expression leads to a differentiation block in 
early B-cells and de-differentiation of even mature B-lymphocytes (Urbanek et 
al., 1994; Nutt et al., 1997; Cobaleda et al., 2007). 
Myeloid Lineage 
Myelocytes, including granulocytes, macrophages and megakaryocytes, play 
roles in different processes including blood clotting, the adaptive and the innate 
immunity. PU.1, whose expression is required both in the lymphoid and in the 
myeloid lineage, is crucial for the myeloid lineage specification. This protein acts 
dose-dependent with low levels promoting B-lymphoid differentiation of 
hematopoietic progenitors and high levels driving macrophage differentiation 
(DeKoter and Singh, 2000; Iwasaki et al., 2003). In the myeloid lineage, the 
transcriptional activity of PU.1 is antagonized by C/EBPα and GFI-1, which are 
able to block monocytic differentiation and commit the progenitors to 
granulocytic differentiation (Dahl et al., 2003; Dahl et al., 2007, Figures 5 and 
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6). However, low levels of PU.1 are still required for proper granulocytic 
development (Friedman, 2007) and it cooperates with GATA-2 to induce mast 
cell differentiation (Walsh et al., 2002). 
Figure 5: Transcription factors in hematopoiesis 
Red circles indicate the stage at which the absence of a respective transcription factor blocks 
hematopoietic development. The red factors have been associated with oncogenesis whereby 
the light red factors have not been found to be translocated or mutated in hematopoietic 
malignancies yet (Orkin and Zon, 2008). 
Erythroid Lineage 
Erythroid cells, having the function to supply the body with oxygen, are derived 
from the same precursor as the myeloid lineage: the megakaryocytic/ 
erythrocytic progenitors (MEP). To allow erythroid differentiation, Gata-1 is 
indispensable. This factor antagonizes PU.1 and is highly expressed in this 
hematopoietic progenitor subtype (Rekhtman et al., 2003; Rekhtman et al., 
1999). Deficiency of GATA-1 in the embryo leads to a block in the early 
proerythroblast stage and subsequent death due to severe anemia (Fujiwara et 
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al., 1996). As depicted in Figure 6, the balance between the erythroid-specific 
Kruppel-like factor (EKLF) and FLI-1 subsequently regulates the differentiation 
towards either the erythroid or the megakaryocytic lineage. Whereas FLI-1 is 
required for megakaryopoiesis and is able to activate the promoters of several 
megakaryocyte-specific genes, EKLF inhibits FLI-1 dependent transcription but 
induces erythroid differentiation (Starck et al., 2003). 
Figure 6: Transcriptional antagonism in myeloid lineage determination (Orkin and Zon, 
2008). 
CMP: common myeloid progenitor, MEP: megakaryocyte/erythroid progenitor, GMP: 
granulocyte/macrophage progenitor, RBCs: red blood cells. 
1.1.3 Hematopoietic Stem Cells 
Although the presence of different lineages within the hematopoietic system is 
well known, the stem cell concept  of a few cells sitting on top of the 
hematopoietic pyramid and possessing the capacity to give rise to all the 
hematopoietic lineages is relatively new. In 1994 Morrison and Weissman were 
the first to isolate and characterize murine LT-HSCs, which they could highly 
enrich by fractionation according to their Thy-1.1lo/Sca-1hi/Lin- phenotype. A few 
years later, in 1997, Bhatia et al. showed in the human system that 
hematopoietic stem cells reside within the Lin-/CD34+/CD38- compartment. Due 
to their in vivo repopulating activity in severe combined immunodeficiency 
(SCID) mice these cells are also referred to as SCID repopulating cells. In the 
following years, the enrichment methods were refined and additional markers 
were identified for isolation of mouse and human HSCs, as depicted in Figure 7. 
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Figure 7: Hematopoietic subpopulations and their phenotype. 
Surface markers used for isolation of the different populations from mouse (bottom) and human 
(top) are indicated. MPP: multipotent progenitors with limited self-renewal leading to transient 
but multilineage reconstitution, CMP: common myeloid progenitor, CLP: common lymphoid 
progenitor, Pro-T: T-cell progenitor, GMP: granulocyte/ macrophage progenitor, MEP: 
megakaryocyte/ erythroid progenitor (Weissman and Shizuru, 2008). 
HSCs, like all stem cells, are characterized by two main properties: 
multipotency, which is the capacity to generate all cell types of the 
hematopoietic lineage, and the ability to self-renew, hereby allowing the 
maintenance of the HSC pool by asymmetric cell division. These characteristics 
allow one single donor HSC to reconstitute the whole blood system of a 
recipient animal and replenish its blood cell pool from thereon in. Besides long-
term (LT-) HSCs with indefinite self-renewal potency there are also short-term 
(ST-) HSCs which possess limited self-renewal capacity. Multipotent 
progenitors (MPPs) show multipotency and have high proliferative potential but 
are not able to self-renew (Morrison et al., 1997). 
After birth, the number of HSCs in the BM is maintained at a steady state and 
the HSCs mainly remain quiescent. Not all of the cellular signals regulating self-
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renewal and quiescence are known, however several candidate factors have 
been identified (Figure 8). One essential factor for maintaining the adult HSC 
pool is the ETS-related transcription factor TEL1/ETV6. Inactivation of this gene 
in the hematopoietic compartment leads to loss of HSCs (Hock et al., 2004). A 
positive regulator of self-renewal is HOXB4 which, when overexpressed in the 
BM, leads to an expansion of the HSC population in vitro and in vivo 
(Sauvageau et al., 1995). A knockout of HOXB4, however, leads to only mild 
defects in the proliferation of HSCs (Brun et al., 2004), suggesting 
compensatory mechanisms by other members of the HOX family. BMI-1, a 
member of the Polycomb group of proteins, regulates self-renewing cell 
division, and a deficiency of BMI-1 leads to proliferation arrest, apoptosis and 
differentiation of leukemic cells (Park et al., 2003). 
Figure 8: Known factors of HSC maintenance (Akala and Clarke, 2006). 
Besides these intrinsic factors, HSC self-renewal also depends on extrinsic 
regulators provided by the microenvironment, i.e. the stem cell niche. Amongst 
those is the Notch signaling pathway, which is highly active in HSCs and 
downregulated with advancing differentiation. Inhibition of this pathway leads to 
enhanced differentiation and depletion of the HSC pool in vivo (Duncan et al., 
2005). The LEF/TCF-dependent WNT/β-Catenin pathway is also required for 
maintaining the HSC function (Reya et al., 2003; Willert et al., 2003). Whereas 
mice lacking β-Catenin expression do not show an altered number of HSCs, β-
Catenin overexpression leads to accumulation of HSCs by blocking HSC 
differentiation (Cobas et al., 2004; Scheller et al., 2006; Kirstetter et al., 2006). 
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1.2 Leukemia 
In normal hematopoiesis self-renewal, proliferation and differentiation are 
delicately balanced. Genetic alterations affecting these processes can thus lead 
to deregulation of the normal hematopoietic program. Blocking differentiation of 
early hematopoietic progenitors and clonal expansion of neoplastic cells in the 
BM leads to an accumulation of the leukemic bulk, replacement of the 
remaining healthy hematopoietic system and finally to a deprivation of mature, 
functional hematopoietic cells. 
Analysis of this cytogenetic and molecular heterogeneous group of diseases 
revealed that genetic alterations occurring in leukemia can be assigned to two 
different groups: one that promotes survival advantage and/or increased 
proliferative potential, and the other one that confers self-renewal properties to 
the affected cells (Dash and Gilliland, 2001; Gilliland et al., 2004). Dash & 
Gilliland observed cooperation in particular between constitutively activated 
tyrosine kinase molecules and fusion of signal transduction genes. In these 
cases, activated tyrosine kinases led to enhanced proliferation and/or 
antiapoptotic activity whereas fused signal transduction genes disturbed 
hematopoietic differentiation and enabled the cells to self-renew. 
1.2.1 Acute Myeloid Leukemia 
AML is a malignant clonal disorder of the myeloid hematopoietic compartment. 
It is the most common form of acute leukemia in adults with an incidence of 3.5 
cases per 100,000 people and year and a median age of 67 years at diagnosis 
(www.seer.cancer.gov). According to the World Health Organization (WHO), 
AML is defined by the presence of more than 20% of myeloid blasts in the BM 
(Gilliland and Tallman, 2002). There is massive evidence that, like many 
cancers, AML is a multistep disease with an accumulation of multiple mutations 
as well. Beside perturbation of the normal differentiation program, the leukemic 
clone additionally has to acquire enhanced self-renewal capacity as well as 
increased proliferative potential promoting clonal expansion. 
Introduction  
 
12 
Chromosomal Translocations in AML (Abnormal Karyotype) 
40% to 45% of AML cases carry chromosomal abnormalities and are referred to 
as AML with abnormal karyotype. In 20-25% of AML, loss of function alterations 
of core binding factor (CBF) subunits can be found. The translocation 
t(8;12)(q22;q22) hereby results in the AML1-ETO fusion protein and correlates 
especially with AML M2, whereas the inversion inv(16)(p13q22) leads to 
expression of CBFβ-SMMHC which is associated with AML M4eo (Gilliland and 
Tallman, 2002). Other translocations, which impair hematopoietic differentiation, 
include rearrangements of the mixed lineage leukemia (MLL) gene. MLL 
rearrangements are mostly found in myelomonocytic, monoblastic, or monocytic 
leukemia (AML M4, M5a and M5b, respectively) and constitute up to 10% of de 
novo AML. The t(15;17) (PML-RARα) translocation strictly correlates with acute 
promyelocytic leukemia (AML M3) and is found in 95% of these cases. Both 
MLL-rearrangements and PML-RARα were shown to immortalize hematopoietic 
progenitors (Gilliland and Tallman, 2002; Cozzio et al., 2003; Gilliland et al., 
2004; Krivtsov et al., 2006, Figure 9A). 
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Figure 9: Genetic alterations in adult AML. 
(A) Pie chart presenting cytogenetic alterations in adult AML and frequency of gene mutations 
in AML with normal karyotype (AML NK). (B) Pie chart showing the relationship between NPM1 
mutations and FLT3-ITD in AML-NK (modified from Falini et al., 2007). 
Mutations in AML (Normal Karyotype) 
Mutations characterize the second group of AML. As these genetic alterations 
cannot be detected by fluorescence in situ hybridization (FISH), AML cases 
harboring these mutations are also referred to as AML with normal karyotype 
(AML NK). 25% to 30% of AML NK is associated with mutations of the tyrosine 
kinase FLT3, This tyrosine kinase is constitutively activated by internal tandem 
duplications (FLT3-ITD) or point mutations of the tyrosine kinase domain (FLT3-
TKD). The resulting autodimerization and subsequent autophosphorylation is 
thought to promote proliferation by activating signaling pathways such as 
RAS/MAPK, STAT and AKT/PI3K. In about 35% of total AML and up to 60% of 
AML NK, mutated cytoplasmatic nucleophosmin (NPMc) can be found (Falini et 
al., 2007, Figure 9). NPM-mutated cases are frequently associated with FLT3-
ITD mutations, which can be detected in approximately 50-60% of the NPMc+ 
patients (Falini et al., 2007, Figure 9B). Other recurrent mutations occur in 
CEBPα or RAS with frequencies of 20% and 10% of AML, respectively (Rau 
and Brown, 2009). 
B 
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Homeobox Gene Deregulation in AML 
Deregulations of homeobox genes, as for example PBX3, MEIS1 or POU4F1, 
are found in both AML with normal and abnormal karyotype (Miller and 
Stamatoyannopoulos, 2010). As reported in several gene expression profiling 
studies, the deregulation of HOX gene expression is a frequent observation 
(Debernardi et al., 2003; Verhaak et al., 2005; Miller and Stamatoyannopoulos, 
2010). As shown in Figure 10, more than 60% of AML patients, particularly 
patients with normal karyotype, show aberrant expression of HOX genes. In a 
small subset of cases deregulation of MLL, a known upstream regulator of HOX 
genes, is responsible for the aberrant HOX gene expression. For the vast 
majority of patients, however, the cause for HOX gene deregulation is still 
unclear as most of the occurring mutations are not able to upregulate 
leukemogenic HOX genes. 
Figure 10: HOX gene deregulation in different subgroups of AML. 
AML subgroups with deregulation of HOX genes are coloured red (frequency of genomic 
aberrations according to www.onkodin.de). 
The largest group characterized by HOX gene deregulation is AML with normal 
karyotype, particularly AML with normal karyotype and mutated NPM, Figure 
11). Again, the reason for HOX gene deregulation is not clear, as NPMc+ is not 
able to deregulate HOX expression and the HOX upstream regulator MLL is not 
deregulated in the majority of cases. In addition, the differentiation stage of the 
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cells cannot explain this situation, as the leukemic blasts in cases with NPMc 
positive AML are negative for CD34 (Figure 11B). 
Figure 11: Homeobox gene expression in AML. 
A) Hierarchical clustering of homeobox gene expression in 27 AML patients (Debernardi et al., 
2003) B) expression signature of NPMc+ AML (Verhaak et al., 2005). red: upregulation, green: 
downregulation, NK: normal karyotype. 
1.2.2 Acute Erythroid Leukemia 
Acute erythroid leukemia (AML M6), a subtype of AML, constitutes about 5% of 
AML. No specific genetic alterations are linked to AML M6, which is associated 
with an especially poor treatment outcome (Kasyan et al., 2010). This subtype 
is characterized by the presence of a predominant erythroid population, which, 
in the case of AML M6a, is mixed with myeloid blasts. In contrast, in pure 
erythroid leukemia (AML M6b) the leukemic clone exclusively consists of 
erythroblasts. Commonly, erythroid markers such as glycophorin A (which 
correlates with Ter119 in the mouse) are used for classification of this subtype 
(Kina et al., 2000). However, cases with more immature erythroid blasts and 
missing known erythroid markers have also been described. These abnormal 
cases are aptly called “cryptic erythroid leukemia” or “early erythroblastic 
leukemia” (Greaves et al., 1983; Villeval et al., 1986). The neoplastic clone 
found in these cases is derived from transformed c-Kit+ BFU-E or c-Kit+/CD71+ 
CFU-E but does not show expression of mature erythroid markers (Shimizu et 
al., 2008, Figure 12). 
B 
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Figure 12: Expression of the lineage markers c-Kit, CD71 and Ter119 in different stages 
of murine erythroid differentiation. 
EEP: early erythroid progenitor, LEP: late erythroid progenitor, BFU-E: burst-forming unit-
erythroid, CFU-E: colony-forming unit-erythroid (according to Shimizu et al., 2008). 
1.2.3 Acute Lymphoblastic Leukemia 
Acute lymphoblastic leukemia (ALL), a malignant disorder of the lymphoid 
compartment, derives from either the B- or the T-lineage. ALL affects both 
children and adults with a median age of 13 at diagnosis and an incidence rate 
of 1.6 per 100,000 people per year (www.seer.cancer.gov). Whereas more than 
80% of childhood ALL can be cured, in the adult there is an increased number 
of molecular subtypes with poor prognosis (Teitell and Pandolfi, 2009). 
Based on immunophenotyping, ALL of the B-cell lineage can be divided in 
common ALL (cALL), pro-B ALL, pre-B ALL and mature B-cell ALL. T-cell ALL 
subtypes comprise pro-T ALL, pre-T ALL, cortical T-ALL and mature T-cell ALL. 
Recurrent chromosomal abnormalities are one hallmark of ALL and can be 
found in 60-70% of the adults (Faderl et al., 2003). With a prevalence of 20-
30%, the most frequent of these chromosomal aberrations is the t(9;22) 
translocation, also known as the Philadelphia (Ph) chromosome. This 
translocation is found almost exclusively in CD10+ precursor ALL and is 
associated with very high-risk ALL (Ottmann and Wassmann, 2005; Ravandi 
and Kebriaei, 2009). Patients with 11q23 (MLL) rearrangements have a poor 
prognosis as well, especially those with a MLL-AF4 translocation which has a 
50% prevalence in adult pro-B ALL (Gleissner et al., 2005; Pui et al., 2008). 
Most characteristic for mature B-ALL are c-Myc rearrangements, whereas the 
most common genetic aberrations in mature T-ALL are T-cell receptor (TCR) 
rearrangements (Faderl et al., 2003). However, in ALL, as in many other 
cancers, there is evidence that chromosomal aberrations alone are not 
sufficient to induce overt leukemia but have to cooperate with other genetic 
EEP LEP 
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lesions. Indeed, by genome-wide analyses, genetic alterations have been 
identified in a number of genes regulating lymphoid development. For example, 
affected in almost one third of ALL cases is PAX5, but TCF3, LEF1, IKAROS or 
NOTCH1 are also frequently targeted by mutations (Weng et al., 2004; 
Mullighan et al., 2007). 
Figure 13: Cytogenetic abnormalities in adult ALL (Faderl et al., 2003). 
Furthermore, deregulated expression of HOX genes is a recurrent event in ALL. 
Deregulation of the whole HOXA gene cluster can be observed in inv(7) positive 
T-ALL cases where the distal part of the HOXA cluster is juxtaposed to the 
TCRβ locus (Soulier et al., 2005). In the affected patients, particularly high 
levels of HOXA10 and HOXA11 are found (Speleman et al., 2005). 
Deregulation of HOXA cluster genes as well as HOXC6 was reported in MLL 
and CALM-AF10 positive T-ALL cases (Ferrando et al., 2003; Soulier et al., 
2005). 
1.2.4 Cancer Stem Cells and the Leukemic Stem Cell Model 
The different subtypes of leukemia are well characterized by means of their 
genetic and morphological phenotype. Already at the beginning of the last 
century, leukemia was classified into chronic lymphocytic leukemia, chronic 
myeloid leukemia, acute lymphocytic leukemia and acute myeloid leukemia/ 
erythroleukemia (Reschad and Schilling-Torgau, 1913). Despite this, the origin 
of the neoplastic clone remained unclear for a long time. Although Arthur 
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Pappenheim postulated the existence of HSCs already in 1917 (Pappenheim, 
1917), the existence of cancer stem cells (CSCs) as a population with similar 
properties was only proven in the late 20th century. In 1994 it was shown that an 
immature subset of leukemic cells derived from AML patients was able to 
engraft SCID or non-obese diabetic severe combined immunodeficiency 
(NOD/SCID) mice and exhibited the same phenotype observed in patients 
(Lapidot et al., 1994; Bonnet and Dick, 1997). Since that time, CSCs have been 
identified for several types of cancer including breast cancer and glioma (Al-Hajj 
et al., 2003; Singh et al., 2003). Due to the establishment of different functional 
in vitro and in vivo assays, CSCs are especially well analyzed within the 
hematopoietic system where they are also referred to as leukemic stem cells 
(LSCs) (Warner et al., 2004). 
CSCs are cells within a tumor which possess the capacity to self-renew and, by 
definition, fulfill three criteria: CSCs are enriched for tumorigenic ability, serially 
propagate tumor growth in vivo and are able to regenerate the whole 
phenotypic diversity of the tumor (Reya et al., 2001). 
Based on gene expression analysis and in vivo studies, the capacity to self-
renew was identified as one key property of both normal HSCs and LSCs, an 
ability that is normally lost during the process of cell differentiation. Therefore, 
an important question to answer is if LSCs are derived directly from normal 
adult HSCs, which escaped regulation networks, or from a more mature 
hematopoietic cell, e.g. a committed progenitor cell, which acquired the capacity 
to self-renew by genetic alterations. Due to the shared attribute of self-renewal 
capacity of both normal and leukemic stem cells, it was first suggested that 
leukemia originates from transformed HSCs by accumulation of multiple 
mutations. This was supported by the fact that the cells capable of initiating 
AML in the NOD/SCID mouse model (SCID leukemia-initiating cell, SL-IC) were 
highly enriched in the CD34-positive compartment (Lapidot et al., 1994; Bonnet 
and Dick, 1997). However, more and more evidence indicates that leukemia 
can also arise from more committed progenitors in which the self-renewal 
program is reactivated due to the activation of appropriate oncogenes 
(Figure 14). Krivtsov et al. (2006) for example described that committed 
granulocyte/monocyte progenitors (GMPs) expressing the fusion gene MLL-AF9 
undergo leukemic transformation. Another example is the CALM/AF10 murine 
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BM transplantation model, where the leukemia propagating cell was found to 
reside within the progenitor compartment positive for the lineage marker B220 
(Deshpande et al., 2006). 
Figure 14: Origin of CSCs. 
CSCs can either be derived from normal stem cells (a) with intrinsic self-renewal properties or 
from progenitor cells (b & c) which reacquired self-renewal properties by genetic lesions 
(Passegue, 2006). 
The fact that both leukemic and normal stem cell share the capacity to self-
renew leads to the assumption that the self-renewal capacity of both cell types 
is driven by equal pathways. Indeed, overlapping pathways were identified 
(Figure 15): BMI-1 for example is essential for the self-renewal of the normal 
HSC but is also indispensable to maintain the self-renewal properties of the 
LSC in the murine model of HOXA9 and MEIS1 coexpressing AML (Lessard 
and Sauvageau, 2003; Park et al., 2003). Frequently observed in cancer is also 
a deregulation of genes associated with embryonic development like SCL or 
RUNX1, which were initially identified because of their aberrant expression in 
leukemia (Izraeli, 2004; Ben-Porath et al., 2008). 
Another critical regulator of self-renewal is the WNT pathway, which was shown 
to regulate Hox expression in the embryo (Lohnes, 2003). Besides being 
required for normal stem cell function, this pathway also leads to leukemic 
transformation when deregulated (Reya et al., 2003; Petropoulos et al., 2008). 
Interestingly, in many tissues in which stem cells are regulated by the WNT 
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cascade, the cancer cells are strictly dependent on this pathway (Reya et al., 
2003). 
Another example is MLL, which regulates developmental processes during 
embryogenesis as a master regulator of Hox gene expression and is found to 
be a fusion partner of various proteins in leukemia. 
Also Hox genes themselves are able to induce leukemia when ectopically 
expressed (Owens and Hawley, 2002). Many of the lesions identified in AML in 
the murine model do not cause leukemia on their own and some of them, as for 
example AML1-ETO, have even been detected in cells of healthy individuals 
(Nucifora et al., 1993). In contrast, many HOX genes possess a strong 
oncogenic potential with their aberrant expression leading to induction of 
leukemia (Perkins et al., 1990; Thorsteinsdottir et al., 2002; Fischbach et al., 
2005). 
Figure 15: Deregulation of genes involved in stem cell self-renewal can cause induction 
of leukemia. 
LT-HSC: long-term hematopoietic stem cell, ST-HSC: short-term HSC, MPP: multipotent 
progenitor, CSC: cancer stem cell. 
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1.3 Homeobox Genes 
Members of the homeobox family are transcription factors characterized by a 
180 bp long homeobox sequence coding for a helix-turn-helix (HTH) motif. This 
region is called the homeodomain. By this highly conserved 60 amino acid (AA) 
region, homeodomain containing transcription factors bind to DNA and regulate 
the expression of their target genes which commonly are involved in 
development and differentiation (Billeter et al., 1993; Wintjens and Rooman, 
1996). 
Figure 16: Crystal Structure of two homeodomain peptides bound to DNA. 
Depicted are the two homeodomains of the HOX protein SCR (red) and the HOX-cofactor EXD 
(blue, homolog of the vertebrate PBX) in complex with DNA (Wang et al., 2009 PDB database 
entry 2r5y). The HOX protein interacts with the EXD cofactor via its N-terminal pentapeptide 
sequence, which is shown here in the binding pocket of EXD. 
HOX genes, as well as CDX genes belong to the ANTP (antennapedia) class of 
homeobox genes, which comprises 119 of 300 currently known (pseudo-) 
homeobox genes in the human. Members of the PAX family on the other hand 
belong to the second largest group, the PRD (paired) class containing 74 
genes. This classification groups eleven different families according to the 
homology to their Drosophila melanogaster counterparts 
(www.homeodb.cbi.pku.edu.cn/families. php?og=Human). However, homeobox 
genes can also be subgrouped depending on their chromosomal organization 
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into clustered homeobox or HOX genes, which are physically linked on a 
chromosome, and non-clustered homeobox genes, which are dispersed 
throughout the genome. Members of the CDX family are classified as non-
clustered homeobox genes. 
1.3.1 Hox Genes 
The clustered homeobox genes of the HOX family are well characterized. This 
conserved system can be found in all higher metazoans and is derived from one 
common ancestral cluster (Graham et al., 1989). Whereas most invertebrates 
like Drosophila possess only one Hox cluster, the cluster was amplified 
throughout evolution and as a result mammals, such as mouse and human 
possess four different Hox clusters (HOXA, HOXB, HOXC and HOXD) with 39 
different Hox genes. The position and order of homologous genes are 
preserved between the Hox clusters of different species (Figure 1) They are 
closely correlating with their spatial and temporal sequence of activation along 
the anterior-posterior axis of the embryo, a characteristic also termed 
“colinearity” (Gaunt, 1988; Duboule and Dolle, 1989; Duboule, 1994). In the 
embryo, expression of Hox genes was reported to be regulated by MLL as well 
as members of the CDX family (Subramanian et al., 1995; Ernst et al., 2004, 
Davidson et al., 2003; Chawengsaksophak et al., 2004). 
In the adult, Hox gene expression can be found in different organs such as 
kidney, colon and liver, each with a specific expression pattern (Cillo et al., 
1992; De Vita et al., 1993). The same applies to Hox gene expression in the 
hematopoietic tissue, where hematopoietic progenitors show the expression of 
HoxA and HoxB genes, but only a few genes of the HoxC cluster and none of 
the HoxD cluster are expressed (Sauvageau et al., 1994). Comparable to the 
embryonic development, expression of 3’ Hox genes can be observed mainly in 
the earliest hematopoietic progenitors. With advancing differentiation towards 
the committed progenitor stage, the expression shifts towards the more 5’ Hox 
genes (Magli et al., 1991; Giampaolo et al., 1994; Sauvageau et al., 1994). 
Hox genes are involved in the self-renewal of HSCs as well as the specification 
of the hematopoietic lineages. A knock down of HOXA5 in human BM cells for 
example leads to a shift from the granulocytic/monocytic hematopoiesis towards 
the erythroid lineage whereas an overexpression of HOXB4 leads to the 
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expansion of HSCs (Sauvageau et al., 1995; Fuller et al., 1999). In the mouse, 
Hoxa9 deficiency results in reduced granulocyte and lymphocyte counts 
(Lawrence et al., 1997). 
To allow final maturation of the hematopoietic cells, Hox gene expression needs 
to be silenced. An aberrant expression of Hox genes can lead to perturbation of 
hematopoietic differentiation and the induction of leukemia which was reported 
amongst others for Hoxa9, Hoxa10, Hoxb6 or Hoxb8 (Perkins and Cory, 1993; 
Borrow et al., 1996; Thorsteinsdottir et al., 1997; Fischbach et al., 2005; Bach et 
al., 2010, Figure 17). 
Figure 17: Deregulation of HOX genes in AML. 
Whereas the expression of most HOX genes is silenced in adult normal hematopoiesis, 
aberrant HOX gene expression is a frequent event in acute myeloid leukemia and leads to a 
block of differentiation. 
As mentioned in section 1.2.1, deregulation of HOX genes can be observed in a 
major subset of human leukemia. However, in only 5-10% of patients this 
aberrant expression can be explained by deregulation of the HOX upstream 
regulator MLL (Falini et al., 2007, Figure 9). The reason for aberrant HOX gene 
expression in human leukemia in many cases still remains to be solved. 
1.3.2 Cdx Genes 
Evolutionary, the Caudal-type or Cdx genes are most closely related to the 
posterior Hox genes (Figure 18) and are equally important for the AP patterning 
during embryogenesis. Caudal genes contribute to posterior segmentation and 
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deficiency of these genes leads amongst others to posterior truncation of the 
embryo, shown for example in zebrafish or mouse (Hammerschmidt et al., 
1996; van den Akker et al., 2002). 
Figure 18: Hox and ParaHox gene clusters originate from a common ancestral cluster. 
Whereby Gsx genes are related to anterior and Xlox genes to group 3 Hox genes, Cdx genes 
and posterior Hox genes are derived from the same common ancestor (Brooke et al., 1998). 
Whereas the Drosophila Cad is involved in segment specification in a HOX-like 
manner, vertebrate CDX proteins act upstream of Hox genes as transducers of 
positional information (Charite et al., 1998; Lohnes, 2003). Members of the 
vertebrate CDX family act as master regulators of Hox gene expression through 
conserved CDX binding sites, which were identified in the cis-regulatory 
elements of several Hox genes (Subramanian et al., 1995; Gaunt et al., 2004; 
Tabaries et al., 2005). Like most homeobox proteins, CDX members possess a 
conserved YPWM motif (also called hexa- or pentapeptide) as well, which 
allows binding of PBC proteins like PBX. 
Figure 19: Domain structure of Cdx genes. 
Green: N-terminal transactivation domain, yellow: homeodomain, violet: PBX interacting motif. 
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CDX1 
Cdx1 was the first Cdx gene isolated from mouse (Duprey et al., 1988) where it 
is expressed starting from day 7.5 post coitum (p.c.). Embryos deficient for 
CDX1 expression show an anterior homeotic transformation accompanied by a 
posterior shift of Hox expression (Subramanian et al., 1995). 
In the adult, CDX1 is known to be involved in the intestinal differentiation and 
the development of intestinal metaplasias (Wong et al., 2005; Bonhomme et al., 
2008). In normal adult hematopoietic tissue, however, no expression of this 
homeobox gene has been reported. 
CDX2 
A knock out of Cdx2, which is the only Cdx member expressed in the extra-
embryonic ectoderm, results in trophoectodermal defects and leads to 
embryonic lethality at day 3.5 due to implantation failure (Chawengsaksophak et 
al., 1997). The expression of the trophoectodermal marker Cdx2 was suggested 
to be positively regulated by RAS/ERK signaling (Lu et al., 2008). 
Cdx2+/- mice are viable, but show a phenotype similar to Cdx1-/- animals with an 
anterior homeotic shift (Chawengsaksophak et al., 1997). A combination of 
Cdx2 heterozygocity with a heterozygous mutation of Cdx1 leads to AP 
patterning defects with a higher penetrance and more severe than the sum of 
defects observed in both the single Cdx mutant mice. Furthermore, an 
exchange of Cdx2 by Cdx1 in a knock-in mouse model was able to fully 
substitute for CDX1 function and thus suggests a certain redundancy between 
members of the Cdx family (van den Akker et al., 2002; Savory et al., 2009). 
From day 12.5 on as well as in the adult, expression of Cdx2 is restricted almost 
exclusively to the intestine like gut epithelium (James and Kazenwadel, 1991) 
and to the α-cells of the pancreas where it activates expression of proglucagon 
(Liu et al., 2006). There is substantial evidence suggesting CDX2 acts as a 
tumor suppressor in the intestine. Mice heterozygous for Cdx2 for example 
show a high incidence of colorectal tumors and in human colorectal carcinomas 
Cdx2 expression was shown to be downregulated as well as to inversely 
correlate to the tumor grade (Chawengsaksophak et al., 1997; Tamai et al., 
1999). Ectopic Cdx2 expression in the stomach or esophagus, on the other 
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hand, has been attributed to the development of intestinal metaplasias (Silberg 
et al., 2002; Almeida et al., 2003; Eda et al., 2003). Interestingly, in colorectal 
carcinoma Cdx2 expression has been shown to be downregulated by a hyper-
activated RAS/ERK pathway, hereby highlighting the differential regulation of 
Cdx2 in adult intestine compared to embryonic tissue (Krueger et al., 2009). 
Cdx2 furthermore is supposed to be targeted by FGF4-FRS2α signaling and to 
induce expression of Bmp4 upon stimulation by this pathway (Murohashi et al., 
2009). Murohashi et al. also found Cdx2 to be a downstream target of ERK in 
trophoblast stem cells and are hereby in line with the results of Lu et al. (2008). 
As described for CDX1, CDX2 positively regulates its own expression. 
Additionally, it is able to cross-regulate the expression of Cdx1 (Xu et al., 1999; 
Mutoh et al., 2009). 
CDX4 
The third member of the caudal family, Cdx4, shows a peak of expression 
during the late streak stage of murine embryonic development (Gamer and 
Wright, 1993) and promotes the differentiation of the hemangioblast towards the 
hematopoietic lineage compared to the endothelial lineage (Wang et al., 2005; 
McKinney-Freeman et al., 2008). Interestingly, compared to CDX1 and CDX2, 
which both suppress hematopoietic factors like GATA-1, PU.1 or RUNX1 and 
inhibit embryonic hematopoietic activity by blocking progenitor differentiation, 
CDX4 strongly induces hematopoietic progenitor formation and confers 
multilineage engraftment potential to embryonic stem cell-derived hematopoietic 
cells (Wang et al., 2005; McKinney-Freeman et al., 2008, Figure 20). 
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Figure 20: Differential effect of CDX proteins on ESC-derived hematopoiesis. 
According to McKinney-Freeman et al. (2008) Cdx genes affect both the formation of 
hematopoietic progenitors and also the hematopoietic potential of already specified progenitors. 
Overexpression of CDX4 in murine ES cells furthermore leads to an effect 
similar to the one observed with HOXB4 with an expansion of stem and 
progenitor cells. Hereby, CDX4 revealed an even stronger stem cell 
amplificatory potential than HOXB4 (Davidson et al., 2003). 
As demonstrated in zebrafish, Cdx4 is important for embryonic blood formation, 
especially for specifying erythroid lineage (Davidson et al., 2003). In this model, 
a loss-of-function mutation of Cdx4 led to perturbation of early hematopoiesis 
mainly due to a severe reduction of hemoglobin-expressing erythroid cells. This 
bloodless phenotype went along with tail defects and an altered expression 
pattern of posterior hox genes suggesting that the deficiency for Cdx4 led to an 
aberrant mesodermal patterning. The phenotype was rescued by 
overexpression of hoxb7a or hoxa9. An additional knock down of cdx1 in a cdx4 
deficient background resulted in a complete failure to specify blood precursors 
and led to a deficiency in forming definitive HSCs as well (Davidson and Zon, 
2006). Also in the latter case, embryonic erythropoiesis as well as HSC 
specification was rescued by hoxa9 overexpression, indicating that the effect of 
Cdx4 in particular is mediated via regulation of hox gene expression. The more 
severe effects of compound Cdx mutants compared to single Cdx mutants 
again suggest partial redundancy of Cdx members (Davidson and Zon, 2006; 
Faas and Isaacs, 2009). 
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Similar to CDX1, CDX4 is also involved in retinoic acid (RA) signaling and was 
shown to regulate expression patterns of raldh2 and the RA catabolizing 
cyp26a1 (Wingert et al., 2007). Both Cdx genes are targets of WNT signaling, 
and are positively regulated by BMP4 and suppressed by Noggin. CDX1 and 
CDX4 were shown to indirectly crossregulate each other by upregulation of 
Wnt3a expression, suggesting WNT3A as well as CDX1 and CDX4 to be part of 
a positive feedback loop (Lengerke et al., 2008; Faas and Isaacs, 2009). 
Furthermore, FGF signaling has been linked to the expression of Cdx4 (Pownall 
et al., 1996; Keenan et al., 2006; Shimizu et al., 2006). 
CDX2 in Leukemia 
Usually, chromosomal translocations involve and activate genes which encode 
proteins controlling cell differentiation, developmental processes and important 
transcriptional pathways (Armstrong and Look, 2005). The developmental gene 
CDX2 was found to be targeted by such a translocation, which was reported by 
Chase et al. in 1999. In a patient with chronic myeloid leukemia, a 
t(12;13)(p13;q12) translocation was identified resulting in the ETV6-CDX2 
fusion gene. The fusion partner, ETV6/TEL1 is an important regulator of 
hematopoietic stem cell survival and frequently affected by translocations (Hock 
et al., 2004). However, Rawat et al. (2004) showed that in the case of the 
ETV6-CDX2 positive leukemia it was the ectopic expression of the 
protooncogene Cdx2, and not the expression of the fusion gene, that led to 
induction of AML in the murine BM transplantation model. The coexpression of 
the fusion gene hereby did not accelerate the course of disease (Figure 21). 
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Figure 21: Ectopic expression of Cdx2 is the transforming event in a mouse model of 
t(12;13)(p13;q12) acute myeloid leukemia (Rawat et al., 2004). 
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2. AIM OF THE STUDY 
Deregulation of HOX genes is a frequently observed phenomenon in acute 
leukemia, especially in acute myeloid leukemia with normal karyotype. So far, 
only in a small subset of these cases the cause for the aberrant HOX 
expression is known. For the vast majority of patients the reason for HOX gene 
deregulation remains unclear. From embryogenesis, members of the CDX 
family are known to be upstream regulators of HOX genes. Based on a single 
case observation in human AML, our lab previously demonstrated that ectopic 
expression of CDX2 induces AML in the murine BM transplantation model 
(2004). However, the role of CDX genes in murine normal and human malignant 
hematopoiesis remained largely unknown. 
One intention of this study therefore was to analyze the role of CDX genes in 
acute leukemia patients with HOX gene deregulation. Furthermore, it was to be 
functionally tested if CDX factors possess the ability to regulate HOX gene 
expression in adult hematopoiesis as well. In contrast to the leukemogenic 
CDX2, Davidson et al. (2003) described another CDX family member, CDX4, to 
possess stem cell amplificatory potential, thereby leading to the expansion of 
hematopoietic progenitors during murine embryonic development. Like the stem 
cell amplificatory HOXB4, CDX4 also seemed to play a role in stem cell self-
renewal. Based on this finding, one major focus of this work was to investigate 
the role of CDX4 in adult murine hematopoiesis in vitro and in vivo by 
establishing and analyzing a murine BM transplantation model. 
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3. MATERIAL 
3.1 Reagents 
1 kb plus ladder New England BioLabs, Ipswich, MA, USA 
100 bp DNA ladder New England BioLabs, Ipswich, MA, USA 
5-fluorouracil TEVA-GRY-Pharma GmbH, Kirchzarten, 
Germany 
Agar Sigma-Aldrich, Taufkirchen, Germany 
Agarose Sigma-Aldrich, Taufkirchen, Germany 
β- Mercaptoethanol Sigma-Aldrich, Taufkirchen, Germany 
Bromphenol blue  Sigma-Aldrich, Taufkirchen, Germany 
Calcium chloride Sigma-Aldrich, Taufkirchen, Germany 
Cholorquine Sigma-Aldrich, Taufkirchen, Germany 
DNAzol reagent Invitrogen, Carlsbad, CA, USA 
Ethanol Sigma-Aldrich, Taufkirchen, Germany 
Ethidium bromide Sigma-Aldrich, Taufkirchen, Germany 
Formaldehyde 40% Sigma-Aldrich, Taufkirchen, Germany 
Giemsa’s azur eosin-methylene 
blue 
Merck, Whitehouse Station, NY, USA 
HEPES GIBCO, Karlsruhe, Germany  
Isopropanol Sigma-Aldrich, Taufkirchen, Germany 
Luria agar Gibco/ Invitrogen, Carlsbad, CA, USA 
Luria broth base Gibco/ Invitrogen, Carlsbad, CA, USA 
May-Grünwald’s eosine-methylene 
blue (mod.) 
Merck, Whitehouse Station, NY, USA 
Methanol Sigma-Aldrich, Taufkirchen, Germany 
Methylcellulose M3434 Stem Cell Technologies, Vancouver, BC, 
Canada 
Methylcellulose M3630 Stem Cell Technologies, Vancouver, BC, 
Canada 
PCR enhancer system Gibco/ Invitrogen, Carlsbad, CA, USA 
Propidium iodide Sigma-Aldrich, Taufkirchen, Germany 
Protease inhibitor cocktail I & II Sigma-Aldrich, Taufkirchen, Germany 
SDS Sigma-Aldrich, Taufkirchen, Germany 
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Sodium chloride Sigma-Aldrich, Taufkirchen, Germany 
TaqMan Universal PCR Master 
Mix NoUNG 
Applied Biosystems, Foster City, CA, 
USA 
Trizol reagent Invitrogen, Carlsbad, CA, USA 
3.2 Consumables 
6-well plates Sarstedt, Newton, NC, USA 
15 ml tubes Sarstedt, Newton, NC, USA 
96-well plates Sarstedt, Newton, NC, USA 
Blunt end needles Stem Cell Technologies, Vancouver, 
Kanada 
Cell culture dishes 100 mm Corning, NY, USA 
Cell culture dishes 150 mm Corning, NY, USA 
Cell scraper Sarstedt, Newton, NC, USA 
Cell strainer Becton Dickinson, Franklin Lakes, NJ, 
USA 
Cryo tubes Nunc, Rochester, NY, USA 
FACS tubes Becton Dickinson, Franklin Lakes, NJ, 
USA 
Filtercards for cytospin Thermo Shandon, Runcore, Chesire, 
England 
Microspin S-300 HR columns Amersham Biosciences, Uppsala, 
Sweden 
Microvettes Sarstedt, Newton, NC, USA 
PCR softtubes Biozym, Oldendorf, Germany 
Petri dishes 100 mm Becton Dickinson, Franklin Lakes, NJ, 
USA 
Protran nitrocellulose transfer 
membrane 
Schleicher & Schuell, Dassel, Germany 
Hybond N membrane Amersham Biosciences, Uppsala, 
Sweden 
Sterile cover sheets Hartmann, Heidenheim, Germany 
Syringe filters 45 and 22 µm Millipore, Billerica, MA, USA 
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3.3 Media and Supplements for Cell Culture 
ACl Stem Cell Technologies, Vancouver, Kanada 
Ciprobay 400 Bayer, Leverkusen, Germany 
Chloroquine Sigma-Aldrich, Taufkirchen, Germany 
DMEM PAN Biotech, Aidenbach, Germany 
DMSO Sigma-Aldrich, Taufkirchen, Germany 
Fetal bovine serum PAN Biotech, Aidenbach, Germany 
IMDM Gibco/ Invitrogen, Carlsbad, CA, USA  
Methocult M3434 Stem Cell Technologies, Vancouver, Canada 
Methocult M3630 Stem Cell Technologies, Vancouver, Canada 
mIL-3 ImmunoTools, Friesoythe, Germany 
mIL-6 ImmunoTools, Friesoythe, Germany 
mSCF ImmunoTools, Friesoythe, Germany 
PBS PAN Biotech, Aidenbach, Germany 
Penicillin/ Streptomycin PAN Biotech, Aidenbach, Germany 
Protamine sulfate Sigma-Aldrich, Taufkirchen, Germany 
RPMI PAN Biotech, Aidenbach, Germany 
Terasaki Park medium BAG Healthcare, Lich, Germany 
Trypan blue Gibco/ Invitrogen, Carlsbad, CA, USA  
Trypsin/ EDTA Gibco/ Invitrogen, Carlsbad, CA, USA  
3.4 Enzymes 
DNA ligase T4 New England BioLabs, Ipswich, MA, USA 
Restriction enzymes New England BioLabs, Ipswich, MA, USA 
Enzymes for PCR and radioactive labeling were purchased as components of 
Kits (see chapter 3.6) 
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3.5 FACS α-Mouse Antibodies 
All antibodies were purchased from BD Pharmingen, Franklin Lakes, USA. 
Tag Antigen Clone BD Cat. Target 
PE Sca-1 (Ly-6A/E)  D7 553108 Hematopoietic stem and 
progenitor cells 
Gr-1 (Ly-6C/ Ly-6G) RB6-8C5 553128 Granulocytes 
CD19 1D3 553786 B-lymphocytes 
CD8a (Ly-2) 53-6.7 553033 T-lymphocytes 
Ter119 (Ly-76) TER-119 553673 Erythroid cells 
CD45.1 (Ly-5.1) A20 553776 Hematopoietic cells of PEB 
APC c-Kit/ CD117 2B8 553356 Hematopoietic stem and 
progenitor cells 
Mac-1/ CD11b M1/70 553312 Myelomonocytic cells 
B220/ CD45R RA3-6B2 553092 B-lymphocytes (+ lymphoid 
dendritic cells) 
CD4 (L3T4) RM4-5 553051 T-lymphocytes 
NK-1.1 (NKR-P1B, 
NKR-P1C) 
PK136 550672 Natural killer cells 
3.6 Kits 
Kit Company 
GenElute Plasmid Miniprep Kit Sigma-Aldrich, St. Louis, MO, USA 
GenElute HP Plasmid Maxiprep 
Kit 
Sigma-Aldrich, St. Louis, MO, USA 
GenElute HP Endotoxin-Free 
Plasmid Maxiprep Kit 
Sigma-Aldrich, St. Louis, MO, USA 
illustra GFX PCR DNA and Gel 
Band Purification Kit 
GE Healthcare, Waukesha, WI, USA 
Megaprime DNA labeling system Amersham Biosciences, Uppsala, Sweden 
Mycoplasma Detection Kit Roche, Basel, Switzerland 
Platinum Taq Polymerase Kit Invitrogen, Carlsbad, CA, USA 
QickChange II XL Site-Directed 
Mutagenesis Kit 
Stratagene, La Jolla, CA, USA 
RNeasy Micro Kit Quiagen, Hilden, Germany 
ThermoScript RT-PCR System 
(cDNA synthesis for PCR) 
Invitrogen, Carlsbad, CA, USA 
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3.7 Kits, Material and Reagents for Microarray 
Acetylated BSA Invitrogen 
cDNA Synthesis System 
(cDNA synthesis for microarray) 
Roche Applied Science, Basel, Switzerland 
GeneChip® Expression 3’-
Amplification Reagents 
Hybridization Control Kit 
Affymetrix, Santa Clara, CA USA 
GeneChip® Sample Cleanup 
Module 
Affymetrix, Santa Clara, CA USA 
GeneChip® IVT cRNA Cleanup 
Kit 
Affymetrix, Santa Clara, CA USA 
GeneChip® Expression 3’-
Amplification Reagents for IVT 
Labeling 
Affymetrix, Santa Clara, CA USA 
Herring Sperm DNA Promega, Madison, WI, USA 
R-Phycoerythrin-conjugated 
Streptavidin 
Jackson ImmunoResearch, West Grove, 
PA, USA 
3.8 Oligonucleotides 
Primer for Standard PCR and Sequencing 
PCR Primer Sequence 5’ → 3’ Tann. [°C] 
Product 
Length [b] Comment 
Murine 
pMSCV.for/ MIG_Seq.rev 
for CAG CCC TCA CTC CTT CTC TA 
58 
100 
(w/o insert) 
 
rev CCT AGG AAT GCT CGT CAA G  
HPRT_fuxa 
for GGG GGC TAT AAG TTC TTT GC 
59 312 
 
rev TCC AAC ACT TCG AGA GGT CC  
Cdx4end 
for CAG CCA ATC GAG ATA CAG CA 59 - for sequencing 
Cdx4 
rev TTA CAG GGA CCT CAG GAT GG 59 222 bp with Cdx2.FP exon 2  
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PCR Primer Sequence 5’ → 3’ Tann. [°C] 
Product 
Length [b] Comment 
Cdx4 
FP AGT GCC CAT GAA TGA CAT GA 
59 344 exon 1 - exon 2 
RP CCA GCT CTG ACT TCC TCC TG 
Human 
hsCDX4 full length 
for ATG TAC GGA AGC TGT CTT TTG 
57 855 
 
rev TCA TTC GGA GAC TAT AAC CTG CT  
CDX2_hum_clon 
for CGG GAA TTC ATG TAC GTG AGC TAC 
CTC CTG 
58 924 Contains EcoRI and XhoI restriction sites rev GGC CTC GAG TCA CTG GGT GAC GGT 
GGG GTT 
CDX2 Exon1.for/ Exon2.rev 
for ACG TGA GCT ACC TCC TGG AC 
58 558 
 
rev TGT CTT TCG TCC TGG TTT TCAa  
CDX2 Exon2.for/ Exon3.rev 
for TGA AAA CCA GGA CGA AAG ACA 
58 1261 
 
rev TAC TCC CCA CTT CCC TTC AC  
CDX2 Exon1neu.for/ Exon3neu.rev 
for CAG ACT ACC ATC CGC ACC AC 
58 708 
 
rev TGC GGT TCT GAA ACC AGA TT  
ACTB_hu 
for CTT CAA CAC CCC AGC CAT 
55 260 not intron-spanning 
rev TAA TGT CAC GCA CGA TTT CC 
Others 
pGL3 basic.rev (= GLprimer2, Promega) 
rev CTT TAT GTT TTT GGC GTC TTC CA sequencing of pGL3 
Mutagenesis Primer 
Cdx4 W157A 
for CAC AGC CCC TAC GCA GCG ATG CGC AAA ACT GTG mutagenesis of Pbx-
binding site rev CAC AGT TTT GCG CAT CGC TGC GTA GGG GCT GTG 
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Cdx4 N51S 
for T CTG GTT TCA GTC TCG CAG AGC CAA GGA GAG G mutagenesis of 
homeodomain rev C CTC TCC TTG GCT CTG CGA GAC TGA AAC CAG A 
Cdx4 S153M 
for GC AGG AGC CGT CAC ATG CCC TAC GCA TGG ATG introduction start 
codon for deltaN rev CAT CCA TGC GTA GGG CAT GTG ACG GCT CCT GC 
Cdx4 deltaN EcoRI.for/ XhoI.rev neu 
for GAA TTC ATG CCC TAC GCA TGG ATG C introduction 
restriction sites for 
deltaN rev GCA GGT CAT AGT TTC TGA ATG ACT CGA G 
shRNAs 
shRNA Sequence 5’ → 3’ (mature siRNA sequence is underlined) 
sh_Cdx4_759 
TGCTGTTGACAGTGAGCGACCGGAGAACTGCCTAACGCTTTAGTGAAGCCACAGATGTAA
AGCGTTAGGCAGTTCTCCGGGTGCCTACTGCCTCGGA 
sh_Cdx4_628 
TGCTGTTGACAGTGAGCGACCTTTCTGAGAGACAGGTGAATAGTGAAGCCACAGATGTATT
CACCTGTCTCTCAGAAAGGCTGCCTACTGCCTCGGA 
sh_Cdx4_112 
TGCTGTTGACAGTGAGCGATCTGCCTGCCTCCAACTTTACTAGTGAAGCCACAGATGTAGT
AAAGTTGGAGGCAGGCAGAGTGCCTACTGCCTCGGA 
sh_Cdx4_719 
TGCTGTTGACAGTGAGCGCGGAGGTTCCGTGCAAAGTGACTAGTGAAGCCACAGATGTAG
TCACTTTGCACGGAACCTCCATGCCTACTGCCTCGGA 
sh_CDX2_487 
TGCTGTTGACAGTGAGCGAGCGGAACCTGTGCGAGTGGATTAGTGAAGCCACAGATGTAA
TCCACTCGCACAGGTTCCGCCTGCCTACTGCCTCGGA 
sh_CDX2_673 
TGCTGTTGACAGTGAGCGAGCTCTCTGAGAGGCAGGTTAATAGTGAAGCCACAGATGTATT
AACCTGCCTCTCAGAGAGCCTGCCTACTGCCTCGGA 
sh_CDX2_672 
TGCTGTTGACAGTGAGCGAGGCTCTCTGAGAGGCAGGTTATAGTGAAGCCACAGATGTAT
AACCTGCCTCTCAGAGAGCCCTGCCTACTGCCTCGGA 
sh_CDX2 698 
TGCTGTTGACAGTGAGCGATTTCAGAACCGCAGAGCAAAGTAGTGAAGCCACAGATGTAC
TTTGCTCTGCGGTTCTGAAACTGCCTACTGCCTCGGA 
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Oligonucleotides for Linker Mediated PCR 
PstI-Linker 
for CTCTCCCTTCTCGTCCTCTCCTTCCTGCA 
rev GGAAGGAGAGGACGCTGTCTGTCGAAGGTAAGGAACGGACGAGAGAAGGGAGAG 
PCR A (Vectorette/ GFP-A) 
for CGAATCGTAACCGTTCGTACGAGAATCGCT 
rev ACTTCAAGATCCGCCACAAC 
PCR B (Nested Vectorette/ GFP-C) 
for TACGAGAATCGCTGTCCTCTCCTT 
rev ACATGGTCCTGCTGGAGTTC 
Assays for qRT-PCR 
All assays for qRT-PCR, which were performed using the TaqMan 7900HT 
system, were purchased from Applied Biosystems, Foster City, CA, USA. 
 Gene Symbol Assay ID/ Product No 
Murine  
 Cdx1 Mm00438172_m1 
 Cdx2 Mm01212280_m1 
 Cdx4 Mm00432452_m1 
 Gapdh (housekeeping gene) 4352932E 
 Hoxa5 Mm00439362_m1 
 Hoxa7 Mm00657963_m1 
 Hoxa9 Mm00439364_m1 
 Hoxa10 Mm00433966_m1 
 Hoxb3 Mm00650701_m1 
 Hoxb6 Mm00433970_m1 
 Hoxb8 Mm00439368_m1 
 Hoxb9 Mm01700220_m1 
 
 
 
 
 
 
  
   
Material 39 
 Gene Symbol Assay ID/ Product No 
Human  
 CDX1 Hs00156451_m1 
 CDX2 Hs01078080_m1 
 CDX4 Hs00193194_m1 
 GSH1 Hs00793699_g1 
 GSH2 Hs00370195_m1 
 HOXA5 Hs00430330_m1 
 HOXA7 Hs00600844_m1 
 HOXA9 Hs00365956_m1 
 HOXA10 Hs00172012_m1 
 HOXB3 Hs00231127_m1 
 HOXB6 Hs00980016_m1 
 HOXB8 Hs00256885_m1 
 LEF1 Hs01547248_m1 
 PDX1 Hs00236830_m1 
 TBP (housekeeping gene) 4333769F 
3.9 Buffers and Stock Solutions 
Cytokine Cocktail (100x) 10 mg/ ml mSCF 
 1 mg/ ml mIL6 
 600 ng/ ml mIL3 
 dissolved in DMEM, stored at -20°C 
  
Freezing medium 90% FBS 
 10% DMSO 
  
HBS  
(hepes buffered saline, ½ x) 
50 mM hepes 
280 mM NaCl 
 0.75 mM Na2HPO4 
 0.75 mM NaH2PO4 
 adjust pH to 7.2/ 7.0 (depending on cell type) 
 stored at 4°C 
  
FACS buffer (1x) 5 µg/ ml propidium iodide 
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 2% FBS 
 in PBS, stored in dark at 4°C 
  
Hybridization solution for 
Southern Blot 
4.0 g fat free milk powder 
40.0 g dextran sulphate 
 120.0 ml 20x SSC 
 40.0 ml formamide 
 20.0 ml 20% SDS 
 1.6 ml 500 mM EDTA 
 ad 500 ml aqua dest. 
  
5x loading buffer for SDS page 31.35 ml 1 M Tris/HCl pH 6.8 
 10 g SDS 
 25 ml Glycerol 
 250 mg Bromphenolblue 
 5 ml β-Mercaptoethanol 
 ad 100 ml aqua dest. 
  
Neutral buffered formalin 4% 55 mM Na2HPO4 (water free) 
 12 mM NaH2PO4 x 2 H2O 
 ad 900 ml aqua dest. 
 100 ml formaldehyde 40% 
 stored in dark at RT 
  
20x SSC 525.9 g NaCl 
 264.6 g NaCitrate 
 ad 3,000 ml aqua dest. 
 pH adjusted to 7.0 
  
TB buffer (1x) 10 mM hepes 
15 mM CaCl2 x 2 H2O 
250 mM KCl 
35 mM MnCl2 
 ad 125 ml aqua dest. 
 sterile filtrated, always made fresh 
TAE buffer (50x) 2 M Tris 
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 50 mM EDTA-Na2 x 2H2O 
 1 M Acetic Acid 
 pH adjusted to 8.5 
  
  
TE buffer (100x) 1 M Tris 
 100 mM EDTA-Na2 x 2 H2O 
 pH adjusted to 8.0 
3.10 Technical Equipment 
7900HT real-time PCR System Applied Biosystems, Foster City, CA, USA 
137Cs source Gammacell 40 Atomic Energy of Canada Limited, 
Missisauga, Ontario, Kanada 
Cyclone 25 PCR Cycler PeqLab, Erlangen, Germany 
FACSCalibur Becton Dickinson, Franklin Lakes, NJ, USA  
FACSVantage Becton Dickinson, Franklin Lakes, NJ, USA 
NanoDrop 1000 
spectrophotometer 
Thermo Fisher Scientific, Waltham, MA, 
USA 
Shandon Cytospin 2 Centrifuge Thermo Fisher Scientific, Waltham, MA, 
USA 
UV GS gene linker. Bio-Rad, Hercules, CA, USA 
3.11 Bacteria Strains 
XL10-Gold® ultracompetent E.coli (TetrΔ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 
endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F´ proAB lacIqZDM15 Tn10 
(Tetr) Amy Camr], Stratagene, La Jolla, CA, USA) were purchased in 
combination with the QuikChange Kit and were used for the transformation of 
the mutated plasmids. For all other purposes DH5α (fhuA2 Δ(argF-lacZ)U169 
phoA glnV44 Φ80 Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17) were 
used. 
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3.12 Cell Lines 
293T human embryonic kidney cell line 
32D mouse myeloid cell line 
NIH-3T3 mouse embryonic fibroblast cell line 
GP+E-86 ecotropic packaging cell line for retroviral 
gene transfer, derived from NIH-3T3 
Phoenix Eco helper-virus free packaging cell line, derived 
from 293T; highly transfectable by calcium 
phosphate- or lipid-based transfection 
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4. METHODS 
4.1 Molecular Biology Methods 
4.1.1 RNA Extraction 
Cell pellets were resuspended in 1 ml Trizol and incubated 5 min at RT. After 
addition of 200 µl chloroform per 1 ml Trizol, the mixture was vortexed for 10 s 
and incubated 10 min at RT. By a 15 min centrifugation step at 12000 rpm and 
4°C, the RNA containing aqueous phase was separated from the lower phenol 
phase. The aqueous phase was transferred to a new tube and mixed with an 
equal volume of isopropanol by inverting several times. The mixture was 
incubated for 10 min at RT and afterwards centrifugated 10 min at 12000 rpm 
and 4°C to precipitate the RNA. The resulting pellet was washed twice with 500 
µl EtOH. To remove residual ethanol, the pellet was dried at RT for several 
minutes. RNA was dissolved in DEPC-treated, RNase free H2O and heated 10 
min at 55°C to completely dissolve the RNA pellet. Dissolved RNA was stored 
at -80°C. 
4.1.2 DNA Extraction 
Cells were resuspended in DNAzol (1 ml per 10 cm dish) and lysed by careful 
pipetting. After 10 min centrifugation at 10.000 g and 4°C, the supernatant was 
transferred into a fresh tube. For precipitation of DNA, 500 µl of 100% EtOH 
was added per 1 ml DNAzol and was then mixed well by vigorous shaking. After 
taking off the supernatant, the DNA pellet was washed twice with 1 ml 75% 
EtOH and after drying resuspended in an appropriate volume of H2O. Dissolved 
genomic DNA was stored at 4°C. 
4.1.3 Quantification of RNA and DNA 
RNA and DNA concentrations were photometrically measured using a 
Nanodrop 1000 spectrophotometer (Thermo Fisher Scientific) at a wavelength 
of 260 nm, which is the absorption peak of nucleic acids. By simultaneously 
measuring the absorption at 280 nm (absorption peak of aromatic amino acids 
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in proteins), the purity of the extract can be estimated. The ratio of A260 to A280 
therefore should be as high as possible and normally is between 1.8 (when 
measured against water) and 2.1 (when measured against Tris buffer). A third 
measuring point at 230 nm can give information about other impurities such as 
salts or phenolic residues. 
4.1.4 Polymerase Chain Reaction (PCR) 
Reverse Transcription PCR 
During reverse transcription (RT), RNA is transcribed into complementary 
cDNA. Besides reverse transcriptase and dNTPs, MgCl2 as a cofactor is also 
needed and is included in the reaction buffer. Random hexamers were used to 
synthesize a complete cDNA library of the total RNA sample. Per 20 µl reaction 
1 µg of RNA was used and filled up to 9 µl with DEPC treated H2O. After 
addition of dNTPs and hexamers, the sample was heated 5 min at 65°C for 
complete denaturation of RNA, then rapidly cooled down on ice to prevent new 
formation of secondary structures. The remaining reagents were added to the 
sample and the mixture successively incubated 10 min at 25°C for primer 
annealing, 50 min at 50°C for synthesis of the DNA strand and 5 min at 85°C for 
inactivation of the reverse transcriptase. For detection of contaminations with 
genomic DNA, RT controls - containing RNA but no enzyme - were performed. 
Until further usage, cDNA samples were stored at -20°C. 
 Volume [µl] 
total RNA ad 10 μl DEPC H2O [µl] 10.0 
10 mM dNTP mix [µl] 2.0 
Random hexamers (50 ng/µl) [µl] 1.0 
5 x cDNA synthesis buffer 4.0 
dTT 0.1 M [µl] 1.0 
RNaseOut 40 U/µl [µl] 1.0 
ThermoScript RT (15 U/µl) 1.0 
Total Volume 20.0 
Tab. 1: Reaction components for RT-PCR. 
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Standard PCR 
For PCR, two specific primers are used to amplify one defined DNA region. The 
primers anneal to the complementary DNA sequence and enable the 
polymerase to attach to the DNA. Normally Taq DNA polymerase is employed, 
an enzyme isolated from the thermophilic bacterium thermus aquaticus. For 
amplification of longer transcripts, special high fidelity polymerases are used.  
The standard PCR consists of a number of cycles, each containing three steps: 
For denaturation of the double-stranded DNA, the sample is heated at 95°C for 
30 s. To enable the annealing of both primers, in the next step the sample is 
cooled down to 55-65°C, with the exact temperature depending on the length 
and GC content of the primer pair in use. Last, in the extension step, the new 
strand is synthesized at the temperature optimum of the polymerase, which for 
example is 72°C for the Platinum® Taq DNA polymerase (Invitrogen) routinely 
used in this study. Ideally, each newly synthesized strand will act as template in 
the next cycle, which would lead to a doubling of PCR products in each cycle 
with a number of 2n products after n cycles. In fact, the PCR efficiency is lower 
and generally is around 1.80-1.85. 
The following reaction components and conditions were used: 
Table 1: Reaction components for standard PCR. 
 Volume [μl] 
10x buffer -Mg 2.50 
MgCl2 50 mM 0.75 
dNTP mix 10 mM 0.50 
Forward primer 0.50 
Reverse primer 0.50 
Taq polymerase 5 U/µl 0.10 
Template DNA 1.0 
PCR-H2O  ad 25.0 
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Step No Cycle(s) 
Target 
Temp. [°C] 
Time 
[s] 
Denaturation 1 94 120 
Denaturation 
ps 
94 30 
Annealing ps 30 
Extension 72 ps 
Extension 1 72 120 
Table 2: Cycler program for standard PCR. 
ps = product-/ primer-specific parameter, Table 3. 
Primer Annealing [°C] 
No 
Cycles 
Elongation 
Time [s] 
Hprt 60 35 30 
Cdx4 FP/rev 59 35 30 
MSCV.for/MIG.Seq.rev 58 30 30 
β-Aktin 58 28 30 
hsCDX4 fl 58 30 60 
Cdx2_hum_clon 62 30 60 
CDX2 E1.for/E2.rev 58 30 30 
CDX2 E2.for/E3.rev 58 30 90 
CDX2 E1short.for/E2short.rev 60 35 20 
CDX2 E2short.for/E3short.rev 60 35 20 
Table 3: Product-/ primer specific parameters for standard PCR. 
To reamplify PCR products, either the whole PCR product, diluted or undiluted, 
or the gel-purified product was used as template for a new PCR reaction. In the 
latter case, the band was either purified using the illustra GFX PCR DNA and 
Gel Band Purification Kit according to manufacturer’s instruction or the band 
was cut and crushed in a 1.5 ml tube with about 50 µl of PCR-grade H2O. 1 µl of 
the supernatant was transferred in the new reaction as template. 
Site Directed Mutagenesis PCR 
For introduction of point mutations or deletions of a few bases into plasmid 
DNA, the “QickChange II XL Site-Directed Mutagenesis Kit” (Stratagene) was 
used. In brief, after denaturation of the plasmid, the mutagenic primers 
containing the desired mutation anneal to the single strand DNA. Both 
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oligonucleotides cover the same region of the DNA strand and are designed 
using following formula: 
TM = 81.5 + 0.41 x %GC - 675/N - %mismatch 
N: length of primer, between 25 and 45 b with mutation in the middle, TM ≥ 78°C 
The primers then are elongated by the high fidelity polymerase PfuUltra™, 
featuring especially high accuracy and processivity compared to normal Taq 
polymerase. To avoid introduction of random mutations during PCR, only 18 
cycles are run. Unmutated plasmid DNA subsequently is digested by DpnI, a 
endonuclease specifically cutting methylated or semi-methylated DNA and 
competent bacteria were transformed with the plasmid DNA (see section 4.2.2). 
Linker Mediated PCR 
For the linker-mediated PCR (LM-PCR), integrated long-terminal repeats 
(LTRs) and flanking genomic sequences were amplified and subsequently 
isolated using a modification of the bubble LM-PCR strategy (Riley et al., 1990). 
1 µg genomic DNA from diseased mice was digested overnight with PstI (New 
England Biolabs) in a volume of 50 µl. The DNA fragments were purified by 
precipitation with Na-Acetate, redissolved in 12 µl H2O and ligated overnight at 
16°C to the double-stranded bubble PstI linker in a total reaction volume of 
100 µl. Subsequently, a nested PCR was performed with the first PCR (PCR A) 
using a primer pair consisting of vectorette primer A and GFP-A primer, 
followed by a nested PCR (PCR B) using the nested vectorette primer B and 
the GFP-C primer. 
Component Volume [μl] 
10x buffer –Mg [µl] 2.50 
MgCl2 50 mM [µl] 0.75 
dNTP mix 10 mM [µl] 0.50 
Vectorette primer 0.50 
GFP-A primer 0.50 
Taq polymerase 1 U/µl [µl] 0.25 
Ligation template [µl] 10.00 
PCR-H2O [µl] 10.30 
Total Volume [µl] 25.30 
Table 4: Reaction components for PCR A. 
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Component Volume [μl] 
10x buffer –Mg [µl] 2.50 
MgCl2 50 mM [µl] 0.75 
dNTP mix 10 mM [µl] 0.50 
Vectorette primer 0.50 
GFP-A primer 0.50 
Taq polymerase 1 U/µl [µl] 0.25 
PCR product PCR A [µl] 1.00 
PCR-H2O [µl] 19.30 
Total Volume [µl] 25.30 
Table 5: Reaction components for PCR B. 
Step No Cycle(s) 
Target 
Temp. [°C] 
Time [s] 
PCR A/ B 
Denaturation 1 94 120 
Denaturation 
30 
94 30 
Annealing 65 30 
Extension 72 120/ 300 
Extension 1 72 120/ 300 
Table 6: Cycler program for LM-PCR A and B. 
To each 25 µl PCR B reaction 2.5 µl 10x loading dye were added and 12 µl of 
this mixture were loaded on a 1.5% agarose gel. Gel bands were excised and 
purified using the illustra GFX PCR DNA and Gel Band Purification Kit (GE 
Healthcare). Fragments of sufficient size were sequenced directly using one of 
the primers of PCR B, smaller fragments were first subcloned into pGM-T easy. 
Real-Time Quantitative Reverse Transcription PCR 
Real-time quantitative reverse transcription PCR (real-time qRT-PCR) allows 
the quantitative determination of PCR products generated during PCR. For real-
time qRT-PCR, fluorescent dyes are used and the increase of fluorescence, 
which is proportional to the number of transcripts, is measured at the end of 
every PCR cycle, i.e. in real-time. The most specific chemistry is based on 
hybridizing probes, which is also employed in the TaqMan method (7900HT fast 
real-time PCR system, Applied Biosystems) used for this study. The gene 
specific assay, which is available predesigned for a large number of different 
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genes, beside the primers also contains the probe, which is designed to 
hybridize with the target sequence. This probe is labeled with 6-FAM at the 5’ 
end and a nonfluorescent quencher at the 3’ end. By the nuclease activity of the 
DNA polymerase, the probe is cleaved during the elongation step leading to a 
separation of the quencher from the reporter dye and hereby to an increase of 
fluorescence. 
 
Figure 22: 5´–3´ Nuclease Activity of the DNA Polymerase System. 
By the nuclease activity of the polymerase the fluorescent dye is separated from the quencher 
and starts to emit light (source: protocol TaqMan® Gene Expression Assays, Applied 
Biosystems). 
The point at which the fluorescence signal of one sample reaches a predefined 
level above the background fluorescence is referred to as threshold cycle (CT) 
and is used to calculate the initial sample concentration. This can be done 
either in an absolute way, by comparing the CT of the target sample with a 
standard curve, or by relative quantification when the CT of the target sample is 
compared to an internal control. The absolute quantification gives information 
about the effective molecule concentration in the sample of interest. However, 
the DNA for the standard curve, e.g. recombinant DNA or RT-PCR product, 
does not undergo the same processing as the unknown mRNA samples which 
have to be reverse transcribed first, thus leading to a certain inaccuracy. More 
robust is the relative quantification, as the expression of the gene of interest is 
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compared to the expression of one or more endogenous controls, mostly called 
housekeeping genes, within the same sample and parameters such as RNA 
quantity or RT efficiency thus lose their relevance. 
Assuming the same efficiency for both target and housekeeping control primers, 
which is given for primers designed by Applied Biosystems, the expression 
height can be calculated using the ΔΔCT method. First, the ΔCT is calculated by 
normalization to the housekeeping gene. In this study, the housekeeping gene 
Gapdh was used for normalization of murine genes and the gene encoding the 
TATA-box binding protein (TBP) for normalization of human genes. 
( ) ( )referenceTetargtTT CCC −=∆  with the standard deviation 
2
reference
2
etargt sss += . 
It is important to note that ΔCT values are inversely correlated to the expression 
height of a gene. For a better understanding, i.e. to achieve a positive 
correlation, ΔCT values were subtracted from the maximum cycle number of 40 
cycles. 
The fold change between a test sample (e.g. treated sample) and a calibrator 
sample (e.g. untreated sample) subsequently can be calculated by 
( ) ( )( )samplecalibratorTsamplettesTT CCC 22 ∆−∆−∆∆− =  with a range of ( )sCT2 +∆∆−  to ( )sCT2 −∆∆− . 
Reactions were run in triplicates with 1 µl of cDNA containing the equivalent of 
50 ng total RNA and in a total volume of 20 µl. Because of less material, patient 
samples were run only once. 
 Volume [μl] 
TaqMan Universal PCR Master Mix No UNG (2x) 10.00 
DEPC-H2O [µl] 8.00 
Assay (primer & probe) 20x [µl] 1.00 
cDNA [µl] 1.00 
Total Volume 20.00 
Table 7: Reaction components for TaqMan qRT-PCR. 
All PCR reactions were run with the standard program and 40 to 45 cycles. 
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Step Cycles Target T [°C] Time [s] 
Activation AmpErase UNG 1 50 120 
Activation AmpliTaq Gold 1 95 600 
Melting 
40-45 
95 15 
Annealing/ Extension 60 60 
Table 8: Standard program for TaqMan qRT-PCR. 
Methylation Specific PCR and Bisulfite Sequencing 
Methylation specific PCR and successive bisulfate sequencing was performed 
commercially by Varionostic GmbH, Ulm, Germany. 
4.1.5 Agarose Gel Electrophoresis 
Preparative and analytical separation of PCR products or plasmids was done by 
agarose gel electrophoresis. For this, 10 µl of PCR product was mixed with 1 µl 
10x probe buffer and loaded on an agarose gel containing 0.005% ethidium 
bromide. Depending on the size of the expected PCR product, gels of 0.8% to 
2.0% were used. For electrophoresis of plasmids, the samples were loaded on 
0.5% agarose gels. As marker, 0.5 µg of a 100 bp or 1 kb ladder (both NEB, 
see chapter 3.1) were loaded. The electrophoretic separation was carried out 
for 60 min at 80-100 V. 
4.1.6 Purification of PCR Products out of Agarose Gel 
To purify PCR products from interfering byproducts for reamplification or 
sequencing, the corresponding bands were cut out of the agarose gel and 
purified using the illustra GFX PCR DNA and Gel Band Purification Kit 
according to manufacturer’s specifications. 
4.1.7 Cloning of DNA Fragments  
For retroviral gene transfer into primary BM cells, the different constructs were 
cloned into the multiple cloning site of the modified murine stem cell virus 
(MSCV) vector (Pineault et al., 2003) upstream of the internal ribosomal entry 
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site (IRES) and the enhanced green or yellow fluorescent protein (eGFP/ eYFP) 
gene. For this, the PCR product as well as the plasmid were digested with 
EcoRI and XhoI for at least 3 h or overnight at 37°C. Subsequently, the plasmid 
was gel-purified to remove the excised fragment. 20 to 100 ng of the digested 
and purified vector were ligated to a 2- to 5-fold excess of the digested PCR 
product in a total reaction volume of 10 µl by incubation over night at 16°C. 
Competent bacteria were transformed with 5 µl of the ligated plasmid according 
to chapter 4.2.2. 
Figure 23: Schematic view of retroviral constructs. 
The MSCV-Cdx4-IRES-eGFP construct kindly was provided by Keith Humphries. 
4.1.8 Restriction Analysis 
To test for successful ligation of a insert into a plasmid, the plasmid was cut with 
appropriate restriction enzymes and analyzed via agarose gel electrophoresis. 
Control digestions were performed at 37°C for 3 h in a total volume of 10 µl and 
with the same enzymes applied for cloning. 
4.1.9 Southern Blot 
Southern blot analyses to assess proviral integration were performed using 
genomic DNA isolated from bone marrow, spleen and peripheral blood of 
leukemic mice by DNAzol reagent according to manufacturer’ instructions (see 
chapter 4.1.2). 
Southern blot was performed using standard protocols (Buske et al., 2001): 
10 µg of genomic DNA were digested over night with PstI in a total volume of 
60 µl to release a fragment specific to the proviral integration site. After a 
reduction of the volume to approximately 40 µl by speed vac (30-40 min at 
55°C), the DNA was loaded on a medium size 0.8% agarose gel with 0.5 µg/ml 
LTR Cdx4 IRES eGFP LTR 
LTR Cdx2 IRES eYFP LTR 
LTR IRES eGFP LTR 
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ethidium bromide and separated with 70 V for several hours. Subsequently, the 
DNA was depurinated by incubating the gel in 0.2 N HCL for exactly 10 minutes 
and denatured for 45 minutes in denaturation solution. Overnight, the DNA was 
transferred to a Hybond N membrane (Amersham Biosciences) by capillary 
action using 10x SSC buffer. Cross-linking of the DNA with the membrane was 
performed by incubating the damp membrane at 150 mJ in a UV GS gene linker 
(Bio-Rad). The membrane was transferred in a prewarmed glass hybridization 
tube and after addition of 25 ml prehybridisation buffer incubated for 15 min at 
65°C. After addition of 100 µl salmon DNA, the membrane was incubated for 
additional 2 h to block unspecific binding. 
In the meantime the probe, a 700 bp eGFP-fragment cut out of the pEGFP-C1 
plasmid (Clontech), was labeled with 4x107 DPM α-32P dCTP, using the 
Megaprime DNA labeling System (Amersham Biosciences) and afterwards 
purified using Microspin S-300 HR columns (Amersham Biosciences). The 
hybridization with the labelled eGFP-probe was performed over night at 62°C 
for eYFP samples and at 65°C for eGFP samples. After two wash steps with 2x 
SSC + 0.2% SDS, each for 15 min, and one wash step with 0.2x SSC and 0.2% 
SDS for 30 min, the membrane was sealed in plastic wrap and X-ray film was 
exposed to the radioactive labelled membrane. 
4.1.10 Sequencing 
PCR products and plasmids were commercially sequenced by Sequiserve 
(Vaterstetten, Germany). 
4.2 Bacteria 
4.2.1 Preparation of Competent Cells 
Bacteria (for example DH5α) were plated on LB plates and incubated over night 
at 37°C. 10-12 colonies were picked and used for inoculation of a 50 ml starter 
culture, which again was incubated at 37°C over night. 250 ml of LB medium 
were inoculated with this starter culture to an OD600 of 0.1 and incubated at 
18°C and 200-250 rpm until a OD of 0.6 was reached (ca. 5 h). The bacteria 
suspension was cooled 10 min on ice and, after distribution into five 50 ml 
Methods  
 
54 
tubes, centrifuged 15 min at 3000 rpm and 4°C. Pellets were resuspended in 
80 ml ice cold fresh and sterile filtered TB buffer, incubated 10 min on ice and 
centrifuged 15 min at 3000 rpm and 4°C. Pellets were resuspended in 20 ml ice 
cold TB buffer and, after mixing with 1.5 ml DMSO, incubated on ice again for 
10 min. The competent bacteria cells were aliquoted in pre-cooled 1.5 ml tubes 
and quick-frozen in liquid nitrogen. For storage cells were kept at -80°C. 
4.2.2 Transformation of E.coli 
For transformation, competent bacteria were thawed on ice. 50 µl of bacteria 
suspension were mixed with 5 µl of plasmid DNA, then incubated at RT for 
10 min. The transformed bacteria were streaked on an appropriate, prewarmed 
agar plate and incubated at 37°C over night. 
4.2.3 Isolation of Plasmid DNA (Miniprep, Maxiprep) 
Depending on the amount of plasmid DNA needed, 5 ml (miniprep) or up to 
200 ml (maxiprep) of LB medium supplemented with 100 µg/ml ampicillin were 
inoculated with transfected bacteria and incubated shaking at 200 rpm and 
37°C over night. The isolation of plasmid DNA from E.coli cultures of 1-5 ml was 
performed with GenElute Plasmid Miniprep Kit, for larger amounts the GenElute 
HP Plasmid Maxiprep Kit or for endotoxin free preparations, the GenElute HP 
Endotoxin-Free Plasmid Maxiprep Kit (all by Sigma-Aldrich) were used. All 
isolations were performed according to manufacturer’s specifications. 
Determination of concentration and purity of isolated DNA was performed 
photometrically (see chapter 4.1.3). 
4.3 Culture of Eukaryotic Cell Lines 
4.3.1 General Culture Conditions 
Eukaryotic cell lines were cultured in DMEM supplemented with 10% inactivated 
FBS. When necessary, cells were passaged at ratios of 1:3 to 1:5. All cell lines 
were cultivated at 37°C, 5% CO2 in a humified atmosphere. 
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4.3.2 Freezing and Thawing of Cells 
For freezing, cells were trypsinized if necessary and after pelleting resuspended 
in freezing medium, which was slowly added to the cells. 1 ml of freezing 
medium was used per 5x105 to 5x107 cells and the cell suspension was 
transferred to cryotubes in aliquots of 1 ml. Cells were stored at -80°C for short 
term and in liquid nitrogen for long term storage. 
Frozen cells were rapidly thawed by incubation at 37°C in a water bath. Directly 
after thawing cells were washed two times with warm medium to remove traces 
of DMSO and seeded in a fresh 10 cm dish. 
4.3.3 Determination of Cell Number and Vitality 
For assessment of cell number and vitality of the cells, trypan blue exclusion 
was performed. This acid diazo dye penetrates the cell membrane of dead cells 
which subsequently appear blue under the light microscope, vital cells in 
contrast shine brightly. To count only living cells, an aliquot of the cell 
suspension to be analyzed was mixed with trypan blue at a ratio of 1:1, pipetted 
in the reservoir of a Neubauer-counting chamber and a defined volume was 
counted using the given grid. The cell number per ml was calculated as follows: 
average cell number per main square x chamber factor 104 x 2 (dilution factor). 
4.3.4 Generation of Packaging Cell Line 
For preparation of ecotropic retrovirus, Phoenix Eco cells were transiently 
transfected using the CaCl2 method. For this, cells were grown in 10 cm dishes 
to a density of around 80% and pretreated 5 min before transfection with 25 µM 
chloroquine. Subsequently, cells were transfected by dropwise addition of the 
transfection mix consisting of 16 µg plasmid DNA, 122 µl 2 M CaCl2 and 1 ml 
HBS buffer pH 7.0 in a total volume of 2 ml. Because of the toxicity of 
chloroquine to the cells, the medium was changed 9-10 h (latest 12 h) after 
transfection. 48 h after the transfection, continuing for the next two days with 
time intervals of 8 h, the virus conditioned medium (VCM) was collected and 
filtered through a 0.45 µm filter. After addition of 5 to 10 µg/ml protamine sulfate 
the VCM was used for transduction of the ecotropic cell line GP+E86 to 
Methods  
 
56 
establish a stable high-titer packaging cell line. Transduced GP+E86 were 
sorted by FACS according to their eGFP or eYFP expression 48 h after 
transduction. 
To determine the virus titer, 5x104 NIH-3T3 cells were seeded in wells of a 6-
well plate. 16 h after seeding, VCM of a fully confluent GP+E86 dish was 
harvested, filtered and pipetted on the NIH-3T3 in dilutions of 1/1, 1/3 and 1/10 
in a total volume of 500 µl and with addition of 1 µl 5 mg/ml protamine sulfate 
stock. Protamine sulfate prevents aggregation of virus particles, and hereby 
increases the efficiency of transduction. Four hours later new medium was 
added to a total volume of 5 ml. After 48 h eGFP or eYFP expression was 
assessed and the titer (infectious particles per ml) calculated: the percentage of 
eGFP/ eYFP positive cells was multiplied with the number of NIH-3T3 cells at 
the beginning of virus exposure and divided by 500 µl (volume of VCM applied 
to the cells). 
4.4 Mice and Murine Primary Cells 
4.4.1 Mouse Strains and Progenitor Enrichment by 5-FU Injection 
Parental strain mice were bred and maintained at the animal facility of the 
Helmholtz Center Munich. Donors of primary BM cells were ≥ 8 week old 
animals of the strain (C57Bl/ 6Ly-Peb3b x C3H/ HeJ) F1 (PebC3). For 
enrichment of hematopoietic progenitors, the mice were injected intravenously 
(i.v.) or intraperitoneally (i.p). with 150 mg 5-FU per kg body weight. The 
pyrimidine analog 5-FU, 5-flourouracil, removes a large proportion of actively 
cycling, more differentiated, cells and thereby enriches the BM for primitive 
hematopoietic progenitors, which are non-cycling or quiescent in nature. 8–12 
week old (C57Bl/ 6J x C3H/ HeJ) F1 (B6C3) mice were used as recipients. 
4.4.2 Collection of Murine BM 
Four days post injection 5-FU mice were euthanized with CO2 and after death 
sterilized in 70% EtOH. Femures, tibiae, hips and sternum of the animals were 
removed and cleaned properly with scissors and tissue paper to remove 
adherent tissue. The cleaned bones subsequently were crushed with mortar 
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and pestle in 3% FBS PBS. The BM cell containing supernatant was harvested 
and filtered through a 40 µm filter unit to remove bone chips and other 
impurities. For lysis of RBCs, cells were pelleted by centrifugation, resuspended 
in 1 ml of DMEM and, after addition of 4 ml ammonium chloride (ACl) 3%, 
incubated on ice for 30 min. After lysis cells were washed with PBS. 
No RBC lysis was performed if later on the BM cells were to be transduced 
retrovirally. 
4.4.3 Cultivation of Murine BM 
To induce cell cycling, murine 5-FU BM progenitors were stimulated for 48 h in 
complete BM medium (DMEM supplemented with 15% FBS and cytokine 
cocktail (CC) with an end concentration of 10 ng/ml mIL-6, 6 ng/ml mIL-3 and 
100 ng/ml mSCF). BM cells were cultivated at 37°C, 5% CO2 within a humified 
incubator.  
4.4.4 Retroviral Transduction 
For transduction BM cells were co-cultured for 48 h with irradiated (40 Gy) 
GP+E86 virus producing cells in complete medium and with addition of 5 μg/ml 
protamine sulfate. Loosely adherent and non-adherent BM cells were harvested 
from the feeder 48 h after the end of transduction by thorough rinsing with PBS. 
To allow expression of eGFP or eYFP, BM cells were further cultured in fresh 
complete BM medium for 48 h. By fluorescence activated cell sorting (FACS) 
successfully transduced BM cells were sorted using eGFP or eYFP as marker. 
In the following, experiments performed on pMIG-, Cdx2-, and Cdx4-transduced 
cells will be termed pMIG, CDX2, and CDX4 arm, respectively. Examples for 
achieved titers are shown in Figure 24. 
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Figure 24: Transduction efficiency of retrovirally transduced 5-FU BM cells. 
Cells were transduced following the above described method and 48 h after transduction sorted 
by FACS Vantage according to fluorescence marker expression. 
4.4.5 Establishment of a Retroviral Packaging Cell Line for Cdx4 
For transduction of murine hematopoietic cells the retroviral MSCV-IRES-eGFP 
vector was used which is known to be able to efficiently transduce primary BM 
cells. The pMIG-Cdx4 construct was kindly provided by RK Humphries (Terry 
Fox Laboratory, Vancouver, Canada). The ecotropic packaging cell line 
GP+E86 was stably transduced with this Cdx4 construct and a high titer clone 
was selected (Figure 24, methods section). 
The expression level of Cdx4 did change only slightly during in vitro culture as 
well as during in vivo experiments with e.g. a ΔCT of 2.5 ± 0.2 SEM 72 h after 
transduction and a ΔCT of 3.3 ± 0.4 SEM in BM of diseased mice. 
MIG-eGFP Cdx2-eYFP 
Cdx4-eGFP Cdx4-eYFP 
28.9% 
19.5% 
14.6% 
27.7% 
eY
FP
 
eYFP 
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Figure 25: Expression levels of Cdx4 in transduced BM cells. 
Expression levels of Cdx4 in BM cells 72 h after transduction, after 1st CFC assay and in 
diseased mice which were transplanted with transduced BM cells were determined by TaqMan 
qRT-PCR. The diagram shows average ΔCT ± SEM, and the numbers of analyzed Cdx4 
transduced samples. 
4.4.6 shRNA-Mediated Knock Down 
Short hairpin RNA against CDX2 (NM_001265) were designed using the RNAi 
oligo retriever tool at http://www.cshl.org/public/SCIENCE/hannon.html. Four 
different shRNAs were obtained and cloned into the MSCV/LTRmiR30-PIG 
retroviral vector (pLMP, kindly provided by Scott W Lowe, Howard Hughes 
Medical Institute, New York, USA). Cell lines were retrovirally transduced as 
described in Chapter 4.4.4. Knock-down of CDX2 was confirmed by Western 
Blot (Figure 26). 
Figure 26: shRNA-mediated knock-down of CDX2 expression by retroviral transduction. 
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4.4.7 Immunophenotyping by Fluorescence Activated Cell Sorting 
Lineage distribution and differentiation stage of cells were analyzed by 
fluorescence activated cell sorting (FACS). For this purpose, cells were washed 
with PBS and stained with PE- or APC-conjugated antibodies (see chapter 3.4, 
0.0625 µg antibody per 1x106 cells). After incubation on ice or at 4°C for 20 
minutes and in the dark, cells were washed with PBS and resuspended in 
FACS buffer (2% FBS and 2 μg/ml propidium iodide in PBS). Cells were 
analyzed using the FACS Calibur system or sorted using the FACS Vantage 
cell sorter. 
4.4.8 Proliferation Assay 
For determination of the proliferative potential of BM cells in vitro, 2.5x104 
transduced BM cells were plated directly after sorting in 6-well suspension 
plates using complete BM medium. Every week, cells were subcultured in 
appropriate dilutions and viable cells were counted using trypan blue exclusion. 
To generate IL-3 dependent cell lines, sorted cells were additionally plated in 
DMEM containing 15% FBS and 10 ng/ml IL-3 only. As above, every seven 
days an appropriate amount of cells was subcultured. 
Left over cells regularly were immunophenotypically and morphologically 
analyzed by cytospin. 
4.4.9 Colony Forming Cell Assay 
For quantification of committed myeloid hematopoietic progenitors, colony 
forming cell (CFC) assays were performed using methylcellulose supplemented 
with cytokines (MethoCult GF M3434, Stem Cell Technologies) which supports 
growth of erythroid (BFU-E, CFU-E), granulocyte/macrophage (CFU-GM, CFU-
M, CFU-G) and multi-potential granulocyte-erythroid-macrophage-
megakaryocyte (CFU-GEMM) progenitors. 
For this assay, 500 highly purified cells per dish, transduced with the gene of 
interest, were resuspended in 300 µl of plain DMEM and added to 3 ml of 
methylcellulose. After vortexing, 1.1 ml of the mixture was transferred into a 35 
mm Petri dish using 3 ml syringes and blunt end needles. Per sample, two 
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dishes were plated and placed into a 10 cm dish together with one open 35 mm 
dish filled with water to avoid desiccation. CFC assays were incubated at 37°C 
in a humified incubator and 5% CO2. After 7-9 days of incubation colony 
number and morphology was microscopically assessed using standard criteria. 
Subsequently, cells were harvested and the total cell number was determined. 
To test the colony forming/ clonogenic capacity, the cells were serially replated 
in appropriate dilutions up to three times. 
4.4.10 Delta CFC Assay 
During in vitro culture, normal BM cells rapidly lose their clonogenic potential. 
To analyze whether progenitors cells expanded in the proliferation assay lost 
their clonogenic potential, CFC-assays were set up at the end of a proliferation 
assay by plating 3,000 to 5,000 BM cells in methylcellulose. After 7 to 9 days of 
culture, colony number and morphology were assessed. 
4.4.11 BM Transplantation of Mice 
Directly after the end of transduction, 1.4x104 – 1.1x106 total BM cells (average 
of 16.25% ± 5.9 % SEM eGFP positivity) were transplanted into primary mice 
lethally irradiated with 800-850 cGy. One small aliquot of the BM cells was 
retained and further cultivated for 48 h to assess the percentage of successfully 
transduced cells by eGFP or eYFP expression with FACS. Lethally irradiated 
secondary recipients were injected with 106 BM cells from a diseased primary 
mouse together with 5x105-1x106 untransduced BM helper cells of a normal 
syngenic animal. 
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4.4.12 Retroviral BM Transplantation Model 
Figure 27: Experimental scheme applied for retroviral BM transplantation experiments. 
5-FU treated BM was prestimulated in complete BM medium to induce cycling of HSCs and 
subsequently retrovirally infected by co-culture with virus producing E86 cell lines. Successfully 
transduced cells were highly purified by FACS and in vitro and in vivo experiments were 
performed. 
4.4.13 Peripheral Blood Analysis 
Peripheral blood (PB) of experimental mice was collected every four to eight 
weeks by tail incision. Directly after, several blood smears were made which 
after drying were stained as described in chapter 4.4.14. 
The RBC count was determined after dilution of 1 µl PB in 5 ml of PBS. For 
evaluation of the WBC count 5 µl of PB were resuspended in 45 µl ACl for 
disruption of RBC and counted after 5 min lysis at RT. For immunophenotyping, 
the rest of the blood was resuspended in 200 µl ACl and for RBC lysis left on 
ice for 30 min. After washing with PBS, cells were stained as described in 
chapter 4.4.7. 
4.4.14 Preparation and Staining of Cytospins 
For cytomorphological analysis of the BM cells, 1x105 cells were resuspended 
in 200-250 µl of PBS and loaded into the sample chamber of a Shandon 
Cytospin 2 centrifuge. By 10 min centrifugation at 450 rpm, cells were 
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transferred to a glass slide as a single layer with  the cellular structure kept 
intact. 
For Pappenheim’s staining, dried slides were stained with undiluted May-
Gruenwald eosine-methylene blue for exactly 3 min, washed 5 min in water and 
transferred to freshly diluted Giemsa solution (4 ml stock solution + 200 ml aqua 
dest.) for 1 h. After two times washing with water for 5 min each, slides were 
ready for assessment of cell morphology. 
4.4.15 Histopathology 
Histopathologic analysis of mice and organs fixed in formalin was performed by 
Dr. Leticia Quintanilla-Fend (Institute for Pathology, Tuebingen). 
4.4.16 Analysis of Sacrificed Experimental Mice 
Sick mice, characterized by cachexia, shortness of breath and lethargy, were 
euthanized using CO2 and PB was taken immediately and directly from the 
heart using a 1 ml syringe and heparin to avoid coagulation of the blood. The 
blood was analyzed according to section 4.4.13. BM was obtained as described 
in chapter 4.4.2. Additionally, the spleen was removed, measured in size and 
half of it was homogenized using a 40 µm filter unit to obtain a single cell 
suspension. The other half of the spleen was fixed in formalin for 
histophatological analysis. 
RNA as well as DNA were prepared from hematopoietic organs and 
immunophenotyping was performed (section 4.4.7). If necessary, ex vivo CFC 
assays and ex vivo proliferation assays were set up and secondary mice were 
transplanted. The rest of the cells was stored at -80°C. 
4.5 Patient Samples 
For analysis, mononuclear cells prepared from diagnostic bone marrow or 
peripheral blood samples were used. The AML cases were classified according 
to the French-American-British criteria and the World Health Organization 
classification (Bennett et al., 1985). The study was approved by the ethics 
committees of all participating institutions, and informed consent was obtained 
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from all patients before they entered the study in accordance with the 
Declaration of Helsinki (http://www.wma.net/e/policy/b3.htm). As a control, bone 
marrow mononuclear cells (BMMCs; CellSystem, St Katharinen, Germany) from 
healthy individuals were analyzed. Cytomorphology, cytochemistry, 
cytogenetics, and molecular genetics were applied in all cases as described. 
4.6 Microarray Analyzes 
4.6.1 Preparation of Microarrays 
First and second-strand cDNA synthesis were carried out using the cDNA 
Synthesis System (Roche Applied Science) and an input of 1-8 µg RNA 
according to manufacturer’s instructions. After clean-up of the cDNA using the 
GeneChip Sample Cleanup Module (Affymetrix), biotin-labeled cRNA synthesis 
was performed in a final reaction volume of 40 µl employing the GeneChip IVT 
Labeling Kit (Affymetrix), the labeled cRNA was again purified and additionally 
fragmented using the GeneChip Sample Cleanup Module (Affymetrix, both kits 
were used according to manufacturer’s instructions). Hybridization of GeneChip 
Mouse Genome 430 2.0 Arrays A+B (Affymetrix) was performed for 16 hrs. 
Array post-hybridization, washing and scanning were performed following 
detailed protocols provided in the GeneChip Expression Analysis Technical 
Manual (Affymetrix). 
4.6.2 Evaluation of Microarray Data 
Data were obtained from Mo430 v2.0 chips and acquired raw data (*.CEL files) 
were normalized using an R statistical package implementation of GCRMA 
(Gene Chip Robust Multi Array) algorithm (R version 2.8.1 and Bioconductor 
version 2.5). Normalized data was subjected to Linear Models for Microarray 
Data (limma) package (Bioconductor version 2.5) to assess genes that are 
differentially regulated or, for a more stringent assessment of differentially 
regulated genes, the R implemented twilight package was used. Probe sets that 
showed statistically significant differential expression at 95% confidence interval 
(p value <0.05, adjusted for multiple hypothesis testing with the Benjamini and 
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Hochberg's method) were selected. Heatmaps were built using the heatmap 
function in R (R version 2.8.1 and Bioconductor version 2.5). 
4.7 Statistical Analyzes 
Data were analyzed using the students t-test (Microsoft Office Excel 2007, 
Microsoft Cooperation, Redmond, WA, USA). Differences with p-values of 0.05 
and less were considered as significant. 
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5. RESULTS 
5.1 CDX2 in Human AML 
Rawat et al. (2004) previously showed that ectopic expression of Cdx2 in adult 
hematopoietic cells leads to induction of AML in the murine BM transplantation 
model. Human AML, especially AML with normal karyotype, is characterized by 
overexpression of a number of HOX genes. As CDX members were shown to 
upregulate Hox gene expression in murine early hematopoiesis, we intended to 
examine if aberrant expression of CDX genes could be responsible for the 
aberrant HOX gene expression observed in human AML patients. 
5.1.1 CDX2 is the Only CDX Member Aberrantly Expressed in Patients 
with Normal Karyotype AML 
For the determination of the expression of CDX2 and CDX4 in normal 
hematopoietic tissues, total normal bone marrow (BM) and cord blood (CB) 
were analyzed by TaqMan real-time qRT-PCR. As Figure 28 depicts, neither 
CDX4 nor CDX2 are expressed in these hematopoietic populations. The 
specificity of the CDX4 assay was confirmed in two different human ES cell 
lines where its expression was readily detected. 
Figure 28: Expression of CDX2 and CDX4 in total normal BM and CB. 
The expression of CDX2 and CDX4 was determined by TaqMan qRT-PCR and the ΔCT values 
calculated by normalization to the TATA-box binding protein gene (TBP). 
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To analyze if an aberrant expression of CDX2 can be observed in AML with 
deregulated HOX expression, diagnostic BM or PB samples of 71 adult AML 
patients with normal karyotype were analyzed by qRT-PCR for expression of 
CDX2. In contrast to normal BM and CB where no CDX2 transcript was 
detected, 89% of the 71 tested AML patients with normal karyotype proved to 
be positive for CDX2 expression (Figure 29). No significant difference was 
observed between NPMc+ and NPMc- patients. 
Figure 29: Expression of CDX2 in AML with normal karyotype. 
ΔCT values were obtained by normalizing for TBP expression. Columns represent average 
expression level of CDX2 ± SEM. 
Furthermore, twenty-four patients (NPMc+: 10, NPMc-: 14) were tested for 
expression of CDX1 and 48 patients (NPMc+: 22, NPMc-: 26) for the expression 
of CDX4. However, none of these patients showed any expression of these 
homeobox genes (Figure 29). 
5.1.2 CDX2 Is Expressed in 64% of AML with Abnormal Karyotype 
Expression of CDX2 was detected not only in patients with normal karyotype, 
but also the majority of patients with abnormal karyotype showed aberrant 
expression. When 44 patients with AML1-ETO, PML-RARα, MLL translocations 
or inv(16) were tested for CDX2 expression, in 64% of these patients 
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expression of the transcript was detected (Figure 30). The positivity for CDX2 
expression varied considerably. Whereas in the AML1-ETO and MLL subgroups 
only half of the patients expressed CDX2, all of the ten tested patients harboring 
the PML-RARα translocation were positive for CDX2 expression. 
Figure 30: Expression of CDX2 in different subgroups of AML with abnormal karyotype. 
Forty-four patient samples with abnormal karyotype, confirmed by FISH, were analyzed. 
Columns represent average ΔCT expression values for each AML subgroup ± SEM. 
5.1.3 CDX2 Is Higher Expressed in AML with Normal Karyotype 
Compared to Abnormal Karyotype 
Interestingly, a comparison of CDX2 expression between patients with normal 
(n=63 of 71 total) and patients with abnormal karyotype (n=28 of 44 total) 
revealed a significantly higher CDX2 expression in patients with normal 
karyotype of more than 15-fold (p<0.001). 
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Figure 31: Expression of CDX2 in AML with normal and abnormal karyotype. 
Columns represent average ΔCT values ± SEM. Only positive patients are shown. 
5.1.4 High HOX Gene Expression Is Common in Patients with Normal 
Karyotype 
As CDX2 is an important upstream regulator of HOX genes, the pattern of HOX 
expression within different AML subgroups was determined by analysis of 
microarray data. Those data were available for 12 of the patients with NPMc+, 
12 patients with NPMc-, and 14 patients with AML-ETO translocation, which 
were tested for CDX2 expression as described before. All of the NPMc+ patients 
and 11 of 12 NPMc- patients were positive for CDX2 expression whereas of the 
AML-ETO positive patients only 50% showed expression of the CDX2 
transcript. In order to allow a better comparison, data of six more AML-ETO 
positive patients as well as 20 PML-RARα positive patients and 10 healthy 
controls (each with unknown CDX2 status) were included. 
Clearly visible is the high expression level of all six analyzed HOX genes within 
the patient group with normal karyotype - not only within the NPMc+ patients but 
also in the group of those patients lacking the NPM mutation. In contrast, 
patients with abnormal karyotype did not display an elevated expression of HOX 
genes but, as for example in the case of HOXA9, even showed a lower 
expression compared to normal BM. 
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Figure 32: Expression of individual HOX genes in CDX2 positive samples with normal 
and abnormal karyotype. 
Log2 expression levels of six different HOX genes are shown in box-and-whisker plots. Bars 
indicate median expression levels and boxes show 25th and 75th percentiles, while whiskers 
indicate maximum and minimum values. Outliers (values that are more than 1.5 interquartile 
ranges above the 75th or below the 25th percentile) are represented by open circles. 
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Previously, HOX deregulation was reported only for AML cases with NPMc+ 
normal karyotype. By performing this analysis, we now show an association of 
aberrant HOX gene expression with AML NK lacking NPM1 mutations. Although 
HOX gene expression in this subtype is not as high as in AML NK and NPMc+, it 
is clearly elevated compared to normal BM and AML with abnormal karyotype. 
5.1.5 CDX2 Expression Levels Positively Correlate with Aberrant HOX 
Gene Expression in AML 
As described above, aberrant CDX2 expression was also detected in AML with 
aberrant karyotype, i.e. in those patient groups in which according to Figure 32 
no significant elevated levels of HOX gene expression was observed. 
Therefore, it was tested if not positivity or negativity for CDX2 expression but 
the level of CDX2 gene expression would be connected to high levels of HOX 
gene expression. For this, the microarray data used for Figure 32 were 
analyzed by unsupervised hierarchic clustering. 
The resulting heat map depicted in Figure 33 is composed of two main clusters. 
One cluster consists of patients with normal karyotype and the other comprises 
both patients with abnormal karyotype and normal BM. Compared to AML 
patients with t(8;21) or t(15;17) as well as normal BM, there is a striking 
elevated level of HOX gene expression within the cluster of normal karyotype 
AML. Notably, the high HOX gene expression is not dependent on the 
expression of the HOX regulating MLL. Another interesting fact is that the three 
normal karyotype patients showing no difference in their HOX expression when 
compared to healthy BM fall into the same cluster as normal BM and aberrant 
karyotype. These patients either show only weak expression of CDX2 (40-ΔCT 
28.5 and 29.4) or have a CEBPα mutation which is assumed to inversely 
correlate with HOX gene expression (Roche et al., 2004, Kirstetter et al., 2008). 
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Figure 33: Hierarchic clustering of CDX2-positive AML samples according to HOX gene 
expression. 
Unsupervised hierarchic clustering according to HOX gene expression demonstrates HOX gene 
deregulation in patients with normal karyotype with or without NPM mutation compared with 
samples with abnormal karyotype or normal bone marrow samples. Normal BM samples n=11, 
AML with t(8;21) n=20, AML with t(15;17) n=20, AML with normal karyotype n=12 and without 
NPM mutation (n=12). Red arrows highlight the boundary between the two main clusters. 
Genes and samples were permutated. 
The NK cluster itself also can be subdivided into two subclusters of which one 
consists mainly of NPMc+, the other of NPMc- patients. NPMc+ patients 
generally show stronger deregulation of HOX expression, which is a common 
feature of this AML type (Debernardi et al., 2003; Alcalay et al., 2005; Verhaak 
et al., 2005). 
To determine if deregulated HOX gene expression might also be associated 
with CDX1 or CDX4, 52 patients with normal karyotype (22 NPMc+, 26 NPMc-) 
were tested for CDX4 expression and 22 patients (10 NPMc+, 14 NPMc-) for 
CDX1 expression. Unlike CDX2, neither transcripts of CDX1 nor CDX4 were 
detectable by qRT-PCR (Figure 29), indicating a possible key role of CDX2 in 
this type of AML. 
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5.1.1 CDX2 Expression Does Not Correlate with Mutations of FLT3 
One gene frequently affected in patients with NK is FLT3, which is mutated in 
about 30% of all the cases of AML NK (Falini et al., 2007). The most common 
mutation of this gene is the internal tandem mutation or FLT3-ITD, which was 
present in 31.0% of the analyzed patients, followed by point mutations present 
in 8.5%. As it was previously reported that FLT3 mutations correlate with HOX 
expression (Roche et al., 2004), four different subgroups of AML NK with or 
without NPMc+ as well as with or without FLT3 mutation were analyzed for 
CDX2 expression. 
As Table 9 indicates, no significant differences were found between any of the 
four groups. In the case of NPMc- patients, this could be due to the low number 
of patients with FLT3 mutation. However, there was still no major difference 
observed between the larger groups of 23 NPMc+ patients with FLT3 mutation 
and 22 NPMc+ without FLT3 mutation (see Table 9), nor when only the FLT3 
mutation status was considered. Therefore, it is unlikely that the correlation 
between CDX2 and HOX expression is influenced by the presence of FLT3 
mutations. 
AML NK 
subgroup 
median 40-ΔCT ± 
SEM 
p-Value 
NPM+/FLT3+ NPM+/FLT3- NPM-/FLT3+ 
NPM+/FLT3+ 30.6 ± 0.56 - - - 
NPM+/FLT3- 31.6 ± 0.53 0.26 - - 
NPM-/FLT3+ 32.9 ± 0.88 0.45 0.76 - 
NPM-/FLT3- 32.9 ± 0.75 0.91 0.43 0.49 
Table 9: CDX2 expression in NK patients with and without FLT3 mutation. 
18 of the patients with NPMc+ had a FLT3 ITD, 5 patients a FLT3 D835 mutation. Of the NPMc- 
4 patients were positive for FLT3 ITD, one for FLT3 D835. 
5.2 CDX2 Is Able to Deregulate Hox Gene Expression in Adult Murine BM 
in vitro 
It is known that Cdx genes are involved in the regulation of Hox genes during 
murine embryonic development. To confirm that CDX2 also possesses this 
capacity for Hox gene upregulation in adult hematopoiesis, murine 5-FU 
enriched BM cells were transduced with Cdx2. 48 h after transduction 
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successfully transduced, eYFP-positive cells were sorted and analyzed for Hox 
gene expression by qRT-PCR. 
Although no significant changes were seen for the expression of Hoxa1 and 
Hoxb4, CDX2 was able to induce the expression of Hoxb6, Hoxb8 and Hoxd13, 
which were not expressed in BM cells transduced with the empty vector alone. 
As shown in Figure 34, CDX2 furthermore significantly upregulated Hoxa5 
(15.3-fold), Hoxa7 (12.0-fold), Hoxa9 (3.8-fold), Hoxa10 (10.1-fold) and Hoxb3 
(10.5-fold) compared to the control and therefore CDX2 does indeed possess 
the capacity for Hox gene deregulation in adult murine BM cells. 
Figure 34: Overexpression of Cdx2 in murine BM progenitors leads to Hox gene 
deregulation. 
Murine progenitor enriched 5-FU BM cells were transduced with Cdx2 or empty pMIG for 
control and 48h after transduction sorted for eYFP and eGFP expression, respectively. ΔCT 
values were obtained by normalizing to Gapdh and fold-expression compared to pMIG was 
calculated. The diagram shows average expression levels of three independent experiments ± 
SD. ° marks calculated values, as pMIG-transduced cells were negative for Hox expression. 
5.3 CDX2 in Human ALL 
As with more than 79% of all AML patients were positive for CDX2 expression, 
we subsequently were interested if this aberrant expression of CDX2 is 
restricted to AML or if it would be a more common feature and observable in 
other kinds of leukemia, as well. 
Results 
 
75 
5.3.1 CDX2 Is Aberrantly Expressed in the Majority of Patients with ALL 
To address this question, samples from 57 adult patients of different ALL 
subgroups were analyzed for expression of CDX2 by TaqMan qRT-PCR. 
In 81% of these patients the CDX2 transcript was detected. The expression of 
CDX2 showed high variation between the different ALL subgroups with highest 
median expression in pre-T ALL followed by cALL and pro-B ALL. ALL patients 
positive for the Philadelphia Chromosome translocation (Ph+) expressed CDX2 
at a median level whereas patients with B-ALL/ Burkitt lymphoma and thymic T-
ALL exhibited only low CDX2 expression. Also the number of patients aberrantly 
expressing CDX2 differed considerably between ALL subtypes, with 100% 
positivity in patients with pro-B ALL, c-ALL and Ph+ ALL versus only 40% 
positivity in B-ALL/ Burkitt lymphoma, 70% in thymic T-ALL and 71% in pre-T 
ALL. 
Figure 35: Expression of CDX2 in 57 patients with ALL. 
The diagram shows median CDX2 expression of each ALL subgroup ± SEM. The dashed line 
represents the median CDX2 expression of total ALL (40-ΔCT of 32.8). Values were obtained by 
normalization against TBP expression. 
In ALL, 50 of 57 patients were tested for expression of CDX4 as well. However, 
the gene was undetectable in all the patients. 
The ALL patients were classified according to the median CDX2 expression 
level of total ALL (40-ΔCT 32.8) in two groups with either high CDX2 expression 
or low/absent CDX2 expression. None of the patients with B-ALL/ Burkitt 
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lymphoma of thymic T-ALL showed high CDX2 expression, whereas all patients 
with pro-B ALL showed high CDX2 expression. With a p-value <0.001 the CDX2 
expression level significantly correlated with the ALL subtype (Figure 36). 
Figure 36: Distribution of patients with low/absent versus high CDX2 expression levels in 
different ALL subgroups.  
Patients with no CDX2 expression or expression below the median (40-ΔCT 38.2) were 
considered as low/absent, patients with CDX2 expression equal to or above the median as 
high. 
In total, with a median expression level of 32.8, ALL patients showed a 
significant higher expression of CDX2 than AML patients (Figure 37, p<0.0001). 
Furthermore, the expression of CDX2 in ALL was even higher than in normal 
karyotype AML which, with a median CDX2 expression of 32.4, was the 
subgroup with highest CDX2 expression in AML. 
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Figure 37: Comparison of CDX2 expression in AML and ALL. 
Shown are relative expression values for each single patient. The red line indicates the median 
CDX2 expression. ΔCT values were obtained by TaqMan qPCR and normalized to TBP 
expression. 
5.3.2 High CDX2 Expression Levels Are Associated with Poor Treatment 
Outcome in ALL 
For 30 of the above analyzed ALL patients complete data sets were available. 
Following statistical analyses these patients were classified as “CDX2 high” if 
their expression was above the median ALL expression or defined as “CDX2 
low/negative” if they showed CDX2 expression lower than the median (Figure 
36). The resulting subgroups each consisted of 15 patients. 
When the CDX2 expression within different risk groups of ALL (classified 
according to Raff et al., 2007) was analyzed, most very high risk and high risk 
patients showed high CDX2 expression. In contrast, the standard risk group 
consisted mainly of patients expressing low levels of CDX2 (p=0.007 according 
to Fisher’s exact test, Figure 38). 
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Figure 38: Expression of CDX2 according to risk groups. 
High and low/ absent CDX2 expression were determined as expression above and below the 
median of total ALL. 
Besides a significant correlation of the CDX2 expression level with risk group 
and ALL subtype as already mentioned above, a significant correlation with 
blast percentage in the BM was also observed (p=0.047). No correlation was 
detected between CDX2 expression and presence of molecular aberrations, 
age or karyotype. An overview of the correlation between high CDX2 
expression and different patient characteristics is given in Table 10. 
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Table 10: Correlation of high CDX2 expression levels with patients characteristics. 
SR: standard risk, VHR: very high risk. The correlations between different patient characteristics 
and high CDX2 expression are indicated. 
In a univariate analysis, high CDX2 expression levels were significantly 
associated with inferior overall survival (hazard ratio (HR) 4.2, 95% CI: 1.1–
15.7, Figure 39). The survival rate two years after diagnosis was 86% of 
patients with low/absent and 52% of patients with high CDX2 expression levels 
(p=0.019, log rank test). The hazard ratio for CDX2 did not change substantially 
after adjusting for age (HR for CDX2 3.3, 95% CI: 0.86–12.85), presence of 
molecular aberrations (HR for CDX2 4.0, 95% CI: 1.07–15.13), ALL subtype 
(HR for CDX2 1.8, 95% CI: 0.36– 8.96), ALL risk category (HR for CDX2 2.9, 
95% CI: 0.69–12.25), presence of karyotype aberrations (HR for CDX2 4.7, 
95% CI: 0.99–12.45), gender (HR for CDX2 6.2, 95% CI: 1.58–24.24) or 
leukocytes at presentation (HR for CDX2 3.8, 95% CI: 0.97–15.18) by bivariate 
Cox regression. In all the cases, CDX2 expression level remained an 
independent risk factor. 
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Figure 39: High expression of CDX2 is associated with poor treatment outcome in ALL. 
Kaplan-Meier plot for overall survival of patients with high versus low/absent CDX2 expression 
levels. 
5.3.3 Knock Down of CDX2 Leads to a Decrease in the Clonogenic 
Potential of the Pre-B Leukemia Cell Line Nalm-6 
The importance of CDX2 for the clonogenic potential of leukemic cells was 
tested in the CDX2-positive human pre-B ALL cell line Nalm-6. For this, Nalm-6 
cells were retrovirally transduced with two validated pLMP-shRNA constructs as 
well as with empty pLMP. Successfully transduced cells expressing eGFP were 
isolated by cell sorting. As determined by qRT-PCR, Nalm-6 cells expressing 
shRNA Hu_672_CDX2 showed a 49% reduction of CDX2 expression levels 
whereas the control shRNA Hu_673_CDX2 did not lead to any change of CDX2 
expression (Figure 40). 
The clonogenic potential of the transduced Nalm-6 cells was determined in the 
CFC assay. Nalm-6 cells transduced with shRNA Hu_672_CDX2 showed a 
significant, 31% reduction in colony formation compared to both the empty 
vector control and the non-active shRNA Hu_673_CDX2 (n=3, p=0.019 and 
0.018, respectively). These results show the importance of CDX2 expression for 
the clonogenic capacity of the Nalm-6 cell line. 
low (≤ median) 
high (> median) 
1-censored 
2-censored 
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Figure 40: Knockdown of CDX2 in Nalm6. 
A) Compared to the empty vector, transduction with sh672 lead to a 49% reduction of the CDX2 
expression level. No effect was observed for sh673. B) Only transduction with sh672 lead to a 
decrease in colony formation, no change of colony number was detected in the inactive sh673 
compared to the empty vector control. Knockdown on protein level was confirmed in Phoenix 
cells (Chapter 4.4.6). 
5.3.4 Aberrant Expression of CDX2 Does Not Depend on Promoter 
Methylation 
One explanation for high expression levels of CDX2 as observed in lymphoid 
leukemia might be epigenetic changes as promoter demethylation. To 
determine if this would be the case, the methylation status of the CDX2 
promoter region (-181 to +163 relative to the transcription start site (Yuasa et 
al., 2005) was quantitatively analyzed by pyrosequencing. Nine patients, six 
positive and three negative for CDX2 expression, were included in this analysis. 
As already demonstrated for AML by Scholl et al. (2007), there was no 
detectable difference in the methylation level of CDX2-positive and -negative 
ALL patients (see Tables 11 and 12). Both groups exhibited a high variation of 
the methylation levels within the promoter region between 7% and 82%. 
Therefore, differential methylation of this CpG rich region as cause for high 
CDX2 expression could be excluded. However, one interesting observation was 
that all four T-ALL samples (3x early T-ALL, 1x thymic T-ALL) showed a 
promoter methylation above 60% whereas the methylation levels of all other 
ALL samples were below 30%. 
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Patient 
No CDX2 ALL subtype Avg SD 
1 + cALL 29 19 
3 + cALL 19 14 
22 + pro-B ALL 7 10 
27 + pro-B ALL 16 18 
42 + early T-ALL 69 12 
43 + early T-ALL 82 19 
32 - B-ALL 16 18 
44 - early T-ALL 80 15 
52 - thymic T-ALL 63 21 
Tables 11 and 12: Methylation analysis of ALL samples 
Quantitative analysis of the % methylation status of CpG islands surrounding the transcription 
start site of CDX2 from the position -181 to +163 in six ALL patients positive and three patients 
negative for CDX2 expression. Table 11 indicates the methylation level per site and Table 12 
the average methylation level of all 24 CpG sites located within the analyzed region. 
5.3.5 CDX2 and HOX Expression Do Not Correlate in ALL 
As microarray data demonstrated a correlation between HOX deregulation and 
CDX2 expression level in AML, ALL patients were examined for the existence of 
a similar relationship via qRT-PCR. 30 ALL patient samples as well as three 
samples from both normal BM mononuclear cells (MNCs) and BM CD34+ were 
screened for the expression of HOXA7, HOXA9, HOXB6 and HOXB8. 
Whereas almost all patient samples revealed HOXA7 and HOXA9 expression 
and two third of the samples showed expression of HOXB6, only two of the 30 
ALL patients were positive for HOXB8 expression. Clearly visible is an 
upregulation of the MLL-AF4 target gene HOXA9 within the MLL-AF4 positive 
pro-B ALL group compared to healthy controls. However, whereas in AML 
Patient 
No CDX2 
No of CpG site 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
1 + 29 45 24 57 60 17 15 10 38 18 10 12 49 34 24 28 22 21 16 21 80 52 7 18 
3 + 31 30 39 37 15 2 4 3 3 4 5 4 34 33 25 35 8 33 11 41 8 30 2 19 
22 + 3 3 3 33 7 1 2 0 3 3 2 1 16 11 3 3 3 6 3 40 7 7 0 2 
27 + 5 4 13 9 5 1 1 0 5 4 3 3 29 36 13 42 40 33 17 51 63 10 0 5 
42 + 67 63 78 76 75 62 66 62 80 72 82 60 72 79 59 77 80 70 67 92 35 70 52 56 
43 + 88 80 98 93 92 82 89 81 95 90 91 58 78 93 70 91 91 82 77 100 5 80 74 79 
32 - 7 4 4 8 14 1 2 1 39 39 14 26 42 15 9 14 21 9 9 12 79 13 4 9 
44 - 84 77 94 88 87 79 86 77 91 84 93 71 78 90 69 90 92 83 74 100 25 81 61 76 
52 - 54 47 60 74 82 70 69 32 79 61 82 64 71 81 62 82 86 74 79 71 11 17 33 66 
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CDX2 expression was clearly associated with HOX gene deregulation, no 
significant correlation between CDX2 expression and expression of HOXA7, A9 
or B8 was found in ALL samples. Only a borderline significance between 
expression of CDX2 and HOXB6 (p= 0.048, Mann–Whitney U-test) was 
detected. 
Figure 41: Expression of HOX genes in CDX2-positive ALL patients and BM of healthy 
individuals.  
Correlations of HOX gene expression with high or low CDX2 levels (according to median 
expression level in ALL) were calculated using the Mann-Whitney-U-test. ΔCT values were 
obtained by qPCR and normalized to TBP expression. Whereas a weak positive correlation can 
be observed for HOXA7, HOXA9 and HOXB6, a significant correlation only was detected 
between the expression levels of CDX2 and HOXB6. 
  HOXA7 HOXA9 HOXB6 HOXB8 
CD34+ 3/3 3/3 3/3 - 
MNC 3/3 3/3 3/3 2/3 
c-ALL 5/6 6/6 5/6 1/6 
cort. T-ALL 4/5 5/5 4/5 - 
Ph+ ALL 6/6 6/6 5/6 1/6 
pre-T ALL 3/4 3/4 1/4 - 
pro-B ALL 6/6 6/6 3/6 - 
B-ALL 3/3 3/3 3/3 - 
Table 13: Number of samples positive for HOX gene expression. 
The table supplements Figure 41 and indicates the number of samples positive for HOX gene 
expression vs. total sample number. 
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5.3.6 CDX2 Deregulates Genes Involved in Lymphopoiesis 
Unlike AML, in which CDX2 is able to influence the self-renewal and 
proliferative potential of the leukemic clone by its ability to activate HOX gene 
expression, CDX2 expression in ALL did only weakly correlate with the 
expression levels of analyzed HOX genes. To test if ectopic expression of 
CDX2 in BM progenitors would also perturb the expression of other genes 
involved in stem cell function, TaqMan Low Density Array (LDA) was performed. 
For this analysis, 92 genes involved in hematopoietic self-renewal, proliferation 
and differentiation were selected and the expression of these genes was 
analyzed in 5-FU BM samples 48 h after transduction with empty vector control 
or Cdx2. 
The results of this assay demonstrated that CDX2 was able to significantly 
upregulate a number of genes involved in self-renewal. Amongst these genes 
were, as expected, Hox genes - including the Hox genes known to be 
deregulated in ALL such as Hoxa10 or Hoxa5 (Figure 42). However, genes 
involved in stem cell function were also differentially expressed, amongst others 
Slamf1 or the Abc transporter coding Abcb1b. 
In accordance with the important function of CDX2 during embryogenesis, Cdx2 
transduced BM cells also showed an upregulation of different genes involved in 
embryogenic development like Ddx4, which is involved in the germ cell 
specification of the embryo or Wnt2, which is regulating the differentiation of the 
hemangioblast. 
Interestingly, besides these genes several genes involved in lymphoid lineage 
determination were deregulated. For example, Flt3a was upregulated 4-fold. 
FLT3 is a marker in hematopoietic stem cell differentiation, but is also crucial for 
B-cell lineage commitment. A 4-fold upregulation was also detected for Lef-1, 
which affects proliferation and apoptosis in B-cell precursors but, as our group 
previously showed, can induce B-lymphoblastic leukemia in the murine model 
when aberrantly expressed. Id3 and Tcf3 both were more than 10-fold 
upregulated. Tcf3 is a gene frequently affected by translocations especially in 
childhood ALL, whereas overexpression of ID3 blocks B-cell specification at an 
early B-cell stage. These results suggest that CDX2 in ALL, unlike in AML, 
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exerts its leukemogenic effect by deregulation of lymphoid pathways rather than 
by deregulation of HOX genes. 
Figure 42: Differential gene expression in Cdx2-transduced bone marrow. 
Differential gene expression in Cdx2-transduced-bone marrow cells. Fold expression levels of 
different genes in murine progenitor enriched 5-FU bone marrow after ectopic expression of 
Cdx2. RNA was extracted 72 h after stopping the transduction. Fold expression difference 
compared with empty vector-transduced bone marrow cells was calculated by averaging three 
independent experiments. Only genes with significant up- and downregulation are shown. 
5.4 Cdx4 in the Murine Transplantation Model 
As reported by Davidson et al., CDX4 plays an important function in embryonic 
hematopoiesis (2003) and is expressed in murine adult hematopoiesis as well. 
However - and unlike CDX2 - no expression of CDX4 was detected in human 
acute leukemia. In contrast, overexpression of CDX4 was reported to result in 
an expansion of hematopoietic progenitor cells and its effect seemed more 
likely to equal that of HOXB4, a HOX member with known stem cell 
amplificatory potential. Using the BM transplantation model, it therefore was 
analyzed, what relevance overexpression of CDX4 would have on HSC function 
and maintenance. 
5.4.1 Cdx4 Is Highly Expressed in Murine BM Progenitors 
To test this, the expression of Cdx4 was determined in different adult 
hematopoietic subpopulations of the mouse by TaqMan qRT-PCR. The highest 
expression of Cdx4 was detected in early hematopoietic cells, i.e. in KSL cells, 
followed by progenitor enriched 5-FU BM cells. Both populations showed a 
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significantly higher expression of Cdx4 compared to BM MNCs with a more than 
1,700-fold difference between normal BM and KSL and an almost 400-fold 
difference between normal BM and 5-FU BM (p=0.008 and 0.005, respectively). 
The same was true for spleen, where the expression level of Cdx4 was more 
than 200-fold lower in total spleen than in 5-FU enriched splenic cells. This is 
consistent with data of Bansal et al. (2006) who reported high expression of 
Cdx4 in early hematopoietic populations, especially in HSCs and CLPs. 
Figure 43: Expression of Cdx4 in hematopoietic populations. 
Expression of Cdx4 in highly purified KSL cells as well as 5-FU enriched and total BM and 
spleen cells was analyzed by TaqMan qRT-PCR and normalized to the housekeeping gene 
TBP. 
Importantly, in human samples no expression of CDX4 was detected, neither in 
normal hematopoietic tissue nor in AML or ALL patients. The CDX4 primers 
were tested successfully using the two human ES cell lines H9 and CA for 
positive control (see chapter 5.1.1). 
5.4.2 CDX4 Confers Proliferative Potential to Murine BM Progenitors in 
vitro 
For assessment of the influence of CDX4 on the proliferative potential of 
hematopoietic cells, progenitor enriched 5-FU BM cells were retrovirally 
transduced with the Cdx4-containing construct or the empty vector for control 
and proliferation assays were performed. 
BM cells transduced with empty pMIG were not able to proliferate in the in vitro 
liquid culture (LC) over a time longer than one week but turned into mast cells. 
Results 
 
87 
In contrast, CDX4 was able to confer proliferative potential to the transduced 
cells with a cell number of 1.8x1011 after four weeks of culture in complete 
medium supplemented with cytokines. The same applied to the culture of Cdx4-
transduced cells in medium supplemented with IL-3 only. CDX4 was able to 
induce IL-3 dependent growth, and after two weeks showed an average cell 
number of 3.7x109 (n=6). Within the four weeks of IL-3 supplemented liquid 
culture, CDX4 promoted a more than 2x106-fold expansion of the initial input 
cell number. 
Figure 44: Proliferation assays of 5-FU murine BM cells transduced with pMIG and Cdx4. 
Transduced cells were sorted for eGFP expression and proliferation assays were set up with 
2.5x104 cells per plate. Cells were cultivated in DMEM 15% FBS supplemented with either A) 
cytokine cocktail (100 ng/ml mSCF, 10 ng/ml IL-6 and 6 ng/ml IL-3) or B) 10 ng/ml IL-3 only. 
Every week a half-medium change was performed, the cell number was determined by trypan 
exclusion and fresh cytokines were added to the culture. The diagram shows average cell 
numbers ± SEM. 
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5.4.3 CDX4 Does Not Block the Differentiation Program of Murine BM 
Progenitors in vitro 
As CDX4 expressing BM cells show high proliferative potential, it was analyzed 
if this could be due to a block in differentiation. To investigate this, 
immunophenotyping of Cdx4-transduced murine BM cells was performed. In 
IL-3 only conditions, the fraction of the different myeloid subpopulations 
remained almost unchanged with 38.2% myeloid cells after one week and 
41.0% after three weeks of culture (Figure 45C). After one week in culture 
supplemented with cytokine cocktail, overexpression of CDX4 resulted in 
increased differentiation into the myeloid lineage: 51.5% of the cells were 
positive for the myeloid markers Gr-1 and/or Mac-1 in the CDX4-overexpressing 
arm vs. 43.8% in the control arm. This difference was mainly due to an 
increased percentage of Gr-1-/Mac-1+ cells (p=n.s., Figures 45A and B). 
Although after three weeks of culture 50.2% myeloid cells were present, the 
ratio of the myeloid subpopulations changed in favor of Gr-1+/Mac-1- 
granulocytes (Figure 45B). The presence of cells with these marker 
combinations indicate that CDX4 overexpressing BM progenitor cells were not 
blocked in their differentiation ability but were able to give rise to mature 
hematopoietic cells. 
In none of the two arms growth of B220+ B-lymphoid cells or CD4 or CD8 
positive T-lymphoid cells was detected by immunophenotyping. 
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Figure 45: Immunophenotypic analysis of BM cells after three weeks of LC. 
5-FU BM cells were transduced with Cdx4 or empty pMIG and immunophenotypically analyzed 
by FACS Calibur each week A) pMIG-transduced cells in cytokine supplemented culture B) 
Cdx4-transduced cells in cytokine supplemented culture C) Cdx4-transduced cells in IL-3 only 
supplemented culture. 
A 
B 
C 
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Transduction of BM cells with Cdx4 additionally resulted in an increase of c-
Kit+/Sca-1+ blast forming cells. After three weeks in CC supplemented medium 
16.9% of the cells were positive for this marker combination, with addition of 
only IL-3 6.5% positive cells were detected. An increase was also observed for 
the population of c-Kit-/Sca-1+ cells, which constituted almost 60% of the cells 
after three weeks of culture in both arms. Although this population is not well 
defined, it was shown that it harbors clonogenic capacity in vitro (Metcalf et al., 
2009). 
Additionally, a small fraction of Ter119+ erythroid cells was observed after one 
week of culture in both arms. Whereas this fraction was almost lost after three 
weeks in IL-3 only conditions, a small percentage of Ter119+ cells was still 
present in CC supplemented culture. 
5.4.4 CDX4 Confers Serial Replating Capacity to Murine BM Progenitors 
in vitro without Blocking Differentiation 
To examine the effect of Cdx4 overexpression on committed hematopoietic 
progenitors, CFC assays were performed using M3434 methylcellulose, which 
supports growth of myeloid colonies. 
CDX4 showed a strong effect on the replating capacity of the transduced BM 
cells. As depicted in Figure 46A, CDX4 was able to confer a significantly higher 
proliferative potential to the transduced progenitors in first plating compared to 
pMIG and resulted in a 1.6-fold higher colony number (p=0.01). In contrast to 
pMIG-transduced BM cells, which were not replatable, CDX4 was able to confer 
replating capacity to the BM cells up to the 4th plating. After four weeks, an 
average colony number of 8.3x109 per dish was achieved. 
The same was observable in total cell number. After one week of culture, the 
number of Cdx4-transduced BM cells was significantly increased compared to 
the control (p=0.003). On average, one CDX4+ colony consisted of 2.7x104 cells 
whereas the median colony size of the pMIG control was 7.9x103. 
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Figure 46: Total number of cells per 500 cells in 1st plating. 
Cells were transduced with pMIG- and Cdx4-constructs, sorted for eGFP expression and plated 
in methylcellulose with 500 cells per dish. For replating, cells were diluted in an appropriate 
dilution. A) Columns represent average total colony numbers ± SEM. B) Columns represent 
average total cell numbers ± SEM. 
Figure 47 displays the colony type distribution of BM cells transduced with Cdx4 
and the empty vector control. Whereas 27.4% of the CFUs in pMIG-transduced 
BM cells were of the G type, no significant number of CFU-G was present in the 
CDX4 overexpressing arm. Instead, Cdx4-transduction led to a significant 
increase in the number of both CFU-M and CFU-blast in first plating compared 
to the control (CFU-M: p=0.02; CFU-blast: p=0.03). The number of blast 
colonies reached its maximum after 2nd plating with 43.1% of total colony 
number and then subsequently decreased. Over the four weeks of culture an 
increase of CFU-M was observed with a final percentage of 31.4% in 4th plating. 
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pMIG-transduced cells were not replatable and after the 1st week produced 
almost exclusively mast colonies. 
Figure 47: Colony distribution of pMIG- and Cdx4-transduced BM cells in CFC assay. 
The diagram shows the average percentage of the different colony types in proportion to the 
total colony number. Errors are SEM-based. 
The observations were confirmed by H&E staining of cells derived from CFC 
assay after 3rd plating. Whereas cells from the control arm revealed a mast cell-
like phenotype, CDX4-overexpressing cells phenotypically were identified as 
either undifferentiated progenitors or mature cells. The presence of terminally 
differentiated cells, especially macrophages, indicated the ability of Cdx4-
transduced progenitor cells to undergo terminal differentiation (Figure 48B). 
Figure 48: Pictures of cell morphology after 3rd plating of CFC assays. 
For assessment of cell morphology, cells were plated on glass slides using the cytospin method 
and stained with H&E. Pictures were taken with 400-fold amplification. 
pMIG Cdx4 
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To determine the lineage distribution, harvested BM cells were 
immunophenotypically analyzed after each round of CFC assay. One week after 
the beginning of the experiment, Cdx4-transduced BM cells showed a 
significant increase of c-Kit-/Sca-1+ clonogenic cells (p=0.023) as well as mature 
macrophages (p=0.015) compared to empty vector transduced cells (Figure 
49). Similar to LC, overexpression of CDX4 led to a decrease in the number of 
myeloid progenitors and committed progenitors in the CFC assay. After the first 
week of CFC culture, the Ter119+ cell population was significantly increased in 
the CDX4 arm (6.2-fold increase, p=0.020). 
As in LC, the Ter119+ population decreased over time in the CFC assay but 
Ter119 positive cells still were present after 3rd plating. Overexpression of CDX4 
was able to maintain this erythroid population up to 5th plating. After the 3rd 
plating, approximately one quarter of the cells showed blast-like c-Kit-/Sca-1+ 
immunophenotype. However, compared to the first plating, a pronounced 
expansion of the c-Kit+/ Sca-1- progenitors was observed with 13.1% of the cells 
displaying this marker combination. 
Figure 49: Immunophenotyping of CFCs. 
Depicted are the results of the immunophenotypic analysis after 1st week of CFC assay for 
pMIG-transduced cells and after 1st and 3rd week of CFC assay for Cdx4-transduced cells. The 
columns represent the number of positive cells per 500 cells in 1° plate ± SEM. 
Results  
 
94 
BM cells from five different CFC experiments (2nd to 4th plating) were 
transplanted into lethally irradiated mice (n=16). In none of these cases any 
long-term engraftment was detected. 
5.4.5 CDX4 Overexpressing BM Progenitor Cells Possess Short-Term 
Proliferation Advantage in vivo 
The previous in vitro results suggest that overexpression of CDX4 in murine BM 
progenitor cells enhances their proliferative and clonogenic potential without 
blocking the differentiation capacity. Subsequently it was investigated if also in 
vivo overexpression of Cdx4 in BM progenitor cells would enhance the self-
renewal properties of HSCs without affecting their differentiation program. To 
test this, lethally irradiated mice were transplanted with Cdx4-transduced 
progenitor enriched 5-FU BM cells and analyzed regularly by PB 
immunophenotyping. 
Cdx4-transduced progenitor cells readily engrafted all the transplanted 
experimental mice. Additionally, Cdx4-transduced cells had an obvious 
advantage in short-term engraftment compared to non-transduced 5-FU BM 
cells, at week four. Whereas at the time of transplantation on average only 
16.3% of the transplanted BM cells were positive for eGFP-expression, four 
weeks post transplantation 41.8% of the PB WBCs showed expression of 
eGFP. After this time point, the number of eGFP-positive cells declined, before 
slowly increasing again from week 12 on, indicating that CDX4 has also some 
effect on long-term stem cells. At week, 36, the percentage of eGFP positive 
cells reached almost 70%. 
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Figure 50: Engraftment of Cdx4 transduced 5-FU BM cells. 
5-FU BM cells were transduced with Cdx4 by cocultivation with stable virus expressing GP+E86 
feeder cells. After 72 h transduction the BM progenitor cells either were sorted for eGFP+ cells 
and transplanted together with mock BM cells (n=1) or transplanted without sorting (n=10). The 
diagram displays average engraftment of mice (at least 10 mice per time point) with eGFP+ cells 
± SEM. 
Despite the bias due to myeloid growth conditions before transplantation, the 
Cdx4-transduced BM progenitors were able to give rise to all lineages in vivo. 
As Figure 51 demonstrates, the PB analysis revealed multilineage engraftment 
of the transplanted BM progenitor cells already in week 4, which was 
maintained up to week 28 after transplantation. This indicates the potential of 
Cdx4-transduced cells to undergo long-term multilineage engraftment. The 
lineage distribution in week 28 hereby resembled that of untransduced BM cells 
with 23.0% (eGFP-, week 4) vs. 17.6% (eGFP+, week 28) expressing the 
erythroid marker Ter119, 33.5% vs. 29.3% the myeloid markers Gr-1 and/or 
Mac-1, and 10.8% vs. 9.5% the T-lymphoid markers CD8 or CD4. Only the 
B220+ B-lymphoid compartment turned out to be diminished in the CDX4-
overexpressing compartment (25.3% vs. 7.0%). 
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Figure 51: Immunophenotypic PB analysis of mice transplanted with unsorted Cdx4-
transduced BM progenitors. 
PB WBCs were analyzed at 4 weeks (n=8), 8 weeks (n=9) and 28 weeks (n=8) after 
transplantation. For week 4 the percentages of both the eGFP- (=untransduced) and eGFP+ 
(=Cdx4-transduced) compartments are shown. 
Within this time span, the number of RBCs constantly declined, starting at an 
average cell number of 1.1x1010/ml and reaching an RBC count of 4.7x109/ml in 
week 36 post transplantation (Figure 52). The WBC count in contrast remained 
nearly on the same level during the first 28 weeks with cell counts between 
4.0x106 and 1.0x107. However, after week 28 the WBC number rapidly 
increased and on average reached a concentration of 2.0x108/ml. 
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Figure 52: Hematological parameters of CDX4 engrafted mice. 
Peripheral blood was regularly taken from engrafted mice, transplanted with Cdx4-transduced 
5-FU BM cells (n=12) and RBC as well as WBC counts were determined. 
5.4.6 CDX4 Induces Myeloid Leukemia with Long-Latency 
As depicted in Figure 53, all mice transplanted with Cdx4-transduced BM 
progenitors succumbed to disease (n=12) with a median latency of 309 days 
post transplantation (range 154 – 504 days). 
Figure 53: Survival curve of mice transplanted with 5-FU BM cells expressing CDX4 or 
pMIG. 
Primary mice were transplanted with either Cdx4-transduced 5-FU BM cells (n=12, black line) 
or 5-FU BM cells transduced with empty pMIG for control (n=3, grey line). BM of four different 
diseased, CDX4-transplanted primary mice was transplanted into each four secondary 
recipients. The dashed line represents secondary transplanted mice (total number of 16). 
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All sacrificed mice (with the exception of mice 4513/A1 and 4513/A2, which 
were sacrificed in an early stage of disease) showed signs of anemia with an 
average RBC count of 5.0x109 and leukocytosis with a WBC count of 3.8x106 
on average. The majority of the analyzed mice additionally displayed 
splenomegaly with an average weight of 313 mg. 
As confirmed also by Wright-Giemsa staining and demonstrated in Figure 54, 
myeloid blasts were present in PB, BM and spleen of all diseased mice. 
Figure 54: Wright-Giemsa stained cytospins of PB, BM and spleen of representative mice 
demonstrate the presence of erythroblasts. 
A) PB of experimental mouse 4698/2, B) spleen of 4698/2, C) spleen of 4468/1, D) BM of 
4468/1. 
All experimental mice sacrificed in a terminal stage of disease showed a blast 
count above 20% in the BM (44% on average) and an equally high blast count 
of 44% in PB, thus confirming the presence of acute myeloid leukemia (Figure 
54 and Table 14). The highest percentage of blasts was detected in the spleen 
with an average 62% of the cells showing blast-like features. Both experimental 
mice 4513/A1 and 4513/A2, which were sacrificed in an early stage of disease, 
revealed an elevated BM blast count with 20% and 11%, respectively. All 
animals had a lymphoid/myeloid ratio below 1.0. Already the animals sacrificed 
in an early stage of disease showed a decreased ratio of 0.8 and 0.9. All other 
animals with more progressed stages of leukemia showed even lower ratios of 
0.01 and less. 
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Construc
t 
Mouse 
No 
Survival 
[d] RBC/ml WBC/ml 
Spleen 
Weight 
[mg] 
Blasts 
BM 
[%] 
Blasts 
Spleen 
[%] 
Blasts 
PB 
[%] 
L/M 
eGFP 1 90 6.0x109 4.5x106 150 0 0 0 5 
eGFP 2 90 4.8x109 3.2x106 200 0 0 0 2 
eGFP 3 90 5.0x109 3.6x106 200 0 0 0 2 
Cdx4 4329/3 423 1.5x109 2.3x106 164 57 >95 56 <0.01 
Cdx4 4401/2 178 7.3x108 1.1x107 449 >95 >95 61 0.02 
Cdx4 4456/1 222 1.3x109* 2.5x106* n.d. n.d. n.d. 52* <0.01* 
Cdx4 4468/1 504 5.9x108 1.2x106 401 35 62 52 <0.01 
Cdx4 4513/A1 364 1.8x1010 1.6x107 129 20 35 52 0.8 
Cdx4 4513/A2 364 1.4x1010 8.3x106 134 11 39 29 0.9 
Cdx4 4513/A3 341 8.5x108* 8.5x107* n.d. n.d. n.d. 63* 0.02* 
Cdx4 4513/B1 276 2.7x109* 3.4x106* n.d. n.d. n.d. 50* 0.1* 
Cdx4 4513/B2 257 2.3x109 2.3x107 505 27 39 2 <0.01 
Cdx4 4513/B3 472 6.1x109* 5.5x106* 345 65 75 25 <0.01 
Cdx4 4621/3 245 1.0x1010* 4.0x106* 398 n.d. n.d. 66* 0.1* 
Cdx4 4698/2 154 1.0x109 5.3x106 296 43 55 24 <0.01 
Table 14: Hematological parameters of experimental mice. 
*As spleen, BM and PB of some mice could not be analyzed due to sudden death of the 
animals, the results of the respective last PB analysis are indicated; n.d.: not determined, RBC: 
red blood cell, WBC: white blood cell, L/M: lymphoid/myeloid ratio in PB. Healthy control mice 
were sacrificed at day 90 post transplantation. 
To assess the lineage distribution within the hematopoietic system, BM, spleen 
and PB cells from euthanized leukemic mice were harvested and 
immunophenotypically analyzed by FACS Calibur. Figure 55 displays the 
immunophenotypic profile of a representative CDX4-transplanted mouse 
(4698/2). The leukemic Cdx4-overexpressing cells did not completely displace 
the healthy, eGFP- BM cells but still contributed to all lineages clearly more than 
1% at time of death. These untransduced, eGFP negative cells show 
differentiation patterns similar to healthy BM. Compared to the eGFP- 
compartment, in the eGFP+ compartment of all organs a profound increase of 
the myeloid cell population was observed. This effect went along with a severe 
decline of the B-lymphoid as well as T-lymphoid lineages, indicating the 
presence of acute myeloid leukemia. 
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Figure 55: Immunophenotype of hematopoietic cells. 
Expression of the myeloid markers Gr-1 and Mac-1, the B-lymphoid marker B220, the erythroid 
marker Ter119 and the T-lymphoid markers CD4 and CD8 on cells isolated from A) BM B) 
spleen and C) PB of a representative CDX4-transplanted animal (4698/2). The proportions of 
positive cells within the eGFP- and eGFP+ compartments are indicated. The untransduced, 
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eGFP- compartment equals normal hematopoiesis whereas the eGFP+ compartment 
demonstrates the leukemic engraftment. 
As depicted in Figure 56, similar results were found for all animals analyzed. All 
organs showed a considerable increase of Gr-1+/Mac-1+ myeloid progenitors 
within the eGFP+ myeloid compartment compared to the eGFP- myeloid 
compartment (PB: p=0.001, spleen: p=0.02). In contrast, the percentages of T-
cells (CD4+ and CD8+) as well as B-cells (B220+) were massively declined 
within the Cdx4-overexpressing compartment. A significant reduction of both the 
CD4+ and the CD8+ T-lymphoid lineage in PB and spleen was observed (spleen 
CD4+: p=0.002, CD8+: p=0.03; PB CD4+: p=0.003, CD8+: p=0.01). Also the 
percentage of B-lymphoid cells was severely reduced in PB and spleen (PB: 
p=0.02, spleen: p=0.0008). No significant change was observed in the erythroid 
compartment although the percentage of Ter119+ cells was slightly decreased 
in Cdx4-overexpressing cells of the spleen. 
In BM, the same trend as in PB and spleen was observed. However, the 
change in lineage distribution were not significant due to the lower number of 
analyzed samples. 
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Figure 56: Immunophenotypic analysis of diseased CDX4-transplanted mice. 
Mice were transplanted with 5-FU BM cells retrovirally transduced with Cdx4. Upon signs of 
disease, mice were sacrificed and the hematopoietic organs A) PB, B) spleen and C) BM were 
immunophenotypically characterized by FACS Calibur. 
A 
B 
C 
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To test for the transplantability of the disease, secondary transplantation 
experiments were performed with BM isolated from four different diseased mice 
(out of four independent experiments. Each 1x106 BM cells from each of the 
four different diseased primary mice, in combination with 5x105 helper cells 
were transplanted into four secondary mice. All these secondary mice were 
deceased with a median of 74 days post transplantation, five times shorter 
survival compared to primary animals, indicating the presence of transplantable 
leukemia. 
As depicted in Figure 57, all secondary mice revealed severe splenomegaly 
with an average spleen weight of 681 mg as well as leukocytosis with an 
average WBC count of 1.1x107. With an RBC count of 7.2x109 on average, no 
major change within the erythroid compartment was observed. 
Figure 57: Splenomegaly of a secondary CDX4-transplanted mouse. 
The spleen of a CDX4-transplanted mouse diseased of leukemia is shown in comparison to the 
spleen of a control mouse transplanted with pMIG-transduced BM cells. 
As depicted in Figure 58 and similar to the primary mice, an increased fraction 
of Gr-1 and/or Mac-1 myeloid cells was observed in secondary mice. 
Figure 58: Immunophenotypic analysis of a secondary CDX4-transplanted mouse. 
Immunophenotypic blot of a sacrificed secondary mouse were stained for Gr-1 and Mac-1. 
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5.4.7 CDX4 Induces Erythroid Leukemia in All Transplanted Mice 
The subtype of the AML was specified by (immuno-) histophatological analyses 
according to the ‘Bethesda proposals for classification of nonlymphoid 
hematopoietic neoplasms in mice’ (Kogan et al., 2002). Six primary animals 
were examined by H&E, Ter119, CD3 and B220 staining. According to their 
high percentage of erythroid precursors cells, all six animals were diagnosed 
with erythroleukemia. One of the mice (4468/1) was in an early stage of disease 
whereas all other five had full-blown erythroleukemia (Table 15, Figure 59). All 
secondary animals were histophatologically diagnosed with erythroleukemia, 
likewise. 
Interestingly, in two out of the six analyzed primary animals older than 40 
weeks, additionally adenocarcinomas of the colon were detected. 
 
Exp. Histopathology Diagnosis 
1° Transplanted Mice 
4329/3 
enlarged spleen with massive erythroid proliferation, few groups of MPO+ myeloid 
precursors; in red pulp proliferation of erythroid precursors in all stages of maturation; no 
other organ is infiltrated 
tumor around the bladder infiltrating the muscular tissue; adenocarcinoma of the caecal area 
erythroleukemia 
4401/2 
diffuse infiltrate in spleen, liver, kidney, lymph nodes, BM and lung, characterized by the 
presence of large cells with blastic chromatin, prominent nucleolus and moderate amount of 
cytoplasm without any sign of maturation; blastic cells are infiltrating the sinusoidal and 
periportal spaces of the liver as well as kidneys and lungs; the vast majority of cells is 
positive for myeloperoxidase; hyperplasia of the erythroid cells in the spleen 
erythroleukemia 
4468/1 
spleen enlarged by a diffuse infiltrate composed mainly of erythroid cells in all stages of 
maturation; only minority of the cells positive for MPO, vast majority positive for Ter119 ; all 
other organs free of infiltration 
early 
erythroleukemia. 
4513/B2 
diffuse infiltrate in spleen, liver, and lung characterized by the presence of large cells with 
blastic chromatin, prominent nucleolus and moderate amount of cytoplasm alternating with 
numerous erythroid precursors in all stages of differentiation; atypical red cells with 
abnormal mitosis; in the liver blastic cells and erythroid components are infiltrating the 
sinusoidal and periportal spaces; presence of blasts positive for MPO, however vast majority 
positive for Ter119 
granulosa cell tumor of the ovary; adenocarcinoma of the colon 
erythroleukemia 
4513/B3 
enlarged spleen. red pulp congested and shows proliferation of erythroid precursors in all 
stages of maturation together with proliferation of megakaryocytes; massive infiltration of 
erythroid precursors in all stages of differentiation intermingled with megakaryocytes; only 
residual groups of myeloid precursors; no other organ infiltrated 
erythroleukemia 
4698/2 
spleen enlarged by diffuse infiltrate composed mainly of erythroid cells in all stages of 
maturation and large cells with blastic chromatin, prominent nucleolus and moderate amount 
of cytoplasm; blastic cells are positive for MPO, erythroid precursors are Ter119+; all other 
organs are free of infiltration, only for MPO+ cells are in the vessels of sinusoids in lung, 
liver and kidney, suggesting circulation of leukemic cells 
erythroleukemia 
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Exp. Histopathology Diagnosis 
2° Transplanted Mice 
4537/2 
2° of 
4401/2 
diffuse infiltrate in multiple organs, characterized by the presence of large cells with blastic 
chromatin, prominent nucleolus and moderate amount of cytoplasm; blastic cells are 
infiltrating the sinusoidal and periportal spaces of liver, kidneys and lungs; vast majority of 
cells is positive for myeloperoxidase; hyperplasia of the erythroid cells in the spleen 
erythroleukemia 
4730/3 
2° of 
4513/B2 
spleen and liver infiltrated by mostly erythroid precursors in all stages of maturation with 
picnotic nuclei and abundant basophilic cytoplasm, atypical red cells with abnormal mitosis; 
minority of the cells is MPO+, vast majority of cells is Ter119+ 
erythroleukemia 
4955/A3 
2° of 
4468/1 
spleen, liver, lung, heart, pancreas, testis, intestine, lymph nodes and thymus show a diffuse 
infiltrate characterized by the presence of large blastic cells alternating with numerous 
erythroid precursors in all stages of differentiation; blastic cells and the erythroid components 
are infiltrating the sinusoidal and periportal spaces of the liver; presence of blasts positive for 
MPO, vast majority of erythroid precursors positive for Ter119; both components are observed 
in all organs 
erythroleukemia 
4955/B4 
2° of 
4698/2 
erythroleukemia 
Table 15: Results of histophatological analyses of diseased mice. 
Mice fixed in formalin were histophatologically analyzed by staining with H&E, Ter119 or MPO 
staining. 
The spleens of all mice showed diffuse to massive infiltration with myeloid 
blasts and erythroid precursors at different ratios. Whereas in mouse 4513/B2 
both MPO+ and Ter119+ blasts were present in almost equal amounts (Figure 
59A), in most of the other mice, especially in the secondary animals, the vast 
majority of blasts stained positive for Ter119 (Figure 59B). 
Figure 59: Histophatological analyses of spleens of diseased mice transplanted with 
CDX4+ 5-FU BM. 
Spleens of analyzed mice show different ratios of MPO+ myeloid blasts and Ter119+ erythroid 
precursors A) 4513/B2: in spleen both myeloblasts and erythroid precursors are present B) 
4730/3 (4513/B2 2°): only a small portion of cells are positive for MPO, however the vast 
majority are Ter119+. 
None of the animals stained abnormally for the B-lymphoid marker B220 or the 
T-lymphoid marker CD3. 
A 
B 
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Only in few of the primary animals leukemic blasts were present in organs other 
than BM and spleen. Of those animals, 4513/B2 showed liver and lung to be 
infiltrated with blasts. In mouse 4698/2, the infiltration of MPO+ cells in the 
sinusoids of lung, liver and kidney suggested circulation of the myeloid blasts. 
The organs, excluding BM and spleen, of the other four primary animals were 
free of MPO+ or Ter119+ blasts. 
In contrast, infiltration of blasts was detected in all secondary animals. Mice 
4573/1 and 4730/3 additionally showed infiltration of the liver, and in both 
4955/A3 and 4955/B4 multiple organ infiltration was present targeting practically 
every single organ except the brain. 
Figure 60: Infiltration of different organs by leukemic cells in 2° transplanted mice. 
Leukemic cells are infiltrating liver, pancreas, testis and lung of 4955/A3 (4468/1 2°) and 
4955/B4 (4698/2 2°). 
5.4.8 The Latency of CDX4-Induced Leukemia Does Not Depend on the 
Number of Transplanted Cells 
With a correlation coefficient (R2) of 0.07, Figure 61 demonstrates that there 
was no correlation between the number of transplanted cells and the survival 
time of primary transplanted experimental mice. Whereas mouse 4698/2 for 
example was transplanted with only 1.4x104 Cdx4-transduced BM cells and 
died after 22 weeks, all three mice of the 4513/A experiment, which were 
transplanted each with 8.1x105 BM cells, survived for more than 48 weeks. 
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Figure 61: Correlation plot of transplanted cell number and survival. 
Diamonds indicate individual CDX4-transplanted mice, crossed diamond indicates two animals. 
Standard PCR and subsequent sequencing of the PCR products confirmed the 
presence of the full-length, wild type Cdx4 transcript in all transplanted mice. All 
mice showed overexpression of Cdx4 compared to total normal BM – which 
was negative for Cdx4 expression with the PCR conditions applied below – and 
expressed WT Cdx4. 
Figure 62: PCR to detect Cdx4 expression in diseased mice. 
The PCR was performed with a cDNA input equivalent to 50 ng total RNA isolated from spleen, 
PB or BM of diseased mice or total normal BM for control. 
5.4.9 CDX4-Induced Leukemia Is of Oligoclonal Nature 
To determine the clonality of CDX4-induced leukemia, Southern blot analyses 
were performed on hematopoietic tissues of leukemic mice. 
The results of this analysis show that the disease in all four primary animals 
was of oligoclonal nature as revealed by the presence of multiple bands of 
different intensities within one sample (Figure 63). In BM and spleen of the 
secondary animal 4955/A4 bands of equal strength were visible, which normally 
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indicates monoclonal disease. However, in this case BM and spleen of the 
secondary animals were infiltrated with different clones. In each case, only one 
band corresponded with one band in the primary animal, and in both BM and 
spleen an additional second integration occurred. 
Figure 63: Southern blot of samples of CDX4-transplanted leukemic mice. 
Genomic DNA of BM, PB or spleen of diseased mice was digested with PstI and hybridized with 
a 32P labelled eGFP-probe. 
5.4.10 Transformation of Cdx4-Transduced BM Progenitors Does Not 
Depend on Common Retroviral Integration Sites 
To test the influence of retroviral insertion mutagenesis on leukemic 
transformation, linker mediated integration PCR was performed. The analysis in 
most cases revealed only one integration band per sample, as in samples from 
mice 4513/A2, 4698/2 or 4468/1 (Figure 64). Also in the spleens of mice 
4513/A1 and 4513/B2 only one band was visible. However, BM and PB showed 
a second faint band in both cases. All integration bands from the different 
organs of one animal were of the same size and corresponded to at least one of 
the bands detected by Southern blot. Where possible, the bands were 
sequenced and a control digestion was performed using KpnI, which resulted in 
a drop out of a 550 bp vector band in all the samples. 
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Figure 64: Results of the linker-mediated integration PCR. 
Arrows indicate faint bands. 
In three cases (4513/B2, 4513/B3b, 4468/1) the sequencing showed the 
provirus to be integrated upstream of repetitive elements, in all other cases one 
integration site was located. In mice 4329/3 and 4513/AS an integration 
occurred in introns of the zinc finger protein genes Zfp407 and Zfyve28, both 
genes of unknown function. However, many of the zinc finger proteins are 
transcription factors. The secondary transplanted animals of 4329/2, 4517/2, 
and 4537/1 showed an integration about 600 bases upstream of Opa3, a gene 
associated with optic atrophy (Reynier et al., 2004). In the case of 4513/A1, the 
integration was located approximately 600 bases upstream of Akap1, which 
codes for a membrane protein of the mitochondrial and endoplasmatic reticulum 
(Rogne et al., 2009). The proviral integration site found in 4513/B3a was located 
between two genes, 15 kb downstream of Coq2, which is involved in the 
biosynthesis of CoQ (Forsgren et al., 2004), and 80 kb upstream of Plac8, a 
gene of an unknown function as well but with high expression in hematopoietic 
tissues (Rissoan et al., 2002; Forsgren et al., 2004). In the case of 4698/2 the 
provirus integrated within an intron of the leukocyte activation antigen Sema4D 
(CD100), which is highly expressed in hematopoietic cells and involved in the 
activation of B- and T-cells (Shi et al., 2000). The integration found in mouse 
4727/2 is located upstream of two genes: about 10 kb upstream of the Pkd1 
gene coding for a transmembrane protein, which is suggested to be involved in 
renal tubulogenesis, and 4 kb upstream of Rab26, a member of the RAB family 
of small G-proteins which regulate intercellular vesicle trafficking. 
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Mouse No. Genomic Location Gene Description 
4329/3 18qE4 intron of Zfp407 zinc finger protein 407 
4517/2 
(4329/3 2°) 
7qA3 intergenic (upstream Opa3) optic atrophy 3 
4537/1 
(4401/2 2°) 
7qA3 intergenic (upstream Opa3) optic atrophy 3 
4513/A1 11qC intergenic (upstream Akap1) a-kinase (PRKA) anchor protein 1 
4513/A2 5qB2 intron of Zfyve28 (between exons 6 and 7) 
zinc finger, FYVE domain 
containing 28 
4513/B2 - (repetitive elements) - 
4513/B3 a 5qE4 intergenic (downstream Coq2, upstream Plac8) 
coenzyme Q2 homolog 
placenta-specific 8 
4513/B3 b - (repetitive elements) - 
4698/2 13qA5 intergenic/ upstream Sema4d (depending on splice variant) semaphorin 4D 
4727/2 17qA3.3 intergenic (upstream of Rab26, Pkd1) 
member RAS oncogene 
family 
polycystic kidney disease 1 
homolog 
4468/1 - (repetitive elements) - 
Table 16: Genomic integrations in hematopoietic cells of mice transplanted with Cdx4-
transduced BM cells. 
Genomic DNA extracted from BM, spleen and/or PB cells of diseased mice was analyzed for 
retroviral integration by linker-mediated PCR. Per mouse, only one integration was found by this 
method. However, none of the identified locations have thus far been described in the 
Retrovirus Tagged Cancer Gene (RTCGD) database (www.rtcgd.ncifcrf.gov). 
None of the integration sites identified in this analysis have been described in 
the Retrovirus Tagged Cancer Gene (RTCGD) database 
(www.rtcgd.ncifcrf.gov). This database comprises a collection of retroviral 
integration sites observed in murine tumors. 
5.5 Differential Effects of CDX2 and CDX4 
Our data demonstrated that aberrant expression of CDX2 is a widespread event 
not only in acute myeloid but also in acute lymphoid leukemia. While this 
supports a possible involvement of CDX2 in the induction of human leukemia, 
no expression of its family member CDX4 was found in leukemic patients. In 
contrast, whereas ectopic expression of Cdx2 in the murine BM transplantation 
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model leads to induction of an aggressive form of AML (Rawat et al., 2004), 
overexpression of Cdx4 in hematopoietic cells resulted in expansion of 
hematopoietic progenitors in vitro (Davidson et al., 2003). In the BM 
transplantation model used in this study, CDX4 induced leukemia only after long 
latency. 
To characterize possible mechanisms for the higher leukemogenicity of CDX2, 
the influence of both genes on murine hematopoiesis was compared and 
differences as well as similarities between the two genes were analyzed. 
5.5.1 CDX2 Possesses a Higher Leukemogenic Potential than CDX4 in 
vivo 
As reported by Rawat et al. (2004), CDX2 leads to induction of leukemia with a 
median latency of 116 days in vivo (Figure 65). The latency of CDX2-induced 
disease thus is significantly lower than that of CDX4-transplanted mice, which in 
median survived more than 353 days (p<0.001). 
Figure 65: Survival diagram of CDX2- and CDX4-transplanted mice. 
Primary mice were transplanted with either Cdx4-transduced 5-FU BM cells (n=12, black line) 
or 5-FU BM cells transduced with Cdx2 (n=16, dashed line). 
Whereas no significant difference of the WBC count was observed, CDX2-
transplanted mice showed an RBC number significantly decreased compared to 
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CDX4-transplanted mice with (p=0.03). A significant difference also was 
observed in the spleen weights, as spleens of CDX2+ mice in median had more 
than the double weight than those of CDX4-transplanted mice (p<0.0001). 
Interestingly, the blast cell count of spleen and PB was significantly higher in 
CDX4+ animals, which additionally showed a much more drastic inversion of the 
lymphoid/ myeloid ratio. 
 
Construc
t 
Survival [d] 
(range) RBC/ml  WBC/ml  
Spleen 
weight 
[mg]  
Blasts 
BM [%]  
Blasts 
spleen 
[%]  
Blasts 
PB [%]  L/M 
eGFP 
123.5 
(85-127)* 
5.7x109 ± 
9.3x108 
3.4x106 ± 
2.6x106 156 ± 59** 0 0 0 5 
Cdx4 
353 
(154-504) 
5.0x109 ± 
1.8x109 
1.4x107 ± 
7.0x106 313 ± 43 44 ± 27  62 ± 24 44 ± 20 0.17 
Cdx2 
111 
(37-229) 
6.8x108 ± 
1.4x108 
1.2x107 ± 
3.8x106 629 ± 68 45 ± 15 38 ± 15 18 ± 10 2 
Table 17: Comparison of hematological parameters of CDX2- and CDX4-transplanted 
mice. 
*a total of 4 (out of 6) healthy eGFP mice were killed for analysis. 2 out of the 6 control mice 
were analyzed by BM biopsy and bleeding. Values are given as average ± SD **Average weight 
of 4 eGFP mice, L/M: lymphoid/myeloid ratio in PB. 
Whereas primary CDX4-transplanted mice in most cases did not show any 
presence of blasts outside the hematopoietic organs, in the case of CDX2 
multiorgan infiltration with myeloid blasts was common (Figure 66). 
CDX2- as well as CDX4- transplanted animals displayed a similar 
immunophenotypic profile. In both experimental arms, a pronounced increase of 
the myeloid compartment was observed whereas both the B-lymphoid and the 
T-lymphoid compartments were severely decreased. 
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Figure 66: Histopathologically analyzed tissue sections of CDX2-transplanted mice 
(Rawat et al., 2004). 
Liver, lymph nodes (LN) and spleen were immunohistochemically analyzed by H&E and MPO 
staining. 
5.5.2 CDX2 and CDX4 Differentially Regulate Expression of Hoxb6 and 
Hoxb8 in vitro 
One possibility for the different oncogenic potential of CDX2 and CDX4 could be 
a differential regulation of Hox genes, which are able to confer self-renewal 
capacities to murine BM progenitors (see introduction, section 1.3.1). To 
analyze if a differential regulation of Hox genes could be responsible for the 
differing leukemogenicity of the two CDX members, 5-FU BM progenitors were 
transduced with CDX2, CDX4 and an empty vector control. The resulting effect 
on Hox gene expression was analyzed using TaqMan LDA 48 h after 
transduction. 
As diagram 67 displays, no significant difference was detected between CDX2- 
and CDX4-transduced BM progenitors in the expression of the analyzed HoxA 
cluster genes. Both genes induced an upregulation of the analyzed HoxA 
genes, which was especially pronounced in the more anterior Hox genes Hoxa5 
and Hoxa7. Transduction with Cdx2 and Cdx4 led to a significant upregulation 
of both genes with a more than 55-fold higher expression of Hoxa5 and a more 
than 65-fold increased expression of Hoxa7 compared to the empty vector 
control (Hoxa5: p<0.0001, Hoxa7: p=0.006). Furthermore, upregulation of 
Spleen 
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Hoxb3 was detected (CDX4: 5.2-fold, CDX2: 4.4-fold). Deregulation of Hoxb4 
was only observed in Cdx4-transduced BM cells where a 2.3-fold higher 
expression of Hoxb4 was measured. However, with a p-value of 0.06 this effect 
was of borderline significance. A 6.8-fold difference between the two CDX 
members was detected for Hoxb6 expression, where CDX2 induced a 
significantly stronger effect compared to CDX4 (p=0.002). Additionally, only 
CDX2 was able to induce Hoxb8 expression, as this gene was not expressed in 
the control nor in Cdx4-transduced BM cells. 
Figure 67: LDA analysis of Cdx2- and Cdx4-transduced BM cells. 
Murine progenitor enriched 5-FU BM cells were transduced with Cdx2, Cdx4 or empty pMIG for 
control and 48 h after transduction sorted for eYFP and eGFP expression, respectively. ΔCT 
values were obtained by normalizing to Gapdh and fold expression compared to pMIG was 
calculated. The diagram shows average expression levels of three independent experiments ± 
SD.° marks calculated values as pMIG-transduced cells were negative for Cdx2 expression. 
*: significant difference towards pMIG and between Cdx2 and Cdx4 respectively. 
Also in mice that died of AML after transplantation with Cdx2- or Cdx4-
transduced BM, Hox expression was analyzed. Here, the only differentially 
expressed Hox gene was Hoxb4, which was significantly 6.0-fold upregulated in 
CDX4-transplanted mice (p=0.04). 
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Figure 68: Expression of Hox genes in diseased, CDX-transplanted mice. 
Mice which died of AML after transplantation with Cdx2- or Cdx4-transduced BM were analyzed 
for expression of Hox genes by TaqMan qRT-PCR. 
5.5.3 CDX4 Is More Potent than CDX2 in vitro 
Although CDX2 compared to CDX4 is more leukemogenic in vivo, 
overexpression of the two Cdx genes leads only to small differences in 
differential Hox gene expression. To analyze if the different leukemogenicity of 
CDX2 and CDX4 would depend on a different clonogenic and proliferative 
potential, in vitro experiments were performed. 
First, the effect of an overexpression of both genes on the proliferative potential 
of BM progenitors was analyzed. Therefore, 5-FU BM cells were transduced 
with both constructs as well as empty vector control and liquid expansion 
assays were performed. As mentioned in section 5.4.2 as well as by Rawat et 
al. (2004), both genes are able to confer proliferative potential to BM 
progenitors. However, the average cell number of Cdx2-transduced cells was 
only 8.1x107 after four weeks of culture in complete medium (supplemented 
with cytokines), when CDX4 was able to expand the cells to a final number of 
1.8x1011. CDX4 hereby showed an almost 2,300-fold higher activity than CDX2 
(p=0.04, Figure 69A). The same is true for culture in medium supplemented 
with IL-3 only. In this assay, both constructs were able to induce IL-3 dependent 
growth and after one week both constructs showed a significantly higher cell 
number compared to pMIG (p<0.001, Figure 69B). After four weeks CDX4 
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promoted a 1,700-fold higher expansion of the transduced BM progenitor cells 
than CDX2 (p<0.001). 
Figure 69: Proliferation assays of 5-FU murine BM cells transduced with pMIG, Cdx2 and 
Cdx4. 
Transduced cells were sorted for eYFP and eGFP expression, respectively and proliferation 
assays were set up with 2.5x104 cells per plate. Cells were cultivated in DMEM 15% FBS 
supplemented with either cytokine cocktail (Figure A, 100 ng/ml mSCF, 10 ng/ml IL-6 and 6 
ng/ml IL-3) or 10 ng/ml IL-3 only (Figure B). The diagram shows average cell numbers ± SEM. 
Also, results from CFC assays show both constructs have a strong effect 
compared to empty pMIG-transduced cells and were able to confer replating 
capacity to the transduced cells up to fourth plating. As in LC, CDX4 
demonstrated a strong effect and led to a significantly increased colony number 
compared to CDX2 (p=0.019). 
1x1011 
1x1010 
1x109 
1x104 
1x105 
1x106 
1x107 
1x108 
1x1011 
1x1010 
1x109 
1x104 
1x105 
1x106 
1x107 
1x108 
A 
B 
Results 
 
117 
Figure 70: Total number of colonies per 500 cells in 1st week of CFC assay. 
Cells were transduced with pMIG-construct, sorted for eYFP and eGFP expression, respectively 
and plated in methylcellulose with 500 cells per dish. For replating, cells were diluted in an 
appropriate dilution. A) Columns represent average total colony numbers ± SEM. B) Columns 
represent average total cell numbers ± SEM. 
This difference was even more obvious in total cell number, where after 4th 
plating the cell number of Cdx4-transduced cells was 161.6-fold increased 
compared to Cdx2-transduced cells (p=0.03). The higher fold-difference in total 
cell number compared to total colony number between both constructs is due to 
a 22.5 times higher colony size within the Cdx4-transduced arm. Whereas 
colonies in the Cdx2-transduced arm after 4th plating contained on average 
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1.7x103 cells, Cdx4-overexpressing colonies at the same time-point on average 
contained 3.8x104 cells. 
This result reflects the different colony morphology of both arms. The CDX4 arm 
had 2.1-fold higher number of CFU-M than the CDX2 arm (p=0.0001, Figure 71, 
Figure 72A). On the other hand, Cdx2-transduced cells gave rise to a higher 
percentage of CFU-GM (p=0.001). Interestingly, CDX4+ CFU-GM generally 
were bigger in size than CFU-GM derived from Cdx2-transduced BM cells. With 
44.0% versus 33.5%, the percentage of blast colonies was significantly higher 
in Cdx2-transduced BM cells compared to Cdx4-transduced cells as well 
(p=0.02). No significant number of CFU-G was observed. 
Figure 71: Colony distribution after 3rd plating of CFC assay. 
The diagram shows the average percentage of the different colony types in proportion to the 
total colony number. Errors are SEM-based. 
This observation was confirmed by H&E staining of cells derived from CFC 
assay after 3rd plating. Whereas the majority of Cdx4-overexpressing cells 
phenotypically were identified as differentiated macrophages, a high fraction of 
the cells derived of the CDX2 arm revealed a primitive blast-like phenotype 
(Figure 72B). The same was seen concerning colony morphology. As indicated 
by Figure 72, a higher percentage of primitive blast-like colonies was present in 
the CDX2 arm after 3rd and 4th plating. Whereas after 4th plating there were 
almost exclusively blast-like colonies in the CDX2 arm, Cdx4-transduced cells 
still were able to generate a high number of CFU-GM and CFU-M. 
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Figure 72: Picture of representative colony cell morphology. 
A) Pictures of the colonies were taken with 50-fold amplification after 4th plating of CFC. B) For 
assessment of cell morphology, cells of 3rd plating were spread on glass slides using the 
cytospin method and stained with H&E. Pictures were taken in 400-fold amplification. 
As depicted in Figure 73, immunophenotypical analysis of Cdx2- and Cdx4-
transducd cells after 3rd plating revealed the majority of cells to express the 
myeloid markers Gr-1 and Mac-1. The positivity for these markers generally 
was higher in the CDX2 arm. 
A 
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Figure 73: Immunophenotypic analysis of Cdx2- and Cdx4-transduced cells after 3rd 
plating of CFCs. 
Transduced BM cells were harvested after 3rd CFC plating and analyzed by FACS Calibur for 
expression of myeloid markers. 
5.5.4 Aberrant Expression of Cdx2 Has a Considerably Higher Effect on 
Differential Gene Expression than Cdx4 
Although both homeobox genes confer clonogenic potential and high 
proliferation capacity to murine BM progenitors, only CDX2 possesses a high 
oncogenic potential whereas CDX4 has a weak oncogenic effect. The DNA-
binding homeodomain of both CDX members is strongly conserved, whereas 
the N-terminus is divergent (see attachment, Figure 76). Therefore, it would be 
interesting to know which targets both CDX members would have in common 
and could be responsible for their high clonogenic and proliferative potential. On 
the other hand, those genes deregulated only in Cdx2-transduced BM cells 
might allow finding pathways particularly critical for leukemogenesis. 
The effects of Cdx2- and Cdx4-overexpression on hematopoietic progenitor 
cells were analyzed by microarray experiments. 5-FU enriched BM progenitor 
cells were transduced with both genes as well as empty pMIG for control and 
total RNA was extracted 72 h after transduction. 
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By a first approach differentially regulated genes were obtained using the R 
implemented LIMMA package. The ectopic expression of CDX2 led to a 
differential expression of 2919 genes whereas by retroviral enhanced 
expression of CDX4 only 1246 differentially regulated genes were identified. 
Furthermore, as depicted in the intersection of the Venn-Diagram, more than 
half of the genes differentially regulated by CDX4 also were found to be 
differentially regulated by CDX2. When those genes were analyzed more 
closely, almost all of these genes were more strongly deregulated by CDX2 
than by CDX4. This indicates a much stronger effect of CDX2 on transcriptional 
gene regulation compared to CDX4. 
Figure 74: Venn-Diagram displaying the number of genes differentially regulated in the 
CDX2 and CDX4 arm compared to pMIG-transduced cells. 
Data obtained with Affymetrix Mouse Genome 430 2.0 microarrays were data normalized using 
the GCRMA package of R. Differentially regulated genes were determined using the R 
implemented LIMMA package. 41.771 genes of 43.431 genes in total were not affected by 
overexpression of Cdx2, Cdx4 or the empty pMIG vector. 
A more stringent approach, using the R twilight package to exclude false 
positive findings, led to a similar result. As before, transduction with Cdx2 
showed a considerably higher effect on differential gene expression when 
compared to the empty vector control than Cdx4. Via this approach, 130 
differentially regulated genes were identified in the CDX2 arm whereas in the 
CDX4 arm only 15 genes were detected. Thus, an 8.7-fold higher number of 
genes were deregulated in Cdx2-transduced BM cells compared to Cdx4-
transduced cells. Furthermore, eight out of the 15 identified genes differentially 
regulated by overexpression of Cdx4 were also deregulated in the CDX2 arm. 
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By the Panther Classification System (http://www.pantherdb.org) the list of 
differentially regulated genes identified by twilight were classified according to 
the ontologies of biological processes, pathways and molecular function. CDX2 
and CDX4 differentially regulated52 and 9 genes, respectively. Signal 
transduction processes were most affected by aberrant CDX2 and CDX4 
expression, followed by protein metabolism, immunity and developmental 
processes. 
Figure 75: Genes differentially regulated by CDX2 and CDX4 compared to pMIG-
transduced cells. 
5-FU enriched BM progenitor cells retrovirally transduced with Cdx2, Cdx4 or empty pMIG and 
highly purified by sorting for eYFP and eGFP expression, respectively. 72 h after the end of 
transduction successfully transduced cells were highly purified by FACS sorting and after an 
additional 24 hours of culture, total RNA was extracted. Affymetrix Mouse Genome 430 2.0 
microarrays were used to compare differential gene expression of Cdx2- and Cdx4- 
overexpressing BM cells to pMIG only expressing cells. Data were normalized using the 
GCRMA algorithm and differentially regulated genes were detected using the R twilight 
package. The Panther Classification System was used to classify differentially regulated genes 
(http://www.pantherdb.org). 
The CDX4 data did not show deregulation of specific pathways due to the low 
number of differentially regulated genes. Within the CDX2 arm the pathways for 
angiogenesis (number of deregulated genes =8), chemokine-mediated 
inflammation and cytokines signaling (n=7) as well as WNT signaling (n=7) 
were found to be significantly deregulated (p<0.001). 
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Interestingly, with a 4.6-fold increase, one of the highest differentially regulated 
genes within the CDX2 arm compared to the eGFP-transduced control was 
Dlk1, a gene which was shown to be upregulated in 61% of all AML cases, 
especially in AML M6 (Sakajiri et al., 2005; Khoury et al., 2010). Other 
significantly upregulated genes were Chi3l4, a chitinase of unknown function 
but high concentration in leukemic mice (Marchesi et al., 2006), the fetal germ 
cell marker Ddx4 as well as the ncRNA Meg3 which was shown to induce p53 
expression and is suggested to function as a tumor suppressor (Zhang et al., 
2009). Furthermore, aberrant CDX2 expression induced a differential 
upregulation of a number of signaling molecules including Wnt2 (4.1-fold), Il2ra 
(3.1-fold), Map3k8 (1.5-fold) or Tgfbr3 (1.4-fold). Downregulated expression 
was found especially for genes associated with differentiated (hematopoietic) 
cells as for example Mgl2 (2.9-fold), coding for a lectin expressed on antigen 
presenting cells, Ebi2, a G-protein coupled receptor which is expressed in 
mature B-cells, or Ffar2, encoding for a polymorphonuclear leukocytes 
expressed receptor (both 1.6-fold). Amongst the Hox genes, only Hoxb3 was 
found to be significantly deregulated (1.6-fold upregulation). 
Within the CDX4 arm, the highest differentially regulated genes, with a 3.8-fold 
increase compared to the eGFP-transduced control, were Peg9/Dlk1, Chi3l4, 
Ddx4 and Meg3/Gtl2. However, in all cases the deregulation of the above-
mentioned genes by CDX4 was less pronounced than by transduction with 
CDX2. Additionally, Cdx4-transduced BM cells showed a significant 1.3-fold 
differential upregulation of Epb4.2, which codes for an erythrocyte membrane 
skeletal protein detected in early erythroblasts and was found to be induced 
during erythroid differentiation (Zhu et al., 1998). Like CDX2, CDX4 also 
induced a significant, 1.5-fold, downregulation of Ebi2. Amongst others the 
expression of Gpnmb, encoding a transmembrane protein highly expressed 
during macrophage differentiation, as well as CD36, which is expressed e.g. on 
macrophages or early erythroid cells, was also significantly decreased (1.3-fold 
and 1.7-fold, respectively). Most highly downregulated in Cdx4-transduced BM 
cells was Sucnr1, a gene coding for the succinate receptor GPR91. This 
receptor stimulates proliferation by activation of the MAPK pathway and is 
highly expressed in human CD34+ progenitor as well as erythroid and 
megakaryocytic cells (Hakak et al., 2009). A significant 1.3-fold decrease also 
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was observed in the transcript levels for the tumor necrosis factor Tnfaip3, a 
zinc finger protein inhibiting NF-κB. 
When the gene expression profiles of both CDX members were compared, 
again signal transduction revealed to be the highest differentially regulated 
process with 22 affected genes followed by immunity & defense and 
developmental processes with 12 genes each. All of these genes were 
upregulated in Cdx2-transduced BM cells compared to Cdx4-transduced cells. 
Amongst those genes, Irs1 was found to be 2.7-fold upregulated in the CDX2 
arm, an oncogene essential for IGF-mediated proliferation and aberrantly 
expressed in several human cancers (Parathath et al., 2008) and Foxo1 (1.3-
fold up) which was shown to be targeted by MAPK signaling (Asada et al., 
2007). The most deregulated signal transduction pathway however was the Wnt 
pathway, which was significantly upregulated in BM cells aberrantly expressing 
CDX2 compared to CDX4-transduced BM cells. Deregulated members of this 
pathway include Wnt2 (4.1-fold upregulated in CDX2 vs. CDX4), Fzd1 (2.6-fold 
up), Tcf4 (1.6-fold up) or Bambi (1.4-fold up). 
The (over-) expression of wild-type Cdx2 and Cdx4 in the transduced 5-FU BM 
samples was confirmed by real-time PCR and subsequent sequencing. 
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6. DISCUSSION 
A primary feature of leukemia propagating cells is their ability to self-renew and 
indefinitely proliferate, acquired by genetic aberrations or epigenetic changes. 
Several factors conferring these abilities are members of the homeobox family, 
amongst others the family of Hox genes, which are found to be deregulated in a 
number of acute leukemia patients. In some of the cases, this aberrant 
expression can be explained by a deregulation of the HOX upstream regulator 
MLL, though in most of the cases the cause for HOX gene deregulation still is 
unclear. 
One group of genes, known to be upstream regulators of Hox genes during 
embryogenesis, is the CDX family. Their role in adult normal and malignant 
hematopoiesis as well as their functional relevance to HOX gene deregulation in 
acute leukemia has not been well characterized thus far and is therefore the 
subject of this study. 
6.1 CDX2 in AML 
Deregulation of HOX genes is a common feature found in about one third of 
human AML. Beside those patients harboring MLL-rearrangements, HOX gene 
aberrations classically are connected to AML NK patients with NPM1 mutations 
(Alcalay et al., 2005; Falini et al., 2007). Microarray analysis of different AML 
subgroups of normal and aberrant karyotype performed in the course of this 
study show that deregulation of HOX cluster genes is not only present in AML 
NK patients with NPMc+ but also in those NK patients missing this mutation. 
The reason for altered HOX gene expression in the cases of AML NK, however, 
is still largely unknown. 
To address this question, AML patients were screened for the expression of 
CDX2, an upstream regulator of Hox genes during embryogenesis. The results 
of this test revealed that CDX2 is aberrantly expressed in 79% of human AML 
patients. Hereby an aberrant expression of CDX2 was not only more common in 
patients with AML NK compared to patients with abnormal karyotype (89% vs. 
64%), but the expression level of CDX2 was also significantly higher (15-fold 
higher) in patients with NK. The screening did not indicate any correlation of the 
NPM1 mutational status with the frequency and height of aberrant CDX2 
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expression. These results are consistent to the findings of Scholl et al. (2007) 
who detected aberrant expression of CDX2 in the vast majority of analyzed 
AML patient samples, as well. Only the expression levels within the different 
AML subgroups differed slightly as Scholl et al. reported the highest expression 
of CDX2 in patients with t(9;11) followed by AML NK and t(15;17) positive 
patients. In this study the highest expression was found in AML NK followed by 
t(9;11) and t(15;17). This, however, most probably reflects the small number of 
patients analyzed in both studies. Interestingly, in both screens a relatively high 
expression level of CDX2 together with almost 100% positivity was detected in 
patients with PML-RARα translocations. PML-RARα leads to a block in 
differentiation, in vivo transgenic mice develop leukemia after a long latency and 
with only incomplete penetrance (Brown et al., 1997; Grisolano et al., 1997). 
Aberrant expression of CDX2 in this case may serve as a second hit by 
conferring enhanced proliferation potential. In two more closely analyzed AML 
patients, Scholl et al. found CDX2 expression levels to correlate with disease 
burden, underlining the importance of aberrant CDX2 expression in acute 
myeloid leukemogenesis. 
HOX gene deregulation was found to be present not only in NPMc+ patients but 
also in those patients without NPM1 mutations. As high expression of CDX2 
was detected in both of these groups, it was tested if the expression pattern of 
CDX2 would correlate with that of HOX genes. This was done by unsupervised 
hierarchical clustering of microarray data from AML patients and normal BM 
data according to HOX gene expression. By this analysis, two main clusters 
were identified: the first consisting of NK patients, which showed profound 
deregulation of HOX genes, the second cluster consisted of patients with 
abnormal karyotype together with normal BM samples, which showed equally 
low HOX expression levels. This suggests that not an aberrant expression of 
CDX2 per se, but rather the height of the CDX2 expression level is of 
importance for deregulation HOX gene expression. Finding that the two NK 
patients with lowest CDX2 expression of all tested NK patients fell into the 
abnormal karyotype cluster moreover supported this hypothesis. Immature, 
CD34+ hematopoietic cells naturally express high levels of HOX genes. As 
NPMc+ patients show less than 5% of CD34+ blasts (Verhaak et al., 2005), the 
increased HOX expression levels cannot be explained by an accumulation of 
immature blast cells. Overexpression of the HOX gene upstream regulator MLL 
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was found in only one case of a patient with NK and therefore did not influence 
the clustering. Also the expression level and the mutational status of FLT3 were 
reported to correlate to upregulated HOX gene expression in AML (Roche et al., 
2004). However, this correlation could not be confirmed in this study. Although 
some possible reasons for high or deregulated HOX gene expression were 
excluded, it cannot be ruled out that other, still unknown factors contribute to 
HOX gene deregulation in AML NK. Contribution of additional regulatory 
mechanisms, for example, would explain the higher deregulation of HOX genes 
in AML NK with NPMc+ compared to NK patients without NPM mutation, which 
did not show any significant differences in their CDX2 expression levels. 
To investigate if CDX2 could be functionally involved in the deregulation of HOX 
genes in AML, the ability of CDX2 to regulate Hox gene expression in adult 
hematopoiesis was tested by retroviral overexpression of CDX2 in murine 
hematopoietic progenitors. In this assay, CDX2 was able to significantly 
upregulate expression of Hoxa5, Hoxa7, Hoxa9, Hoxa10 as well as Hoxb3, 
Hoxb6 and Hoxb8 compared to empty vector-transduced cells. All of these Hox 
genes have been reported to possess leukemic potential (Bach et al., 2010, 
Perkins et al., 1990; Thorsteinsdottir et al., 2001; Fischbach et al., 2005). The 
N-terminal transactivation domain of CDX2 is clearly important for the regulation 
of Hox gene expression (Rawat et al., 2008). This data is in line with previous 
findings reporting CDX2 to be able to deregulate Hox gene expression in 
embryonic as well as adult nonhematopoietic tissues (Chawengsaksophak et 
al., 2004; Liu et al., 2007). Interestingly, CDX2 especially deregulated Hox 
genes of the HoxA and HoxB cluster, those clusters reported to be upregulated 
in NPMc+ patients (Verhaak et al., 2005). 
To test if expression of other members of the CDX family could be responsible 
for the deregulation of HOX cluster genes, 24 AML NK patients were tested for 
CDX1 and 48 AML NK patients for CDX4 expression. However, neither CDX1 
nor CDX4 expression was detectable in any of the samples analyzed. This is in 
contrast to the findings of Bansal et al. (2006) who reported aberrant expression 
of CDX4 in 10 out of 44 analyzed AML patients. However, in this study a 
different primer set was used, which possibly was of a different efficiency, and 
the expression of CDX4 was not tested in human normal hematopoietic tissue. 
Therefore, it is impossible to tell if CDX4 in AML was actually overexpressed 
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compared to normal BM or detectable in their study only due to a higher overall 
sensitivity of the applied test. As the expression of CDX4 in this study 
furthermore did not correlate to those AML subtypes where HOX gene 
deregulation can be observed, an eventual expression of CDX4 in some AML 
cases seems to be of only low relevance for aberrant HOX gene expression in 
AML. 
As shown by Rawat et al. (2004), CDX2 possesses a strong leukemogenic 
potential in the murine BM transplantation model where it induced fully 
penetrant AML. This capacity, combined with its ability to deregulate HoxA and 
HoxB cluster genes in adult hematopoietic progenitors and its high expression 
in the AML subtypes with high HOX gene deregulation strongly support the 
hypothesis of an involvement of CDX2 in the leukemogenesis of AML via 
deregulation of HOX genes. 
6.2 CDX2 in ALL 
To test if aberrant expression of CDX2 is a feature characteristic for AML only 
or if it can also be found in different types of leukemia, 57 newly diagnosed ALL 
patients were tested for CDX2 expression. In this study, it was shown for the 
first time that CDX2 is aberrantly expressed in the majority of ALL patients with 
81% overall positivity. The overall expression level of CDX2 in ALL exceeded 
that of AML patients with NK, demonstrating that aberrant expression of CDX2 
is not restricted to myeloid malignancies. 
The expression level of CDX2 in ALL significantly correlated with subtypes and 
survival. High expression levels were associated with high and very high risk 
and with an inferior overall survival. Although this study was performed with a 
low number of patients, CDX2 remained an independent risk factor even after 
adjusting for the risk factors age and presence of molecular markers by 
bivariate Cox regression. This indicates aberrant CDX2 expression is an 
important mechanism in the leukemogenesis of ALL. As reported by Riedt et al. 
(2009) the same is true for pediatric ALL where the vast majority of patients 
showed aberrant expression of CDX2. Also in this study, aberrant expression of 
CDX2 significantly correlated to an inferior disease outcome, which was 
determined by linking CDX2 expression as minimal residual disease (MRD) to 
treatment outcome. 
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Unlike AML, HOX gene deregulation is less common in ALL (Armstrong et al., 
2002; Quentmeier et al., 2004). Additionally in ALL - in contrast to AML - only 
low correlation between the expression of HOX genes with the expression of 
CDX2 was found. This could indicate that in ALL the leukemogenic effect of 
CDX2 does not depend on HOX gene perturbation to the same extent as in 
AML. The oncogenic potential of CDX2 rather seems to be mediated through 
different regulatory networks. Results of TaqMan LDA demonstrated that 
besides Hox deregulation aberrant CDX2 expression also led to an altered 
expression of a number of genes involved in lymphopoiesis. Affected for 
example were Lef1, Tcf3 or Id3, genes which are frequently deregulated in 
lymphoid leukemia (Ferrando et al., 2003; Mullighan et al., 2007) or, in the case 
of Lef-1, lead to induction of AML and B-ALL when deregulated (Petropoulos et 
al., 2008). An aberrant expression of CDX2 therefore may play a role in 
induction and/or maintenance of myeloid as well as lymphoid leukemia, possibly 
depending on the cell stage and type in which aberrant CDX2 expression 
initially occurs. 
The functional relevance of CDX2 for growth of transformed lymphoid cells was 
confirmed by a knockdown experiment where reduced expression of CDX2 in 
the human pre-B cell line Nalm-6 led to an impaired growth and clonogenic 
potential of the cell line. The same was previously shown for different AML cell 
lines by Scholl et al. (2007) and highlights the importance of CDX2 expression 
for the transformation of lymphoid and myeloid hematopoietic cells in human 
leukemic cell lines. 
This data demonstrates CDX2 is a novel proto-oncogene aberrantly expressed 
in the majority of adult ALL patients where it serves as an independent risk 
factor for inferior overall survival. In contrast to AML, aberrant expression of 
CDX2 in ALL was not associated with the deregulated HOX gene expression. It 
was shown that ectopic expression of CDX2 affects several pathways involved 
in lymphoid commitment and differentiation and is important for the growth of 
the leukemic cell line Nalm-6. This hints at a functional relevance for CDX2 for 
initiation and/or maintenance of the lymphoblastic clone, but also at common 
pathways activated in both lymphoid and myeloid leukemia. 
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6.3 Aberrant Expression of CDX2 in Acute Leukemia 
Different to the publication of Chase et al. (1999) (who reported CDX2 to be 
expressed in only one AML patient and absent in all other cases analyzed but 
used the less sensitive standard PCR) this and other studies show that aberrant 
expression of CDX2 is a frequent event both in AML as well as ALL (Scholl et 
al., 2007; Rawat et al., 2008; Riedt et al., 2009; Thoene et al., 2009). 
Nevertheless, the mechanisms leading to aberrant CDX2 expression in acute 
leukemia is still unclear. 
As demonstrated in this study, the methylation level of the promoter region did 
not correspond to the expression level of CDX2, which is in line with previous 
publications (Scholl et al., 2007; Pereira et al., 2009). In addition, treatment of 
CDX2-negative cell lines with demethylating agents did not lead to an induction 
of CDX2 expression (Hinoi et al., 2003), suggesting that CDX2 expression in 
leukemia is independent of promoter hypomethylation as well as the 
methylation level of cis-regulatory elements. Amplification of the CDX2 locus 
was detected only in a small percentage of patients with complex karyotype, 
however not in AML patients with normal or other aberrant karyotypes (Rucker 
et al., 2006; Scholl et al., 2007). Sequencing of the coding region of CDX2 did 
not – neither in the study of Scholl et al., nor in this study –reveal any mutations 
that could affect mRNA stability. 
One other possibility, leading to aberrant transcription of CDX2 could be 
deregulation of trans-acting pathways, which target cis-regulatory elements in 
the 5’ region of the CDX2 gene as suggested by Hinoi et al. (2003). No 
mutations were found in the promoter region of CDX2, however one cannot 
exclude the possibility that still unknown mutations in cis-regulatory elements of 
the CDX2 gene might account for its aberrant expression. It would be 
interesting, therefore, to expand the sequence analysis of the CDX2 gene 
beyond its coding and promoter region and to conduct a more comprehensive 
sequence analysis on the above-mentioned regulatory regions. For example, 
genetic alterations could occur in negative regulators, which Wang & 
Shashikant (2007) postulated to be present in an 11.4 kb sequence flanking 
Cdx2. Disruption of these elements in hematopoietic cells subsequently could 
lead to an aberrant expression of the generally silenced CDX2. Mutations within 
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two enhancer regions in the first intron of CDX2, which were demonstrated to 
induce ectopic expression of Cdx2 in the murine embryo, could lead to aberrant 
CDX2 expression (Wang and Shashikant, 2007). Interestingly, several binding 
sites for FGF and Wnt signaling were identified in these regions. Mutations in 
the non-coding regions of Cdx2 therefore could possibly affect the binding of 
factors like FGF4, which was previously shown to target Cdx2 (Murohashi et al., 
2010). Furthermore, it is probable that CDX2 not only regulates but is also 
targeted by WNT signaling as already shown for its paralogs CDX1 and CDX4 
(Shimizu et al., 2005; Pilon et al., 2006). Another pathway which was described 
to regulate CDX2 expression is RAS/MAPK signaling (Lu et al., 2008), a 
pathway which links extracellular stimuli, amongst others, to proliferation, 
differentiation and cell survival (Milella et al., 2001; Lee and McCubrey, 2002; 
Steelman et al., 2008). Both the WNT and RAS/MAPK pathway are frequently 
deregulated in leukemia. Their deregulation, in combination with genetic 
alterations in trans- or cis-regulatory elements of Cdx2, could possibly affect the 
transcription of the gene. As these two pathways are important for lymphoid and 
myeloid leukemogenesis, localization of CDX2 downstream of one or more of 
these signaling pathways could explain the high number of CDX2 positive cases 
in AML and ALL. A better investigation of the mechanisms leading to aberrant 
expression of CDX2 thus might lead to a better understanding of common 
molecular mechanisms of leukemogenesis in both myeloid and lymphoid 
leukemia. 
6.4 CDX4 in the Murine Transplantation Model 
In contrast to the highly leukemogenic CDX2, its paralog CDX4 was reported to 
possess high stem cell amplificatory potential on murine embryonic 
hematopoietic progenitors in vitro, which even exceeded that of Hoxb4 
(Davidson et al., 2003). The aim of this study therefore was to functionally 
analyze the role of CDX4 in adult hematopoiesis by use of the murine BM 
transplantation model. 
In vitro, overexpression of CDX4 led to an enhanced proliferative as well as 
clonogenic capacity of the transduced cells and promoted growth, especially 
growth of myeloid cells. The high proliferative potential of CDX4-transduced BM 
cells could be due to a pronounced increase of c-Kit-/ Sca1+ cells in both LC 
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and CFC assays. This marker combination is expressed on primitive cell 
populations, which are shown to possess high clonogenic capacity in vitro 
(Metcalf et al., 2009). This is in line with data previously published by Bansal et 
al. (2006) who demonstrated CDX4 is able to confer enhanced replating and 
proliferative potential to transduced murine hematopoietic cells. In addition, 
Davidson et al. (2003) and Wang et al. (2005) observed an expansion of 
particularly the progenitor population. Both publications additionally reported an 
increase of myeloid colonies after transduction of murine embryonic 
hematopoietic progenitors and ESCs, with CDX4. 
Although the overall fraction of myeloid cells in LC remained stable over time, 
immunophenotypic analysis revealed an increase of the Gr-1+/Mac-1- fraction 
and a decrease of the Gr-1-/Mac-1+ compartment in the IL-3/IL-6/SCF 
supplemented culture. As this effect was not observed in IL-3 only culture the 
shift in fraction seems to depend on the presence of IL-6 or SCF, the c-Kit 
ligand. This suggests an altered differentiation behavior of c-Kit+ committed 
progenitors. A function of CDX4 particularly on the level of early hematopoietic 
progenitors is indicated by the expression profile of CDX4. According to the 
expression analysis performed in this study as well as according to the results 
of Bansal et al. (2006), Cdx4 is highly expressed in 5-FU enriched 
hematopoietic progenitors and particularly high in the lineage-committed CMP 
population. 
Overexpression of CDX4 in vivo initially did not lead to a block in hematopoietic 
differentiation. However, aberrant CDX4 expression in vivo conferred a short-
term proliferation advantage to the transduced BM cells compared to non-
transduced cells with an engraftment of almost 42% four weeks after 
transplantation and a decrease in the eGFP+ compartment after this time point. 
Whereas the myeloid and T-lymphoid lineage distribution of the eGFP+ 
compartment resembled that of the eGFP- compartment, the B-lymphoid 
lineage was reduced in eGFP+ hematopoietic cells. As this effect of CDX4 led to 
a change in the lymphoid/myeloid ratio, it suggests an alteration in the 
differentiation behavior of the transduced stem cells. The fact that all lineages 
were present in the eGFP+ fraction suggests that retrovirally enforced 
expression of CDX4 in vivo acts on the level of multipotent progenitor cells, 
which are able to differentiate into all the hematopoietic lineages. Furthermore, 
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it indicates that CDX4-overexpression did not block differentiation but allowed 
terminal differentiation of the transduced hematopoietic cells. 
All mice transplanted with Cdx4-transduced BM died of transplantable leukemia 
of long latency. The median latency for primary transplanted animals was 353 
days whereas secondary transplanted animals succumbed to leukemia with a 
median latency of 74 days. This equals the results published by Bansal et al. 
(2006) who reported primary CDX4-transplanted animals to die with a median 
latency of 300 days after transplantation. However, in the Balb/c mouse model 
of Bansal et al. aberrant expression of CDX4 did not lead to complete 
penetrance of the leukemia, only transplantation with BM cells coexpressing 
CDX4 and MEIS1 led to induction of disease in all experimental animals. Meis1 
was shown to collaborate with certain Hox genes such as Hoxa9 and Hoxb3 
(Kroon et al., 1998; Thorsteinsdottir et al., 2001), which in this and other studies 
was shown to be deregulated by overexpression of CDX4 (Davidson et al., 
2003; Bansal et al., 2006; Yan et al., 2006). This finding therefore suggests that 
the leukemic effect of CDX4 is, at least to a certain part, due to the induction of 
aberrant Hox gene expression (Kroon et al., 1998; Thorsteinsdottir et al., 2001; 
Davidson et al., 2003; Bansal et al., 2006). The long latency of primary 
transplanted animals furthermore suggests that aberrant expression of CDX4 
alone is not sufficient to induce leukemia. To investigate possible additional hits, 
contribution of retroviral insertions to the induction of leukemia was tested by 
LM-PCR. Although most of the intergenic insertions were located within a 
distance to genes, which could possibly affect their transcription (Bartholomew 
and Ihle, 1991), none of the examined integrations was inside the ‘Retrovirus 
Tagged Cancer Gene Database’ (RTCGD), a database comprising retrovirus 
and transposon insertion sites. Additionally, none of the affected genes were 
reported to be involved in hematological malignancies. However, as it was not 
possible to analyze every retroviral integration site in all the mice, therefore an 
involvement of insertional mutagenesis in this leukemia model cannot be 
excluded. Nevertheless, aberrant CDX4 expression may serve as an initiating 
event in leukemogenesis by conferring enhanced clonogenic and proliferative 
capacity to hematopoietic cells. This would be supported by previous findings of 
Yan et al. (2006) who demonstrated by an in vitro approach that after activation 
of HoxA cluster genes, expression of CDX4 is no longer required. The group 
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therefore proposed that expression of CDX4 is required only in early stages of 
MLL-fusion gene induced transformation to induce Hox expression.  
Histopathologically, the diseased primary and secondary transplanted mice 
were diagnosed with erythroleukemia in all the cases. Most of the blasts were of 
the erythroid lineage, but in all the cases at least 20% of MPO+ myeloid blasts 
additionally were present in the histophatologically analyzed organs. The 
highest percentage of blasts was found in the spleen with an average blast cell 
count of 61%. This might be due to the induction of stress erythropoiesis, which 
in the mouse occurs in the spleen (Socolovsky et al., 2001). A block in 
differentiation of erythroid cells and a thereby decreased count of differentiated 
RBCs leads to expansion of the erythropoietic tissue and hereby would induce 
splenomegaly as observed in CDX4-transplanted mice. 
Taken together, these results suggest that CDX4 exerts its influence on the 
level of multipotent and/or very early committed progenitors and that, at least in 
part, this effect is due to the upregulation of Hox genes. The long latency of 
CDX4-induced leukemia, however, indicates that overexpression of this gene is 
not sufficient to induce leukemia on its own. 
6.5 CDX4 in the Erythroid Lineage 
Enforced overexpression of CDX4 in the murine BM transplantation model led 
to an expansion of hematopoietic progenitors and to the development of 
erythroleukemia in all cases indicating, that perturbed expression of CDX4 also 
disturbed the erythroid lineage. 
The effect of CDX4 on erythroid cells was observable already in vitro where in 
liquid culture as well as in CFC assay the maintenance of a population of 
Ter119+ erythroid cells was observed over more than three weeks of culture. 
This indicates that CDX4 is able to confer serial replating capacity to erythroid 
progenitors. Interestingly, an effect of CDX4 in particular on the erythroid 
lineage was already shown in embryonic development, where Wang et al. 
(2008) observed a reduction in the formation of primarily multipotent and 
erythroid progenitors in CDX4-deficient murine ESCs. Overexpression of CDX4 
in an ES cell line on the other hand led to an increase of primitive erythroid 
colonies (Wang et al., 2005). Wang et al. furthermore showed CDX4 is able to 
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induce strong upregulation of PU.1, which is known to block erythroid 
differentiation and is required for induction of erythroleukemia (Amaravadi and 
Klemsz, 1999; Afrikanova et al., 2002). PU.1 also drives lineage specification 
towards macrophage differentiation (Dahl et al., 2003), which may explain the 
increase of this lineage in Cdx4-transduced BM cells in the first week of LC as 
well as in CFC assay. 
In vivo CDX4 was reported to affect the erythroid lineage, as well. Davidson et 
al. (2003) demonstrated that a loss of function mutation of cdx4 leads to a 
defect in early hematopoiesis in the zebrafish embryo resulting in a severe 
decrease of hemoglobin-expressing erythroid cells combined with a reduction of 
gata1+ erythroid precursors. An overexpression of CDX4 in contrast led to 
ectopic blood formation in vivo (Davidson et al., 2003). However, the long 
latency of the erythroid leukemia observed in CDX4-transplanted mice indicates 
the need for accumulation of further genetic alterations. 
The fact that CDX4-transplanted leukemic mice died of erythroleukemia may 
explain why no leukemic ex vivo cell line could be derived of those mice. For 
PU.1+ erythroleukemia, for example, it was reported that despite their 
transformation permanent erythroleukemic cell lines could be obtained only by 
culture in Epo-supplemented conditions (Moreau-Gachelin, 2006). However, the 
culture conditions routinely employed in this study did not include any addition 
of Epo and thus may have led to an exhaustion of the leukemic erythroblast 
cells. This is in contrast to erythroleukemia induced by the Friend leukemia 
virus, which leads to aberrant activation of the erythropoietin receptor (EpoR) 
(Ruscetti, 1999) and would indicate that CDX4 does not lead to altered activity 
of EpoR, but drives transformation by alternative pathways. 
The results of this study suggest a role of CDX4 in the expansion of erythroid 
progenitors as well as an involvement in the leukemic transformation of 
erythroid cells. CDX4 therefore might be a novel factor in the determination of 
erythroid cell fate but may also be of importance for induction of erythroid 
leukemia in humans. In particular, it would be interesting to investigate whether 
the results of the BM transplantation model can be  repeated in humans and to 
investigate a possible involvement of CDX4 in human erythroleukemia. 
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6.6 Differential Effects of CDX2 and CDX4 
CDX2 and CDX4 both belong to the conserved group of caudal-like group of 
homeobox genes and are about 45% similar at the protein level in mouse and 
human (see attachment, Figure 76). The homeodomain, which determines the 
binding to target genes and was described to be crucial for the leukemogenic 
effect of both CDX proteins, is highly conserved between the two genes (Rawat 
et al., 2004; Bansal et al., 2006). On the other hand, a comparatively low 
conservation can be observed at the N-terminal transactivation domain, which 
was found to be crucial for deregulation of Hox genes (Rawat et al., 2008). 
Despite this weak homology, both genes were able to upregulate HoxA cluster 
genes in a similar manner. A significant difference, however, was detected in 
the expression levels of Hoxb6 and Hoxb8. CDX2 induced an almost 7-fold 
higher ectopic expression of Hoxb6 compared to CDX4 and ectopic Hoxb8 
expression was found only in Cdx2-transduced BM. Both Hoxb6 and Hoxb8 
have been described to be direct targets of CDX2 before (Scholl et al., 2007, 
McKinney-Freeman et al., 2008; Wang et al., 2008). Overexpression of HOXB8 
in vitro results in immortalization of myeloid progenitors and leads to 
development of AML with a latency of about 8 months (Perkins et al., 1990; 
Perkins and Cory, 1993). However, neither in AML nor in ALL was aberrant 
expression of HOXB8 detected and in ALL most of the patients were negative 
for the HOXB8 transcript rendering it unlikely that this HOX gene has a major 
impact on the leukemogenic potential of CDX2. Aberrant expression of HOXB6 
in vitro can result in a differentiation block of myeloid precursors, combined with 
an increase of blast-like colonies (Fischbach et al., 2005). The same effect was 
observed in this study for Cdx4-, and even more pronounced in Cdx2-
transduced BM cells. In the mouse model, aberrant expression of HOXB6 leads 
to induction of AML with a median latency of approximately 8 months 
(Fischbach et al., 2005). Overexpression of HOXB6 was described to inhibit 
erythroid maturation, and may therefore contribute to the development of 
erythroid leukemia in the CDX4 mouse model (Zimmermann and Rich, 1997, 
Shen et al., 1992; Kappen, 2000). Interestingly, in AML lacking chromosomal 
aberrations, including NPM+ AML – the AML subtype with highest expression of 
Cdx2 – overexpression of HOXB6 can be found in up to 60% of all the cases 
(Giampaolo et al., 2002). Furthermore, the results of this study, showing that 
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HOXB6 was the only HOX gene correlating with the expression level of CDX2 in 
ALL, suggest that aberrant HOXB6 expression contributes to the leukemogenic 
potential of CDX2. 
Despite the higher effect of CDX2 on expression of Hoxb6 and Hoxb8, in vitro 
overexpression of CDX4 resulted in a significantly higher effect compared to 
CDX2 and conferred a higher proliferative potential as well as self-renewal 
capacity to the transduced hematopoietic progenitors. Nevertheless, BM cells 
overexpressing Cdx4 still were able to differentiate to a higher extent than 
Cdx2-transduced cells. After third plating, for instance, a significantly increased 
number of mature macrophage colonies was observed in the CDX4 arm 
compared to the CDX2 arm whereas transduction with Cdx2 led to growth of a 
significantly higher number of blast colonies. This was reflected by the 
immunophenotypic staining as well as cytomorphological analysis, 
demonstrating that CDX4 blocks differentiation of the transduced BM cells to a 
lower extent than CDX2. On the other hand, immunophenotyping of CDX4+ 
colonies after third plating showed a significant higher percentage of cells to be 
c-Kit+/Sca-1-, a marker combination of lineage committed progenitors (Metcalf et 
al., 2009). This suggests that CDX4 more likely acts by an expansion of 
lineage-restricted progenitors whereas the effect of Cdx2 transduction most 
probably is due to a block of differentiation. 
The fact that Cdx2-transduced cells derived from in vitro culture were able to 
engraft transplanted mice long-term and induce leukemia (Rawat et al., 2004) 
demonstrates that CDX2 leads to transformation of the transduced cells in vitro. 
Cdx4-transduced cells in contrast did not possess this capacity, which indicates 
that CDX4 – unlike CDX2 – alone is not sufficient to transform hematopoietic 
cells in vitro. 
In vivo, with a difference of more than 230 days in median latency compared to 
CDX4, CDX2 transplanted mice succumbed to transplantable leukemia 
significantly earlier than mice transplanted with CDX4-transduced BM. This 
relatively short latency of CDX2 induced leukemia suggests that aberrant CDX2 
expression leads to a more advanced preleukemic stage of the transduced BM 
cells than overexpression of CDX4. CDX2 therefore must require less additional 
alterations needed for induction of full-blown leukemia. The leukemia induced 
by CDX2 furthermore was considerably more aggressive compared to CDX4, 
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as indicated by multiorgan infiltration, a significantly lower PB RBC count as well 
as a significantly higher spleen weight at time of death. 
The results of this study indicate that both CDX2 and CDX4 are able to confer a 
high proliferative and clonogenic capacity to transduced BM progenitor cells. 
Although in vitro, CDX4 conferred the stronger effect overexpression of CDX4 
did not block differentiation to the same extent as observed with aberrant 
expression of CDX2. As potent upstream regulators of Hox genes, the 
enhanced proliferative and clonogenic capacity of the two CDX members may 
be mainly due to the upregulated Hox gene expression. The reason why CDX4 
is more potent in inducing proliferation in vitro remains to be clarified. 
Interestingly, McKinney-Freeman et al. (2008) demonstrated that during 
embryonic hematopoiesis, CDX2 strongly inhibits differentiation whereas CDX4 
dramatically enhances the expansion of hematopoietic progenitors. Their 
observations resemble the results of this study and indicates the presence of 
additional pathways regulated by Cdx genes. 
To investigate the role these pathways play in the different leukemogenicity of 
CDX2 and CDX4, the effect of their aberrant expression on global gene 
expression of murine BM progenitors was analyzed. In this assay, aberrant 
expression of CDX2 led to a clearly higher number of deregulated genes than 
aberrant CDX4 expression. The dataset, as analyzed by the R twilight package 
for example, revealed an almost 9-fold higher number of significantly 
deregulated genes within the CDX2 arm compared to the CDX4 arm. This result 
corresponds with data from Nishiyama et al. (2009), who reported that 
transduction with CDX2 amongst 50 different transcription factors resulted in the 
most pronounced perturbation of the transcriptome in ES cell lines. In addition, 
the differential expression profile of 5-FU BM cells transduced with CDX4 
showed a pronounced overlap with that of CDX2 transduced BM. More than half 
of the genes differentially regulated by CDX4 overexpression were found to be 
deregulated in the CDX2 arm as well. In addition, with exception of only one 
gene, the deregulation of those genes was always more pronounced in CDX2-
transduced cells. 
In both arms, especially high upregulation of Dlk1 was detected. DLK1, a 
member of the epidermal growth factor-like family also known as PREF-1 or 
FA1, belongs to the group of imprinted genes and is expressed only from the 
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paternal allele (Kobayashi et al., 2000). During embryonic development, it is 
expressed predominantly in immature cells and its expression in BM stromal 
cells promotes expansion of primitive hematopoietic progenitors (Moore et al., 
1997; Floridon et al., 2000). With advancing fetal development, DLK1 is 
downregulated and in the adult, its expression is restricted to non-hematopoietic 
cell types (Kim et al., 2007). In 61% of AML, however, an overexpression of 
DLK1 can be observed which, in 76% of the cases, is due to bi-allelic 
expression (Khoury et al., 2010). Especially in AML M6, overexpression of 
DLK1 is a frequent event (Sakajiri et al., 2005) and therefore may be involved in 
erythroid leukemogenesis in the CDX4 mouse model. Interestingly, DLK1 was 
shown to activate MEK/ERK signaling by increasing ERK1/2 phosphorylation 
(Kim et al., 2007), a pathway which was shown to be highly activated in 
leukemia. Furthermore, CDX2 was shown to be a target of RAS/MAPK 
signaling itself (Lu et al., 2008), suggesting a positive feedback loop, which 
could be partly mediated by DLK1. This is supported by upregulation of several 
genes involved in MAPK signaling including MAP3K8, IRS2 or SPRY1. In 
contrast, no differential regulation of these MAPK signaling molecules was 
found in Cdx4-transduced cells pointing to a difference in the regulatory 
mechanism of the two CDX proteins. Interestingly, another transcript 
significantly upregulated in both CDX2- and CDX4-transduced 5-FU BM cells 
was Meg3, a non-coding RNA which is located contiguous to Dlk1 at the 
imprinted region on chromosome 14q32.2 in the human and on the long arm of 
chromosome 12 in the mouse (Kircher et al., 2008; Wallace et al., 2010). The 
deregulation of both imprinted genes may suggest an involvement of CDX 
members in the co-regulation of Dlk1 and Meg3, which was described for some 
tissues during embryonic development (da Rocha et al., 2007). 
In both the CDX2 and CDX4 arms, only few genes were found to be 
downregulated in comparison to empty vector control. For example, Tnfaip3 
was affected by aberrant expression of CDX4. A knock-down of this gene 
showed an enhanced clonogenicity (Honma et al., 2009) and could possibly 
contribute to the relatively high colony forming capacity of Cdx4-transduced BM 
cells. Again, a higher number of deregulated genes was found in Cdx2-
transduced cells compared to Cdx4-transduced cells. Most of the genes 
downregulated in the CDX2 arm encode proteins expressed mainly on/in 
differentiated cell types. This result therefore mirrors the effect of aberrant 
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expression of CDX2 on hematopoietic progenitor cells, leading to a block of 
differentiation and decrease of mature hematopoietic cells. 
Pathways, which were significantly upregulated in Cdx2-transduced BM cells 
compared to Cdx4-transduced cells, were for example the PI3 kinase or the 
TGF-β signaling pathways, which were both upregulated in the CDX2 arm. 
However, the most deregulated pathway in the CDX2 arm was the WNT 
signaling pathway and, with a more than 4-fold difference, its member Wnt2 
was the highest differentially regulated gene when Cdx2-transduced BM cells 
were directly compared to Cdx4-transduced cells. Whereas CDX4 previously 
was shown to be targeted by WNT signaling, particularly by WNT3A (Shimizu et 
al., 2005; Pilon et al., 2006), no regulation of CDX2 by this pathway was 
observed so far. In contrast, recent reports suggested WNT3A to be a direct 
target of CDX2 (Savory et al., 2009) and the results of this gene expression 
analysis indicate CDX2 to be able to deregulate the WNT pathway as well, by 
targeting Wnt2 but also several other members such as Fzd1 or Tcf4. This 
pathway is known to be a critical pathway involved in embryonic development 
and confers self-renewal properties to hematopoietic and also cancer stem 
cells. Deregulation of this pathway is a frequent event in various cancers (Reya 
et al., 2003; Reya and Clevers, 2005). The ability to deregulate the WNT 
pathway therefore turns CDX2 into a potent oncogene and is most probably one 
main reason for its stronger leukemogenic effect compared to CDX4. 
6.7 Role of CDX2 in Leukemia 
The high oncogenic potential of CDX2 was suggested to be linked to its function 
as an upstream regulator of Hox genes. This hypothesis was supported by the 
finding that a deletion mutant of CDX2 missing the N-terminal transactivation 
domain – which was shown to be crucial for transcriptional activation of Hox 
genes (Taylor et al., 1997) – did not exhibit any leukemogenic effect (Rawat et 
al., 2008). In contrast to CDX4, aberrant expression of CDX2 led to a 
pronounced deregulation of the transcriptome in murine BM progenitors and an 
upregulation of additional pathways involved in self-renewal such as the WNT 
pathway. Indeed, the relevance of CDX2 for self-renewal was already shown for 
trophoblast stem cells, which upon withdrawal of CDX2 undergo differentiation 
(Niwa et al., 2005). The results of this study suggest that CDX2 possesses a 
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similar function in transformed hematopoietic cells, as a knock down of CDX2 in 
the ALL cell line Nalm-6 strongly reduced the clonogenic capacity of the cells in 
CFC assay, an in vitro surrogate for self-renewal. This finding confirmed the 
results of Scholl et al. (2007), who observed the same effect in AML cell lines 
and demonstrated the dependency of the leukemic clone on the expression of 
CDX2. As CDX2 is not expressed in normal adult hematopoietic cells, the 
absence of (sufficient) regulatory mechanisms controlling CDX2 induced gene 
transcription may contribute to its high leukemogenicity. 
The high self-renewing capacity, in addition to a block of differentiation 
conferred by CDX2, explains the pronounced growth advantage of CDX2-
transduced BM progenitors in vivo, as well as the high leukemogenicity of the 
gene in the murine BM transplantation model (Rawat et al. 2004). Despite the 
results of these in vivo studies in the mouse, it is not yet clear to what extent 
CDX2 is involved in induction and/or maintenance of human AML and ALL. An 
analysis of CDX2 expression in different leukemic subpopulations would help to 
solve this question, as a functional involvement of CDX2 in leukemogenesis 
suggests expression in the CD34+/CD38-, LSC enriched compartment. A 
subsequent knock down of CDX2 in this compartment with analysis of the 
CDX2-deficient LSCs in vivo finally would prove the dependency of the leukemic 
clone on CDX2 function. If aberrant CDX2 expression is causally involved in the 
induction of leukemia, the leukemia subtype may also result from a different cell 
type targeted by CDX2 induced leukemogenesis. The kind of disease hereby 
would depend on whether aberrant CDX2 expression first occurs in a myeloid or 
a lymphoid progenitor. To investigate this possibility, different murine 
hematopoietic subpopulations could be transduced with CDX2. By this 
approach, it would be possible to investigate if CDX2 is able to transform 
lymphoid progenitors in the same manner as already shown in this study where 
transduction of bulk BM under myeloid conditions resulted in transformation of 
the myeloid lineage. 
Interestingly, aberrant CDX2 expression seems to be associated with an acute 
stage of leukemia. Whereas more than 80% of ALL patients (Riedt et al., 2009; 
Thoene et al., 2009) and up to 90% of AML patients (Scholl et al., 2007, Rawat 
et al., 2008) were positive for the CDX2 transcript, only a small number of 
patients with CML or MDS showed expression of CDX2. Of the 10 CML patients 
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tested for expression of CDX2 by Scholl et al. (2007) only two patients, which 
were in accelerated stage or already in blast crisis, showed expression of the 
transcript, and one out of the two CDX2+ MDS patients progressed to AML 
within one month after the analysis. As acute leukemias, in contrast to chronic 
leukemias, are associated with a block of differentiation (Rabbitts, 1991; Sell, 
2005), aberrant expression of CDX2, leading to this block, therefore might be 
one key event associated with the induction of acute leukemias. 
Summary 
 
143 
7. SUMMARY 
In this study, it was demonstrated for the first time that aberrant expression of 
CDX2 is a frequent and functionally relevant event in human ALL. In ALL, high 
expression of CDX2 correlates to an inferior overall survival. It was 
demonstrated that CDX2 is frequently deregulated in human AML, where its 
expression positively correlates with the high HOX expression found particularly 
in AML patients of normal karyotype. As CDX2 was able to deregulate Hox 
gene expression in adult murine hematopoiesis, aberrant expression of CDX2 
may present an explanation for the still unknown cause of HOX gene 
deregulation in the subset of human AML of normal karyotype. 
Like CDX2, aberrant expression of CDX4 induced AML in the murine BM 
transplantation model. While Hox gene deregulation contributed to the 
leukemogenic potential of both CDX members, CDX2 was also able to disturb 
additional pathways involved in self-renewal and proliferation. Particularly WNT 
signaling was upregulated in CDX2-overexpressing BM cells. Aberrant 
expression of CDX2 was able to transform murine hematopoietic cells and was 
essential for the enhanced proliferative and self-renewal potential of human 
leukemic cell lines. CDX2 therefore may be an important factor in human 
leukemogenesis and serve as an interesting target for the development of new 
agents in the therapy of acute leukemias. 
The results of this study moreover indicate that CDX4 possesses a relatively 
low leukemogenic potential in vivo although it is able to confer higher 
proliferative and clonogenic potential compared to CDX2 in vitro. 
Overexpression of CDX4 in the murine BM transplantation model led to 
induction of acute erythroid leukemia. Together with its ability to expand 
erythroid cells in vitro, these results suggest that CDX4 plays a role in 
specification of the erythroid lineage in adult hematopoiesis and propose CDX4 
to be a novel factor in the development of erythroid leukemia. Thus, the CDX4 
mouse model might serve as a model system to better understand the biology 
of this disease with especially poor outcome. 
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8. ZUSAMMENFASSUNG 
In dieser Arbeit konnte erstmalig gezeigt werden, dass die aberrante 
Expression von CDX2 ein häufiges und funktionell relevantes Ereignis in der 
humanen ALL darstellt und mit einem ungünstigen Krankheitsverlauf korreliert. 
Auch in der Mehrheit der Patienten mit AML konnte eine Überexpression von 
CDX2 nachgewiesen werden. Ein hohes Transkriptlevel von CDX2 korrelierte in 
der AML mit einer erhöhten HOX Expression, welche insbesondere AML-
Patienten mit normalem Karyotyp kennzeichnet. Es konnte gezeigt werden, 
dass CDX2 in der adulten murinen Hämatopoese in der Lage ist Hox-Gene zu 
deregulieren. Die aberrante Expression von CDX2 könnte damit auch in der 
AML mit normalem Karyotyp eine der bisher unbekannten Ursachen für die 
HOX-Überexpression dieser Subgruppe darstellen. 
Ähnlich zu CDX2 induzierte auch die aberrante Expression von CDX4 AML im 
murinen Knochenmark-Transplantationsmodell. Die Überexpression beider 
Cdx-Gene führte zu einer verstärkten Hox-Expression. Zusätzlich führte CDX2 
zu einer Deregulation weiterer, an Selbsterneuerung und Proliferation beteiligter 
Signaltransduktionswege, wie unter anderem der Aktivierung des WNT-
Signalwegs. Es konnte nachgewiesen werden, dass eine aberrante Expression 
zu einer leukämischen Transformation muriner hämatopoetischer Zellen führt. 
Auch in humanen leukämischen Zelllinien ist die aberrante Expression von 
CDX2 für Klonogenität und Proliferation von entscheidender Bedeutung. 
Möglicherweise trägt CDX2 dadurch auch zur humanen Leukämogenese bei 
und könnte somit als potentielles Target für die Entwicklung neuartiger 
Krebstherapien dienen. 
Die Ergebnisse dieser Arbeit zeigen weiterhin, dass eine aberrante Expression 
von CDX4 in vivo eine relativ geringe leukämogene Wirkung besitzt, obwohl 
CDX4 in vitro im Vergleich zu CDX2 ein deutlich höheres Proliferations- und 
Selbsterneuerungspotential verleiht. Im Mausmodell führte die Überexpression 
von CDX4 zu der Induktion einer akuten erythroiden Leukämie sowie in vitro zu 
einer Expansion von Zellen der erythroiden Linie. Dies deutet auf eine Rolle von 
CDX4 in der adulten Erythropoese hin, sowie auf eine Beteiligung von CDX4 in 
der Entwicklung der erythroiden Leukämie. Das CDX4-Mausmodell der 
erythroiden Leukämie könnte daher zum Verständnis dieses AML-Subtyps 
beitragen, der durch eine besonders schlechte Prognose gekennzeichnet ist. 
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10. ATTACHMENTS 
10.1 Patient Characteristics 
10.1.1 AML 
AML 
Subtype 
Patient 
No. Age Gender Karyotype 
Other relevant 
markers Treatment and outcome 
CDX2 
Status 
t(8:21) 
AML1-
ETO 
1 48 M n.a. MLL-PTD- molecular relapse after 
BMT 
+ 
2 63 M 45,X,-Y,t(8;21)(q22;q22) AML1-ETO+, cKIT 
D816+, LAIP 
n.a. + 
3 70 F 45,X,-X,t(8;21)(q22;q22) AML1-ETO+, LAIP n.a. + 
4 57 F 46,XX,t(8;21)(q22;q22) AML1-ETO+ n.a. + 
5 31 M 46,XY,t(8;21)(q22;q22) AML1-ETO+ n.a. + 
6 78 F 47,XX,t(8;21)(q22;q22), 
+13 
AML1-ETO+, LAIP n.a. - 
7 65 M 46,XY,t(8;21)(q22;q22) AML1-ETO+ MRD after treatment - 
8 45 W 45,X,-X,t(8;21)(q22;q22) AML1-ETO+, LAIP n.a. + 
9 38 M 46,XY,t(8;21)(q22;q22) AML1-ETO+, LAIP n.a. - 
10 64 W 45,X,-
X,t(8;21)(q22;q22),del(9)(
q22) 
AML1-ETO+, Jak-2 
Mutation, LAIP 
death 3 months after 
diagnosis without relapse 
+ 
11 54 W complex aberrant AML1-ETO+, cKIT 
D816+, LAIP 
n.a. - 
12 42 W 45,X,-X,t(8;21)(q22;q22) AML1-ETO+, LAIP n.a. + 
13 57 W 47,XX,+8,t(8;21)(q22;q22
) 
AML1-ETO+, LAIP n.a. - 
14 78 M 45,X,-Y,t(8;21)(q22;q22) AML1-ETO+, PML-
RARA+, LAIP 
n.a. - 
15 37 W 46,XX,t(8;21)(q22;q22) AML1-ETO+, LAIP relapse 23 month after 
diagnosis, alive 29 month 
after diagnosis 
+ 
16 38 M 45,X,-Y,t(8;21)(q22;q22) AML1-ETO+, BCR-
ABL+, LAIP 
n.a. - 
17 54 M 46,XY,t(8;21)(q22;q22) AML1-ETO+, LAIP n.a. - 
18 51 M 46,XY,t(8;21)(q22;q22) AML1-ETO+, LAIP n.a. - 
19 41 M 46,XY,t(8;21)(q22;q22) AML1-ETO+, LAIP n.a. - 
20 41 W 45,X,-X,t(8;21)(q22;q22), 
t(9;22) 
AML1-ETO+, BCR-
ABL+, NRAS-Mutation 
(Codon12)+, LAIP 
n.a. - 
21 41 M 46,XY,t(8;21)(q22;q22), 
t(1;3) 
AML1-ETO+, LAIP n.a. + 
22 52 W 46,XX,t(8;21)(q22;q22), 
del9 
AML1-ETO+, NRAS-
Mutation (Codon61)+, 
LAIP 
n.a. - 
23 61 M 45,X,-Y,t(8;21)(q22;q22) AML1-ETO+, LAIP n.a. - 
24 39 M 46,XY,t(8;21)(q22;q22) AML1-ETO+, LAIP n.a. + 
AML NK 
NPMc+ 
25 59 W 46,XX NPM1+, LAIP n.a. + 
26 47 M 46,XY NPM1+, FLT3-ITD+ n.a. + 
27 66 W 46,XX NPM1+, LAIP n.a. + 
28 53 M 46,XY NPM1+, FLT3-ITD+ n.a. + 
29 66 W 46,XX NPM1+, LAIP secondary to CMML + 
30 77 M 46,XY NPM1+ n.a. + 
31 56 W 46,XX NPM1+, LAIP n.a. + 
32 77 M 48,XY,+8,+8 
[9]/49,idem,+8[6]/46,XY[8
] 
NPM1+, FLT3-ITD+, 
LAIP 
n.a. + 
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AML 
Subtype 
Patient 
No. Age Gender Karyotype 
Other relevant 
markers Treatment and outcome 
CDX2 
Status 
33 71 W 46,XX NPM1+, FLT3-ITD+, 
LAIP 
n.a. + 
34 60 W 46,XX NPM1+, FLT3-D835+ n.a. + 
35 55 W 46,XX NPM1+ n.a. + 
36 48 M 46,XY NPM1+, FLT3-ITD+, 
LAIP 
n.a. + 
37 42 W 46,XX NPM1+, LAIP n.a. - 
38 58 M 46,XY NPM1+, LAIP n.a. + 
39 65 W 46,XX NPM1+, FLT3-D835+, 
LAIP 
n.a. + 
40 49 M 46,XY NPM1+ n.a. + 
41 43 M 46,XY NPM1+, LAIP n.a. + 
42 65 W 46,XX NPM1+, FLT3-ITD+, 
LAIP 
n.a. - 
43 63 W 46,XX NPM1+, FLT3-D835+, 
LAIP 
n.a. - 
44 61 W 46,XX NPM1+, FLT3-ITD+, 
LAIP 
n.a. + 
45 76 W 46,XX NPM1+ n.a. - 
46 69 W 46,XX NPM1+, FLT3-ITD+ n.a. + 
47 60 M 46,XY NPM1+, FLT3-ITD+ n.a. + 
48 39 W 46,XX NPM1+, FLT3-ITD+, 
LAIP 
n.a. + 
49 82 M 46,XY NPM1+, FLT3-D835+, 
LAIP 
secondary to MDS + 
50 49 M 46,XY NPM1+ BMT 3 month after 
diagnosis, relapse and 
death 14 month after BMT 
+ 
51 47 M 46,XY NPM1+, FLT3-ITD+ relapse 9 month after 
diagnosis 
+ 
52 71 M 46,XY NPM1+, FLT3-ITD+, 
CEBPA+, LAIP 
relapse 7 month after 
diagnosis, death 8 month 
after diagnosis 
+ 
53 80 W 46,XX NPM1+, NRAS-
Mutation (Codon12)+ 
death 1 month after 
diagnosis 
+ 
54 60 W 46,XX NPM1+ n.a. + 
55 33 M 46,XY NPM1+, LAIP alive 26 month after 
diagnosis 
+ 
56 58 M 46,XY NPM1+, FLT3-ITD+, 
LAIP 
n.a. + 
57 60 M 46,XY NPM1+, LAIP n.a. + 
58 68 M 46,XY NPM1+, FLT3-ITD+, 
LAIP 
relapse 7 month after 
diagnosis, death 9 month 
after diagnosis 
+ 
59 61 W 46,XX NPM1+, FLT3-ITD+, 
LAIP 
n.a. + 
60 69 W 46,XX NPM1+, FLT3-ITD+, 
LAIP 
n.a. + 
61 37 W 46,XX NPM1+, LAIP n.a. + 
62 58 M 46,XY NPM1+, NRAS-
Mutation (Codon12)+, 
LAIP 
n.a. + 
63 57 W 46,XX NPM1+, FLT3-D835+, 
LAIP 
alive 6 month after 
diagnosis 
+ 
64 30 W 46,XX NPM1+, CEBPA+, LAIP n.a. + 
65 81 M 46,XY NPM1+, FLT3-ITD+, 
LAIP 
n.a. + 
66 39 W 46,XX NPM1+, NRAS-
Mutation (Codon12)+, 
LAIP 
n.a. + 
67 39 W 46,XX NPM1+, LAIP BMT 8 month after 
diagnosis, alive 9 month 
after diagnosis 
+ 
68 77 W 46,XX NPM1+, LAIP n.a. + 
69 48 W 46,XX NPM1+, FLT3-D835+, 
LAIP 
n.a. + 
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AML 
Subtype 
Patient 
No. Age Gender Karyotype 
Other relevant 
markers Treatment and outcome 
CDX2 
Status 
AML NK 
NPMc- 
70 79 M 46,XY NPM1- death 2 weeks after 
diagnosis 
+ 
71 68 M 46,XY NPM1- relapse 10 month after 
diagnosis, death 16 month 
after diagnosis 
+ 
72 59 M 46,XY NPM1- death 2 month after 
diagnosis 
+ 
73 76 M 46,XY NPM1- death 11 month after 
diagnosis 
+ 
74 65 M 46,XY NPM1- secondary to MDS, death 
13 month after diagnosis 
+ 
75 58 M 46,XY LAIP secondary to MDS, alive 
12 month after diagnosis 
+ 
76 70 W 46,XX LAIP relapse 15 month after 
diagnosis, death 26 month 
after diagnosis 
+ 
77 32 M 46,XY LAIP autologous PBSCT 5 
month after diagnosis, 
relapse 9 month after 
diagnosis, BMT 12 month 
after diagnosis, alive 33 
month after diagnosis 
+ 
78 63 M 46,XY MLL-PTD+, LAIP death 1 month after 
diagnosis 
+ 
79 39 M 46,XY LAIP alive 23 month after 
diagnosis 
+ 
80 69 W 46,XX NPM1- secondary to CMML, death 
3 month after diagnosis of 
AML 
+ 
81 45 M 46,XY LAIP n.a. + 
82 72 M 46,XY LAIP secondary to MDS, death 
2 month after diagnosis of 
AML 
+ 
83 71 M 46,XY NRAS-Mutation 
(Codon61)+, EVI1+ 
death 1 month after 
diagnosis 
+ 
84 72 M 46,XY MLL-PTD+, LAIP relapse 4 month after 
diagnosis, death 7 month 
after diagnosis 
+ 
85 72 M 46,XY FLT3-ITD+, LAIP n.a. + 
86 72 M 46,XY FLT3-ITD+, MLL-PTD+, 
LAIP 
n.a. + 
87 55 M 46,XY FLT3-ITD+, LAIP BMT 5 month after 
diagnosis, relapse and 
death 7 month after 
diagnosis 
+ 
88 61 W 46,XX FLT3-ITD+ alive 3 month after 
diagnosis 
+ 
89 57 W 46,XX NPM1- alive 2 month after 
diagnosis 
- 
90 28 M 46,XY CEBPA+, LAIP n.a. + 
91 66 M 46,XY LAIP secondary to MDS + 
92 75 M 46,XY FLT3-D324+, LAIP refractory to induction 
therapy, death 1 month 
after diagnosis 
+ 
93 78 M 46,XY LAIP alive 1 month after 
diagnosis 
+ 
94 32 W 46,XX CEBPA+, LAIP alive 3 month after 
diagnosis 
+ 
95 79 M 46,XY LAIP n.a. + 
t(15;17) 
PML-
RARα 
96 81 M 46,XY, t(15;17)(q22;q21) PML-RARA+, LAIP n.a. + 
97 66 M 47,XY,+8,t(15;17)(q22;q2
1) 
PML-RARA+, FLT3-
ITD+, LAIP 
n.a. - 
98 28 W 46,XX, t(15;17)(q22;q21), 
der15 
PML-RARA+, LAIP n.a. + 
99 44 W 46,XX, t(15;17)(q22;q21) PML-RARA+, FLT3-
ITD+, LAIP 
n.a. + 
100 54 W 46,XX, t(15;17)(q22;q21) PML-RARA+, FLT3-
ITD+ 
n.a. - 
101 70 W 46,XX, t(15;17)(q22;q21) PML-RARA+, FLT3-
ITD+, LAIP 
n.a. + 
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AML 
Subtype 
Patient 
No. Age Gender Karyotype 
Other relevant 
markers Treatment and outcome 
CDX2 
Status 
102 38 M 46,XY, t(15;17)(q22;q21) PML-RARA+, FLT3-
ITD+, LAIP 
n.a. + 
103 64 M 46,XY, t(15;17)(q22;q21) PML-RARA+, LAIP n.a. + 
104 54 W 46,XX, t(15;17)(q22;q21) PML-RARA+, FLT3-
ITD+ 
n.a. + 
105 69 W 46,XX, t(15;17)(q22;q21), 
del9, der10 
PML-RARA+, LAIP n.a. + 
11q23 
MLL-
Rearr. 
106 43 W n.a. MLL-AF9+ n.a. - 
107 33 W 46,XX,t(6;11)(q27;q23) MLL-AF6+, FLT3-ITD+ alive 14 months after 
diagnosis + 
108 36 M 46,XY,t(9;11)(;q23) MLL-AF9+; LAIP after BMT AML in CR - 
109 23 W 46,XX,t(9;11)(;q23) MLL-AF9+; FLT3-ITD+, 
LAIP 
n.a. - 
110 48 W 46,XX,t(9;11)(;q23) MLL-AF9+; MLL-PTD+, 
LAIP 
n.a. + 
111 25 M 47,XY,t(3;6;11)(q13;q27;
q23),der(14)t(14;17)(p11;
?),+21[12] 
MLL-AF6+; MLL-PTD+, 
LAIP 
n.a. + 
inv(16) 112 82 W 46,XX,inv(16)(p13q22) CBFβ-MYH11+, NRAS-
Mutation (Codon12)+, 
LAIP 
n.a. + 
113 60 W 47,XX,+8,inv(16)(p13q22
) 
CBFβ-MYH11+, LAIP n.a. - 
114 37 M 46,XX,-
21,+22,inv(16)(p13q22) 
CBFβ-MYH11+, LAIP n.a. + 
115 17 M 46,XY,inv(16)(p13q22)[ CBFβ-MYH11+, LAIP n.a. + 
10.1.2 ALL 
ALL 
Subtype 
Patient 
No. Age Gender Karyotype 
Other 
Relevant 
Markers 
Treatment 
and Outcome 
WBC 
[/µl] 
CDX2 
Status. 
Pre-B/c-
ALL 
1 49 F 46,XX  n.a. n.a. + 
2 22 F 48,XX,+X,+7  n.a. n.a. - 
3 62 F 46,XX  n.a. n.a. + 
4 26 F 46,XX,del(2)(q12q14)  
still in CR 56 
months after 
diagnosis 
n.a. + 
5 34 M 
44,XY,t(2;10)(p25;q24), 
del(5)(q13q31),dic(7;17)(p11;p11), 
dic(9;12)(p11;p11),del(9)(q11), 
der(20)t(9;20)(q21;p13) 
 
death 9 
months after 
diagnosis 
9000 + 
6 48 M 46,XY  
death 56 
months after 
diagnosis 
 + 
7 40 M 46,XY  
death 27 
months after 
diagnosis 
2040 - 
8 34 M 46,XY  n.a. 15900 + 
9 25 F 46,XX,+8,dic(9;12)(p13;p11)  
alive 53 
months after 
diagnosis 
 + 
10 21 M 46,XY  
alive 19 
months after 
diagnosis 
31000 + 
Ph+ ALL 
11 36 M 46,XY,t(9;22)(q34;q11) Ph+ 
alive 77 
months after 
diagnosis 
8800 - 
12 82 M 46,XY,t(1;4;11;8)(p11;q33;p12;p11), t(9;22)(q34;q11) Ph+ n.a. 56500 - 
13 57 M 
46,XY,der(9)t(9;22)(q34;q11)t(9;22)(p11
;q11), 
der(22)t(9;22)(q34;q11) 
Ph+ 
death 4 
months after 
diagnosis 
 + 
14 38 M 45,X,-Y,t(9;22)(q34;q11),i(9)(q10), der(16)t(1;16)(q21;q13) Ph+ 
death 15 
months after 
diagnosis 
26300 + 
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ALL 
Subtype 
Patient 
No. Age Gender Karyotype 
Other 
Relevant 
Markers 
Treatment 
and Outcome 
WBC 
[/µl] 
CDX2 
Status. 
15 43 M 46,XY,t(9;22)(q34;q11),del(9)(p22) Ph+ 
death 4 
months after 
diagnosis 
400 + 
16 66 M 46,XY,t(9;22)(q34;q11) Ph+ alive 09/2002 47900 + 
17 83 F 46,XX,t(9;22)(q34;q11),t(9;11)(p22;q25) Ph+ n.a. n.a. + 
18 58 F 
51,XX,+5,+6,i(7)(q10),+8,t(9;22)(q34;q1
1), 
+15,+der(22)t(9;22) 
Ph+ n.a. n.a. - 
19 29 F 
46,XX,der(7;9)(q10;q10)t(9;22)(q34;q11
), 
der(7;9)(p10;p10)del(7)(p?)del(9)(p?) 
Ph+, FLT3 
D324 
CR 16 
months after 
diagnosis, 
alive 44 
months after 
diagnosis 
n.a. + 
20 62 F 
46,XX,der(9)t(4;9)(q31;q34)del(9)(p13)(
ABL-
),del(10)(q24),der(19)t(19;22)(q13;q11) 
(BCR+,ABL+,BCRconABL,BCR+), 
der(22)t(9;22)(ABL+) 
Ph+ 
death 7 
months after 
diagnosis 
63600 + 
21 72 F 46,XX,t(9;22)(q34;q11) Ph+ n.a. 39510 + 
Pro-B- 
ALL 
22 77 F 46,XX,t(4;11)(q21;q23) MLL-AF4 n.a. n.a. + 
23 47 F 46,XX,t(4;11)(q21;q23) MLL-AF4 alive 11/201 n.a. + 
24 64 F 46,XX,t(4;11)(q21;q23) MLL-AF4 
CR 6 months 
after 
diagnosis, 
death 25 
months after 
diagnosis 
n.a. + 
25 40 F 46,XX,t(4;11)(q21;q23) MLL-AF4 
alive 4 
months after 
diagnosis 
48740 + 
26 53 F n.a. MLL-AF4 
death 7 
months after 
diagnosis 
17500 + 
27 39 M 47,XY,+X,t(11;19)(q23;p13) MLL-ENL 
alive 25 
months after 
diagnosis 
124600 + 
28 62 M 46,XY,t(4;11)(q21;q23) MLL-AF4 
CR 12 
months after 
diagnosis 
n.a. + 
29 34 M 47,XY,+X,t(4;11)(q21;q23) MLL-AF4 n.a. n.a. + 
30 61 F 46,XX,t(4;11)(q21;q23) MLL-AF4 n.a. n.a. + 
B-ALL/ 
Burkitt 
31 42 F 
46,XX,del(2)(q31),t(8;14)(q24;q32), 
der(11)dup(11)(q21q25)t(2;11)(q31;q25
) 
IgH-cMYC-
Rearr. n.a. n.a. - 
32 54 M 46,XY,dup(7)(q11q36),t(8;14)(q24;q32) IgH-cMYC-Rearr. n.a. n.a. - 
33 61 F 
46,XX,dup(1)(q21q44),der(1)t(1;9)(p36;
q?), 
der(3)del(3)(p21)t(1;3)(q25;q25), 
der(6)t(3;6)(p21;q24), 
IgH-cMYC-
Rearr. n.a. n.a. - 
34 34 F 46,XX,t(8;14)(q24;q32) IgH-cMYC-Rearr. n.a. n.a. - 
35 80 F 
46,XX,dup(1)(q11q44),der(2)t(2;11)(p25
;q23), 
t(3;9;14)(q27;p13;q32),t(8;14)(q24;q32), 
del(11)(q11q23),der(22)t(11;22)(q23;q1
3) 
IgH-cMYC-
Rearr. n.a. n.a. - 
36 72 F 
49,X,del(X)(q24),+7,+8,t(8;14)(q24;q32) 
,ider(13)(q10)dup(13q?q?)t(13;14)(q34;
q24) 
t(14;18)(q32;q21),der(14)t(X;14)(q26;q2
4), 
der(18)t(14;18)(q32;q21),+17 
FLT3 D324, 
IgH-cMYC-
Rearr., IgH-
BCL2-
Rearr. 
n.a. n.a. - 
37 79 M 46,XY,t(8;14)(q24;q32) IgH-cMYC-Rearr. n.a. n.a. - 
38 40 M 
47-
51,XY,dup(1)(q21q44),+2,del(2)(q21), 
+7,t(8;14)(q24;q32),+13,+15,+16 
IgH-cMYC-
Rearr. 
03/2002 in 
CR n.a. - 
39 27 M 
48,XY,+Y,+i(7)(q10),t(8;14)(q24;q32), 
der(17)t(1;17)(q12;p13) [13] 49,XY,+Y, 
+i(7)(q10),t(8;14)(q24;q32), 
+der(14)t(8;14) [4] 
IgH-cMYC-
Rearr. n.a. n.a. - 
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ALL 
Subtype 
Patient 
No. Age Gender Karyotype 
Other 
Relevant 
Markers 
Treatment 
and Outcome 
WBC 
[/µl] 
CDX2 
Status. 
40 26 M 46,XY,dup(1)(q21q44),t(8;14)(q24;q32), inv(13)(p11q21) 
IgH-cMYC-
Rearr. 
12/2006 in 
CR n.a. - 
Pre-T-ALL 
41 46 M 47,XY,t(10;11)(p12;q21),+13 CALM-AF10 
relaps 5 
months after 
diagnosis, 
death 6 
months after 
diagnosis 
n.a. + 
42 70 F 46,XX,t(2;9)(q37;p11),t(3;7)(q27;p11), del(13)(q?)  n.a. 7020 + 
43 56 F 46,XX,der(5)t(4;5)(q25;q15)  07/2002 in CR n.a. + 
44 34 M 46,XY,t(10;11)(p12;q13),del(12)(p11) CALM-AF10 n.a. 1136 - 
45 27 M 46,XY  03/2004 in CR 85000 + 
46 52 F 46,XX  08/2004 in CR 1570 - 
47 54 M 46,XY,t(2;14)(p25;q11)  BMT, 11/2004 in CR n.a. - 
Cortical T-
ALL 
48 39 M 46,XY  n.a. 1120 - 
49 29 M 
46,XY,t(1;14)(p34;q11),der(9)t(9;16)(p2
2;q22), 
der(16)t(7;16)(?;p13)t(9;16)(p22;q22) 
 01/2003 in CR 158600 - 
50 62 M n.a.  n.a. 8250 - 
51 38 M n.a.  BMT, 08/2004 in CR 18900 - 
52 22 F 46,XX  n.a.  - 
53 37 M 46,XY,del(6)(q21),i(9)(q10)  n.a. 73800 - 
54 46 M 46,XY,t(5;7)(q35;q22),del(9)(p13) TLX-Rearr. 04/2005 in CR 49400 - 
55 24 M 47,XY,t(7;14)(q35;q11),+16  n.a. 310000 - 
56 42 M 46,XY,del(9)(p13),t(10;14)(q24;q11)  n.a. 101000 - 
57 29 M 46,XY FLT3 D324 n.a. 90700 - 
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10.2 Alignment of CDX2 and CDX4 
CDX2 and CDX4 share 46.3% and 44.6% similarity at the protein level in 
mouse and human, respectively (EMBOSS/needle method for pairwise global 
alignment, http://www.ebi.ac.uk/Tools/emboss/align/index.html). The DNA-
binding homeodomain is highly conserved whereas the N- and C-termini are 
more divergent. 
Figure 76: Alignment of human and murine protein sequences of CDX2 and CDX4. 
The alignment of the protein sequences of CDX2 NM_001265, Cdx2 NM_007673, CDX4 
NM_005193 and Cdx4 NM_007674 was performed using the multiple sequence alignment 
program T-Coffee (available on http://www.ebi.ac.uk/Tools/t-coffee/index.html) and edited by 
Jalview. The amino acids were colored according to their physicochemical properties: aliphatic/ 
hydrophobic (ILVAM) dark green, aromatic (FWY) orange, positive (KRH) dark blue, negative 
(DE) violet, hydrophilic (STNQ) light green, conformationally special (PG) light blue and 
cysteine (C) yellow. 
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10.3 Heatmaps of Differentially Regulated Genes in Cdx2- and Cdx4-
transduced murine BM progenitors. 
Figure 77: Genes significantly deregulated in Cdx4-transduced BM cells compared to 
empty pMIG-transduced cells. 
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Figure 78: Genes significantly regulated in Cdx2- vs. pMIG- transduced 5-FU BM cells. 
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